,PageNo,Text
0,page_1,"['ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY', 'ALLIANCE A171601', 'A PHASE II TRIAL ASSESSING THE TOLERABILITY OFPALBOCICLIB IN COMBINATION WITH', 'LETROZOLE OR FULVESTRANT IN PATIENTS AGED 70 AND OLDER WITH ESTROGEN RECEPTOR-', 'POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER', 'Commercial agent(s): Palbociclib; (IND: exempt)', 'ClinicalTrials.gov Identifier: NCT03633331.', 'Study Chair', 'Mina S. Sedrak MD, MS', 'City of Hope Comprehensive Cancer Center', 'Study Co-Chair', 'Aminah Jatoi MD', 'Mayo Clinic', 'Community Oncology Co-Chair', 'Correlative Study Co-Chair Pharmacogenomics Study Co-Chair', 'Imaging Co-Chair', 'Pharmacokinetics Study Co-Chair', 'Breast Committee Study Co-Chair', 'Study Co-Chair', 'Cancer in the Elderly Committee Co-Chairs', 'Breast Committee Co-Chairs', 'Primary Statistician', 'Secondary Statistician', 'Data Manager', 'Protocol Coordinator', 'In memory of Dr. Arti Hurria', 'Participating NCTN Groups:', 'Alliance/Alliance for Clinical Trials in Oncology (lead), ECOG-ACRIN/ECOG ACRIN Cancer Research Group,', 'NRG/NRG Oncology, SWOG/ SWOG', '1', 'NCIVersion Date: 5/29/2020', 'Update 5']"
1,page_2,"['Alliance A171601', 'Study Resources:', 'Expedited Adverse Event Reporting', 'Medidata Rave® iMedidata portal', 'OPEN (Oncology Patient Enrollment Network)', 'Biospecimen Management System', 'Protocol Contacts:', 'A171601 Nursing Contact', 'A171601 Pharmacy Contact', 'IROC', 'Alliance Biorepository at Mayo Clinic', 'University of Pittsburgh Cancer Institute', 'Protocol-related questions may be directed as follows:', 'Questions', 'Contact (via email)', 'Questions regarding patient eligibility, treatment,', 'Study Chair, Nursing Contact, Protocol', 'and dose modification:', 'Coordinator, and (where applicable) Data Manager', 'Questions related to data submission, RAVE or', 'Data Manager', 'patient follow-up:', 'Questions regarding the protocol document and', 'Protocol Coordinator', 'model informed consent:', 'Questions related to IRB review', 'Alliance Regulatory Inbox', 'Questions regarding CTEP-AERS reporting:', 'Alliance Pharmacovigilance Inbox', 'Questions regarding specimens/specimen', 'submissions:', 'Appropriate Alliance Biorepository', 'Questions regarding drug administration', 'Pharmacy Contact', '2', 'NCI Version Date: 5/29/2020', 'Update 5']"
2,page_3,"['Alliance A171601', 'CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT INFORMATION', 'For regulatory requirements:', 'For patient enrollments:', 'For data submission:', 'Regulatory documentation must', 'Refer to the patient enrollment', 'Data collection for this study will', 'be submitted to the CTSU via', 'section of the protocol for', 'be done exclusively through', 'the Regulatory Submission', 'instructions on using the', 'Medidata Rave. Refer to the data', 'Portal.', 'Oncology Patient Enrollment', 'submission section of the protocol', 'Network (OPEN). OPEN is', 'for further instructions.', '(Sign in at', 'and', 'accessed at', 'select the Regulatory >', 'Regulatory Submission.)', 'Do not submit study data or forms', 'to the CTSU. Do not copy the', 'Institutions with patients', 'CTSU on data submissions.', 'waiting that are unable to use', 'Contact the CTSU Help Desk', 'the Portal should alert the', 'with any OPEN-related', 'CTSU Regulatory Office', 'questions by phone or email :', 'immediately at', 'or', 'to receive further instruction', '.', 'and support.', 'Contact the CTSURegulatory', 'Help Desk at', 'for regulatory assistance.', 'The most current version of the study protocol and all supporting documents must be downloaded', ""from the protocol-specific page located on the CTSU members' website"", 'Access', ""to the CTSU members' website is managed through the Cancer Therapy and Evaluation Program -"", 'Identity and Access Management (CTEP-IAM) registration system and requires log in with a CTEP-', 'IAM username and password', 'Permission to view and download this protocol and its supporting documents is restricted and is based', 'on person and site roster assignment housed in the CTSU Regulatory Support System (RSS).', 'Institutions will order the following supplies from the CTSU Operations Office: Questionnaire booklets.', 'Supplies can be ordered by downloading and completing the CTSU Supply Request Form (available on', 'the protocol-specific page on the CTSU website) and submitting it as instructed on the form.', 'For clinical questions (i.e., patient eligibility or treatment-related) see the Protocol Contacts, Page 2.', 'For non-clinical questions (i.e., unrelated to patient eligibility, treatment, or clinical data', 'submission) contact the CTSUHelp Desk by phone or email:', 'CTSU General Information Line -', 'or', '.', 'All calls and', 'correspondence will be triaged to the appropriate CTSU representative.', '3', 'NCIVersion Date: 5/29/2020', 'Update 5']"
3,page_4,"['Alliance A171601', 'A PHASE II TRIAL ASSESSING THE TOLERABILITY OFPALBOCICLIB IN COMBINATION WITH', 'LETROZOLE OR FULVESTRANT IN PATIENTS AGED 70 AND OLDER WITH ESTROGEN RECEPTOR-', 'POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER', 'Eligibility Criteria (See Section 3.2)', 'Required Initial Laboratory Values', 'Estrogen receptor positive nd/orprogesterone receptor (PR) positive,', 'ANC 1500/mm³', 'HER2 negative metastatic breast cancer See 3.2.1', 'Platelet count: 100,000/mm³', 'Measurable disease or non-measurable disease See 3.2.2', 'Creatinine: 30 ml/min*', 'Planning to begin palbociclib for metastatic disease. Patients should', 'Totalserum', '< 1.5 ULN (<3 ULN', 'have failed one prior line of endocrine therapy. See 3.2.3', 'bilirubin', ""if Gilbert's disease)"", 'No prior therapy with a CDK inhibitor See 3.2.4', 'AST and/or', '3x ULN (<5.0x', 'Resolution of all acute toxic effects of prior therapy or surgical', 'ALT', 'ULN if liver', 'procedures to CTCAE Grade 1 (except alopecia) or to baseline', 'metastases present)', 'toxicities prior to previous therapy or surgical procedures. See 3.2.5', 'Alkaline', '<2.5xULN(<5x', 'No untreated brain metastases See 3.2.6', 'phosphatase', 'ULN if bone or', 'No known interstitial lung disease. See 3.2.7.', 'liver metastases', 'No secondmalignancies other than non-melanoma skin cancers or', 'present)', 'cervical carcinoma in situ See 3.2.8.', 'Calculated using the Cockcroft-Gault', 'No active infection requiring treatment with antibiotics See 3.2.9.', 'formula', 'Patients mustbe able to swallow and retain oral medication See', '3.2.10.', 'Patient Age:> 70 years See 3.2.11.', 'ECOG Performance Status 0, 1 or 2 See 3.2.12.', 'Patients mustbe able to readand comprehend Englis h or Spanish See', '3.2.13', 'Schema', '1 cycle = 28 days', 'Treatment:', 'Palbociclib 125 mg a day (Once daily orally', 'Registration', 'on days 1-21 of each 28-day cycle) and', 'Letrozole or Fulvestrant', '(Per treating investigator discretion)', 'Dosing per packet insert in each 28-day', 'cycle', 'Continue protocol treatment until unacceptable toxicity or disease progression', 'Please refer to the full protocol text for a complete description of the eligibility criteria and', 'treatment plan.', '4', 'NCIVersion Date: 5/29/2020', 'Update 5']"
4,page_5,"['Alliance A171601', 'TABLE OF CONTENTS', '1.0', 'BACKGROUNI', '7', '1.1', 'Aging and a Decrease in Physiologic Reserve: Rationale for Studying Cancer Therapy in', 'Older Adults', '7', '1.2', 'Factors Other than Chronological Age that Impact Drug Tolerance', '7', '1.3', 'Palbociclib', '8', '1.4', 'A Rationale for Combining Palbociclib and Endocrine Therapy', '8', '1.5', 'Measurement of Sarcopenia', '11', '1.6', 'Quality of Life Questionnaires: EuroQol 5D 3L and EQ Visual Analog Scale (EQ VAS)', '12', '1.7', 'PRO-CTCAE', '12', '2.0', 'OBJECTIVES', '13', '2.1', 'Primary Objective', '13', '2.2', 'Secondary objectives', '13', '2.3', 'Correlative science objectives', '13', '3.0', 'PATIENTS SELECTION.', '15', '3.1', 'On-Study Guidelines', '15', '3.2', 'Eligibility Criteria', '16', '4.0', 'PATIENTREGIS TRATION.', '17', '4.1', 'Investigator and Research Associate Registration with CTEP', '17', '4.2', 'CTSU Registration Procedures', '18', '4.3', 'Patient Registration Requirements', '20', '4.4', 'Patient Registration/Randomization Procedures', '20', '4.5', 'Registration to Correlative and Companion Studies', '21', '4.6', 'Grouping Factor', '22', '5.0', 'STUDY CALENDAR', '23', '6.0', 'DATA AND SPECIMEN SUBMISSION', '24', '6.1', 'Data Collection and Submission', '24', '6.2', 'Specimen collection and submission', '26', '6.3', 'Digital Image Submission Using TRIAD', '29', '7.0', 'TREATMENTPLAN/INTERVENTION', '31', '7.1', 'Palbociclib', '31', '7.2', 'Letrozole', '32', '7.3', 'Fulvestrant', '32', '7.4', 'Adherence, Geriatric Assessment, and Patient Perspective', '32', '8.0', 'DOSEAND TREATMENT MODIFICATIO NS', '33', '8.1', 'Ancillary Therapy, Concomitant Medications, and Supportive Care', '33', '8.2', 'Dose Modifications', '35', '9.0', 'ADVERSE EVENTS', '36', '9.1', 'Routine Adverse Event Reporting', '36', '9.2', 'CTCAE Routine Reporting Requirements', '37', '9.3', 'Expedited Adverse Event Reporting (CTEP-AERS)', '37', '9.4', 'CAEPR', '42', '10.0', 'DRUG INFORMATION', '45', '10.1', 'General Considerations', '45', '5', 'NCIVersion Date: 5/29/2020', 'Update 5']"
5,page_6,"['Alliance A171601', '10.2', 'Palbociclib', '45', '10.3', 'Fulvestrant', '46', '10.4', 'Letrozole', '48', '11.0', 'MEASUREMENT OF EFFECT', '49', '11.1', 'Patient reported outcome measures', '49', '11.2', 'Measurement of tumor response and schedule of evaluations', '50', '11.3', 'Definitions of Measurable and Non-Measurable Disease', '51', '11.4', 'Guidelines for Evaluation of Measurable Disease', '52', '11.5', 'Measurement of Treatment/Intervention Effect', '53', '11.6', 'Definitions of Analysis Variables', '56', '12.0', 'END OF TREATMENT/INTERVENTION', '56', '12.1', 'Duration of Treatment', '56', '12.2', 'Follow-up for patients who discontinue protocol therapy', '56', '12.3', 'Managing ineligible patients and registered patients who never receive protocol intervention', '57', '12.4', 'Extraordinary Medical Circumstances', '57', '13.0', 'STATIS TICAL CONSIDERATIONS', '58', '13.1', 'Primary Endpoints:', '58', '13.2', 'Primary Endpoint Analysis:', '58', '13.3', 'Secondary Endpoints:', '58', '13.4', 'Secondary Endpoint Analyses', '58', '13.5', 'Sample Size', '60', '13.6', 'Interim analysis and stopping rules:', '60', '13.7', 'Study Reporting', '61', '13.8', 'Inclusion of Women and Minorities', '62', '14.0', 'EXPLORATORY CORRELATIVE AND COMPANIONSTUDIES', '63', '14.1', 'Correlative Science: Circulating markers of inflammation as potential markers predictive of', 'toxicity among elderly patients enrolled to Alliance A171601 (Alliance A171601-ST1)', '63', '14.2', 'Pharmacogenomics: (Alliance A171601-ST2): Genetic determinants of Palbociclib Efficacy', 'and toxicity in the elderly', '67', '14.3', 'Pharmacokinetics: (Alliance A171601-PP1) Population Pharmacokinetics of Palbociclib 72', '15.0', 'GENERAL REGULATORY CONSIDERATIONS AND CREDENTIALING', '76', '15.1', 'Geriatric Assessment Training', '76', '16.0', 'REFERENCES', '77', '17.0 MODEL CONSENTFORM', '87', 'APPENDIXI I:PATIENTINFORMATION SHEETS', '100', 'APPENDIX II: GERIATRIC ASSESSMENT', '104', 'APPENDIX III: WAS IT WORTH IT QUES TIO NNAIRE', '124', 'APPENDIX IV: OVERALL TREATMENT UTILITY', '125', 'APPENDIX V: EQ-5D-3L HEALTH QUES TIO INNAIRE', '127', 'APPENDIX VI: PRO-CTCAE * -NCI-PRO-CTCAE TMITEMS', '129', 'APPENDIX VII: PATIENT MEDICATION DIARY - PALBOCICLIB', '136', 'APPENDIX VIII: TABLEOF TAGSNPs FOR A171601 STUDY', '138', 'APPENDIX IX: PATIENT PHARMACOKINETIC QUESTIO NNAIRE', '140', '6', 'NCI Version Date: 5/29/2020', 'Update 5']"
6,page_7,"['Alliance A171601', '1.0', 'BACKGROUNI', 'This protocol addresses a key research priority of the Cancer and Aging Research Group, National', 'Cancer Institute, National Institute on Aging, and the Institute of Medicine: the assessment of', 'cancer therapy in older adults 6, 7 Palbociclib is a novel drug with the potential to change the', 'treatment of metastatic breast cancer- a primary disease of older adults. The combination of', 'palbociclib and endocrine therapy (the aromatase inhibitor, letrozole, or fulvestrant) is associated', 'with an improvement in progression-free survival (PFS) compared to endocrine therapy alone. 1,2', 'However, a small proportion of patients enrolled in these studies were age 75 and older. The pivotal', 'trial of palbocicli reported in the package insert notes that only 37 patients (44%) were >65 years', 'of age and 8 patients (10%) were >75 years of age. The goal of this study is to fill this gap in', 'knowledge by utilizing a phase II design to examine the tolerability of palbociclib and endocrine', 'therapy among older adults age 70 and older with estrogen receptor positive, HER2 negative breast', 'tumors. A comprehensive cancer-specific geriatric assessment which includes an evaluation of', 'functional status, other medical conditions, cognitive function, nutritional status, social support,', 'psychological state, and a review of medications will be included, as well as an assessment of', 'adherence.', '1.1', 'Aging and a Decrease in Physiologic Reserve: Rationale for Studying Cancer Therapy in', 'Older Adults', 'Aging brings about a progressive decrease in physiologic reserve that affects each individual at', 'a unique pace. 8,! The age-related physiological decline in organ systems typically begins in the', '3rd decade of life and is not evident at times of rest but becomes most apparent when the body', 'is', 'stressed. 10Both cancer and cancer treatment can be considered a physiological stressor, and', 'age-related decreases in physiologic reserve may affect tolerance to cancer treatment.', 'A number of age-related changes in drug absorption, distribution, metabolism, and excretion', 'with aging may contribute to differences in treatment tolerance between older and younger', 'patients. The absorption of drugs can be affected by decreased gastrointestinal motility,', 'decreased splanchnic blood flow, decreased secretion of digestive enzymes, and mucosal', 'atrophy. 11,12 With the increased use of oraltherapy, medication compliance is an important issue', 'as', 'well. 13 As a person ages, body composition changes, with an increase in body fat and decrease', 'in lean body mass and total body water. The increase in body fat leads to a rise in the volume', 'of distribution for hydrophilic drugs. In the population of older adults with cancer, malnutrition', 'and hypoalbuminemia may result in an increased concentration of drugs that are albumin-', 'bound. 14', 'Hepatic mass and blood flow also decrease with age. 8 The impact of the dec line in hepatic mass', 'and blood flow on hepatic enzyme function is controversial. 15 In a study of 226 patients, the', 'cytochrome P-450 content in liver biopsy samples decreased by approximately 30% in patients', 'over the age of 70. 16 Renal function also declines with age, and renal insufficiency is common', 'in older adults. 17,18', 'A progressive reduction in the functional reserve of various organ systems may alter the', 'pharmacokinetics of anti-cancer therapies 11, 19 and increase the susc ceptibility of older individuals', 'to complications of treatment. 14,20-22 Normal tissues may be less able to repair the molecular', 'damage caused by antineoplastic agents due to cellular senescence, resulting in greater potential', 'cardiotoxicity, neurotoxicity, mucositis, and hematologic toxicities.23', '1.2', 'Factors Other than Chronological Age that Impact Drug Tolerance', 'Aging is a heterogeneous process. While certain declines in organ function are universal as the', 'human body ages, the rate of this decline and the consequences of this decline on everyday', 'function proceeds at a unique pace in each individual. Therefore, chronological age tells us', '7', 'NCIVersion Date: 5/29/2020', 'Update 5']"
7,page_8,"['Alliance A171601', 'relatively little about the specific individual. A more detailed evaluation of an older adult patient', 'is needed in order to capture factors other than chronological age that predict for morbidity and', 'mortality. A comprehensive geriatric assessment may serve this purpose. The comprehensive', 'geriatric assessment includes an evaluation of functional status, co-morbid medical conditions,', 'cognitive function, nutritional status, social support and psychological state, and a review of', 'medications3,4 Conclusions from several studies are emerging regarding the benefits of', 'performing a comprehensive geriatric assessment for older patients with cancer.', '1. Factors evaluated in a comprehensive geriatric assessment predicts survival. 24', '2.', 'Factors evaluated in a comprehensive geriatric assessment predicts toxicity to', 'chemotherapy. 25', '3.', 'A comprehensive geriatric assessment uncovers problems not detected by routine history', 'and physical in initial consultation and follow-up care. 26', '4.', 'Patients undergoing a comprehensive geriatric assessment and intervention based on the', 'results had improved pain control. 27', '5.', ""A comprehensive geriatric assessment and intervention improves an older patient's mental"", 'health and well-being. 27', '6.', 'Consensus guidelines recognize the benefits and recommend the inclusion of a geriatric', 'assessment as part of the evaluation of an older patient. 28', '1.3', 'Palbociclib', 'Palbociclib is a reversible, selective, cyclin dependent kinase (CDK) 4/6 inhibitor that is able to', 'stop the normal process of the cell cycle as the cell travels from G1 phase to S phasel. In the', 'absence of palbocicli these kinases will phosphorylate the retinoblastoma (Rb) protein to cause', 'a release of transcription factors which allows the cell to move through the cell cycle, thus', 'allowing the growth of cancerous cells¹. When palbociclib inhibits CDK4 and CDK6, the', 'retinoblastoma protein is arrested at the G1 phase, prohibiting ""S-phase entry and cell growth""', 'of the cancerous cells29', '1.4', 'A Rationale for Combining Palbociclib and Endocrine Therapy', 'Palbociclib in combination with endocrine therapy compared to endocrine therapy alone', 'improves progression-free survival. Data from the PALOMA-1 trial demonstrates the efficacy', 'of palbociclib with letrozole in the first line treatment of estrogen receptor positive metastatic', 'breast cancer.¹ In this randomized open-label phase II study, 165 women ranging from ages 54-', '72 had advanced estrogen receptor positive and HER-2 negative breast cancer. One cohort of', 'women (mean age 65) was enrolled because of their estrogen receptor positive and HER2-', 'negative breast cancer, whereas a second cohort (mean age 62.5) was enrolled because they also', 'had cancers with amplification of CCNDI and/or loss of P16. These cohorts received either', 'letrozole alone (orally 2.5mg/day) or letrozole (orally 2.5mg/day) with palbociclib (orally 125', 'mg/day for three weeks on and one week off). Eighty-four patients were assigned to the', 'palbociclib-letrozole group and 81 to letrozole alone. The median progression-free survival was', '20.2 months for the palbociclib and letrozole arm, compared to 10.2 months for letrozole alone.', 'Common side effects for palbociclib with letrozole compared to letrozole alone (Table 1) were:', 'grade 3-4 neutropenia (54% VS. 1%), leukopenia (19% VS. 0%), and fatigue (4% VS. 1%). Four', 'percent of patients receiving palbociclib with letrozole experienced a pulmonary embolism.', 'Among patients in the palbociclib and letrozole group, 13% discontinued due to side effects', 'whereas only 2% of the letrozole group discontinued the study.', '8', 'NCI Version Date: 5/29/2020', 'Update 5']"
8,page_9,"['Alliance A171601', 'Table 1: Common Adverse Reactions with an Incidence of > 5% in Patients who Received', 'Palbociclib plus Letrozole or Letrozole Alone in PALOMA-1 Study¹', 'Palbociclib plus Letrozole (N=83)', 'Letrozole (N=77)', 'Grade 3', 'Grade 4', 'Grade 3', 'Grade 4', 'Any adverse event', '49 (59%)', '14 (17%)', '16 (21%)', '0', 'Neutropenia', '40 (48%)', '5 (6%)', '1 (1%)', '0', 'Leukopenia', '16 (19%)', '0', '0', '0', 'Anemia', '4 (5%)', '1 (1%)', '1 (1%)', '0', '* Data are in n (%) unless otherwise specified', 'PALOMA-230 - which was designed to expand efficacy and safety data for palbociclib and', 'letrozole treatment - had a sample size of 666 postmenopausal women with ER-positive, HER2-', 'negative, breast cancer. In PALOMA-2, the median age of patients receiving palbociclib-', 'letrozole was 62 with a range from 30-89, with only 39.3% of participants age 65 and over with', 'no published information for patients older than 75. Among patients receiving placebo and', 'letrozole the median PFS was 14.5 months (95% CI 12.9-17.1). This efficacy improved with', 'palbociclib-letrozole to 24.8 months (95% CI 22.1-Not reached). The most common grade 3 or', '4 adverse events were neutropenia with 66.4% of patients treated with palbociclib-letrozole', 'experiencing this compared to 1.4% in the placebo-letrozole group. Leukopenia (24.8% VS. 0%),', 'anemia (5.4% VS. 1.8%) and fatigue (1.8% VS. 0.5%) were also reported.', 'Further support for use of palboc ic lib in conjunction with hormone therapy was carried out in', 'the PALOMA-3 trial.² This phase III trial inc cluded 521 patients randomized into 2 groups:', 'palbocicl lib and fulvestrant (N=347) or fulvestrant alone (N=174). Patients were eligible to', 'participate in this study if they were estrogen receptor positive. Patients enrolled in this study', 'could have had prior endocrine therapy (38.8% first line, 25.5% second line, 10.9% third line', 'and above). In addition, patients were allowed one prior line of chemotherapy. The median', 'progression-free survival was 9.2 months for the palbociclib and fulvestrant arm, compared to', '3.8 months for fulvestrant alone. Common side effects for palbociclib and fulvestrant', 'compared to fulvestrant alone were: neutropenia (62% VS. 6%), leukopenia (25.2% VS. 0.6%),', 'anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% VS. 0%), fatigue (2.0% VS. 1.2%), and', 'febrile neutropenia (0.6% for both groups). Among patients in Group 1, 2.6% discontinued', 'the study while 1.7% of patients in Group 2 discontinued due to side effects.', '1.4.1 Age Specific Data from PALOMA-1, PALOMA-2 and PALOMA-3', 'Limited evidence exists to guide therapy with palbociclib and endocrine therapy in older', 'adults. In PALOMA-1, the mean age of patients was 64 with a range from 54-72. In', 'PALOMA-2, the median age of patients receiving palbociclib-letrozole was 62 with a range', 'from 30-89, with only 39.3% of participants age 65 and over with no published information', 'for patients older than 75. In PALOMA-3, the mean age of patients was 64 with a range', 'from 29 to 88. In PALOMA-3, only 25% of the participants were age 65 and over. Review', 'of the data obtained from 165 patients in the PALOMA-1 trial, as well as the 521 patients', 'in the PALOMA-3 trial, did not show any apparent differences in systemic exposure related', 'to age. A subgroup analysis of the efficacy and safety of first-line palbociclib plus letrozole', 'compared with letrozole alone in patients in the PALOMA-1 study evaluated 165', 'postmenopausal women. Of the 76 patients age 65 and older, 37 were treated with', 'palbociclib and letrozole, and the remainder received letrozole alone. Among patients', 'receiving palbociclib and letrozole the median PFS for patients age 65 and over was 26.6', 'months (95% CI 12.6-NR) in comparison to 7.7 months (95% 13.7-10.9) for patients who', '9', 'NCI Version Date: 5/29/2020', 'Update 5']"
9,page_10,"['Alliance A171601', 'received letrozole alone. Grade 3-4 neutropenia occurred in 56.8% of patients receiving', 'palbociclib and letrozole (compared to 2.7% in patients with letrozole alone). In addition,', 'grade 3-4 leukopenia occurred in 29.7% of the patients receiving palbocic lib and letrozole,', 'and grade 3-4 fatigue was reported in 10.8% of patients receiving palbocic lib and letrozole.', 'Neither of these adverse events occurred in any patients taking letrozole alone.', '31', 'Another subset analysis of the PALOMA-1 study evaluated the time to onset of neutropenia,', 'leukopenia, anemia, and thrombocytopenia. They found that 97.9% of all adverse events', 'occurred within the first 6 months and stayed relatively stable or decreased in incidence over', 'time. Within the first 6 months, 69.5% of the 95 participants presented with neutropenia,', '33.7% with leukopenia, and 22.1% with anemia. The median time to onset for neutropenia', 'was 20 days, for leukopenia was 36 days, for anemia was 168 days, and for', 'thrombocytopenia was 140 days. They did not see any evidence of specific cumulative or', 'late onset of toxicity with treatment on palbocicl lib and letrozole. 32', '1.4.2 Filling a Gap in Knowledge', 'Palbociclib and endocrine therapy is emerging as a novel treatment for estrogen receptor', 'positive metastatic breast cancer. A gap in knowledge specifically exists with regard to the', 'tolerability of this combination in adults age 70 and over. This is an important research area,', 'sincecancer is a disease associated with aging. Twenty percen of patients with breast cancer', 'are age 70 and older. This phase II study will evaluate the safety and tolerability of the', 'combination of palbociclib and letrozole or fulvestrant in patients age 70 and over, as well', 'as describe the full toxicity profile, estimate the objective response rate and clinical benefit,', 'as well as survival. A geriatric assessment and measures of adherence will be included', 'within the study. Overall our goal is to close this gap in knowledge in older adults with', 'metastatic breast cancer who may derive significant benefit from this novel treatment', 'option.', '1.4.3 Rationale for the Study', 'Limited evidence exists to guide therapy with targeted agents in the older adult population', 'because older adults have been under-represented in clinical trials. Adults age 70 and older', 'make up only 20% of subjects enrolled in FDA registration trials but 46% of all patients', 'with cancer diagnoses. Dose-finding studies specifically in older adults are not routinely', 'performed. This is despite changes in drug metabolism, absorption, and distribution with', 'increasing age. The combination of palbociclib and endocrine therapy is a novel treatment', 'approach for postmenopausal women with estrogen receptor positive, human epidermal', 'growth factor receptor 2 (HER2)-negative advanced breast cancer. The combination', 'significantly improves progression-free survival compared to endocrine therapy alone.', 'However, these studies primarily focused on women less than age 75. For example, the', 'randomized phase II trial (PALOMA-1) of palbociclib and letrozole compared to letrozole', 'alone (mean age 63 and 64, respectively) only included 8 patients age 75 and older, and the', 'phase III trial (PALOMA-3) of palbociclib and fulvestrant compared to fulvestrant alone', '(mean age 57 and 56, respectively) included only 25% of participants age 65 and older,', 'while not reporting on participants age 75 and older. 1,2 In PALOMA-2, the median age of', 'patients receiving palbociclib-letrozole was 62 with a range from 30-89, with only 39.3%', 'of participants age 65 and over with no published information for patients older than 75. In', 'addition, the pivotal trial of palbociclit and letrozole reported in the package insert notes', 'that 37 patients (44%) were > 65 years of age and only 8 patients (10%) were > 75 years of', 'age.', 'The most common adverse events of palbocic lib in combination with endocrine therapy are', 'neutropenia, leukopenia, and fatigue. In particular, in PALOMA-1 patients receiving the', '10', 'NCI Version Date: 5/29/2020', 'Update 5']"
10,page_11,"['Alliance A171601', 'combination palbociclib and letrozole experienced grade 3 or 4 neutropenia (54%),', 'leukopenia (19%), or fatigue (4%). In PALOMA-3, patients receiving palbociclib and', 'fulvestrant experienced grade 3 or 4 neutropenia (62%), leukopenia (25.2%), or fatigue', '(2%). The package insert specifically warns of potential febrile neutropenia and infection;', 'although, neutropenic fever is very rare with the combination (PALOMA-1 with 0%,', 'PALOMA-3 with 0.6%). In addition, the package insert includes warning of', 'thromboembolism (PALOMA-1 with 4%, PALOMA-3 with 0%). These side effects are of', 'particular concern in older adults. In particular, there is a decrease in bone marrow reserve', 'with aging, hence amplifying the potential risk of neutropenia and myelosuppression.', 'Furthermore, older adults often have other co-morbid medical conditions which may', 'predispose them to thromboembolism thereby increasing the risk. Because of this, a', 'definitive study in the older adult population will diminish any reservations oncologists may', 'have in prescribing palbociclit with letrozole or fulvestrant and can provide guidance', 'regarding the dosing and toxicity management in older adults.', 'This is an open label, single arm, phase II study of the combination of palbociclit and', 'letrozole or fulvestrant in 88 patients age 70 or over with estrogen receptor positive, HER2', 'negative metastatic breast cancer. The primary goal of this study is to estimate the safety', 'and tolerability (adverseeventrate) of the combination of palbociclib and endocrine therapy', 'in older adults with estrogen receptor positive, HER2 negative metastatic breast cancer.', 'Secondary aims are to describe the full toxicity profile, describe dose modifications,', 'evaluate disease response in this population, evaluate patient adherence and treatment', 'perspective, and to explore factors other than chronologic age that predict toxicity using a', 'cancer-specific geriatric assessment. Correlative studies in this proposal will also aim to', 'evaluate circulating markers of inflammation as potential markers predictive of toxicity or', 'physical function as assessed by the cancer-specific geriatric assessment, and to examine', 'single nucleotide polymorphisms (SNPs) in cell cycle genes and genes that metabolize', 'palbociclib.', '1.5', 'Measurement of Sarcopenia', '1.5.1 Background and Methods', 'Age-related loss of muscle mass and function, otherwise known as sarcopenia, is highly', 'prevalent in older adults and associated with functional impairment, disability, loss of', 'independence, and mortality. 33-35 Losses in skeletal muscle mass and strength are apparent', 'as early as the 4th decade of life and progress linearly with increasing age. 36 Sarcopenia', 'in', 'older adults with cancer is additionally complicated by cancer-related cachexia and', 'frailty. 37,38 The elevated inflammatory response and alterations in metabolism related to', 'cancer cachexia lead to further losses of muscle mass 39,40 There is a high prevalence of', 'sarcopenia in adults with breast cancer, particularly in older adults (~63%) 41 Sarcopenia', 'has been associated with increased grade 3/4 chemotherapy toxicity, hospitalizations, and', 'adverse events in adults with metastatic breast cancer undergoing taxane-based', 'chemotherapy42 The presence or absence of sarcopenia may help explain the inter-', 'individual variability in treatment tolerability of older adults with cancer and could', 'ultimately be used to individualize treatment planning. Although there have been several', 'studies examining the association of sarcopenia and chemotherapy, this unique small study', 'will explore its association with targeted therapy in older adults. This proposal also aims to', 'evaluate the impact of sarcopenia on targeted therapy toxicity and adverse events in older', 'adults with breast cancer undergoing treatment with palbociclib and endocrine therapy.', 'Practical and precise measurement approaches have been developed to quantify body', 'composition in patients with cancer using CT images acquired during routine care that', '11', 'NCI Version Date: 5/29/2020', 'Update 5']"
11,page_12,"['Alliance A171601', 'require minimal additional resource allocation. 43 The L3 landmark from cross-sectional', 'imaging has been identified as the strongest predictor of whole body fat and fat-free mass', 'when compared to dual-energy x-ray absorptiometry (DXA). 43 The advantage of using', 'advanced imaging modalities, such as CT imaging, is the ability to provide additional', 'qualitative measurements of muscle and fat beyond purely quantitative measures 44', '1.6', 'Quality of Life Questionnaires: EuroQol 5D 3L and EQ Visual Analog Scale (EQ VAS)', 'In addition to the reporting of symptoms, understanding how quality of life may be affected by', 'palbociclib and hormonal therapy in the metastatic setting in older patients has not been', 'evaluated previously and will add important information to this study. The EQ-5D (Appendix', 'V) is a measure of health status for use in evaluating health and healthcare. The EQ-5D-3L is', 'comprised of 2 pages: the EQ-5D descriptive system (page 1) and the EQ visual analogue scale', '(EQ VAS) (page 2). It provides a simple descriptive profile of five functional dimensions:', 'mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It generates a', 'single index value for health status on which full health is assigned a value of 1 and death a', 'value of 0. Thus, the index can be used to obtain a utility for these dimensions for use in', 'economic analyses. The EQ-5D has been specially designed to complement other quality of life', 'measures such as the SF-36, or cancer-specific measures. Each dimension has three levels', ""designated simply as 'no problem', 'some problem', or extreme problem', with patients checking"", 'the level most descriptive of their current level of function on each dimension. Five dimensions,', 'each with three levels, yield 243 possible distinct health states comprising the classification', 'system. The classification system has been assigned different standardized scores derived', 'through population-based samples of respondents who assign values to subsets of the 243 states', 'using the anchoring labels noted above. For example, health state 11212 represents a patient', 'who indicates some problems on the usual activities and anxiety/depression dimensions. A set', 'of valuation weights has thus been derived from a U.S. sample. 45 The Agency for Healthcare', 'Research and Quality has funded a study to develop definitive weights. EQ-5D is designed for', 'self-completion by patients and has been used extensively in mailed surveys. It is cognitively', 'simple, taking no more than a few minutes to complete.', '1.7', 'PRO-CTCAE', 'We will evaluate how well symptoms reported by patients correlate/agree with those compared', 'to what is reported in clinic using traditional AE evaluations.', 'Patient-reported outcomes (PRO) are an important part of new drug evaluation and may play a', 'role in regulatory approval of novel agents in oncology 46 PROs can be the consequences of', 'disease and/or its treatment as reported by the patient. PROs are evaluated through the use of', 'questionnaires developed to assess topics a patient can report about his or her own health and', 'are often completed electronically. This includes symptoms, physical functioning, and mental', 'health.', 'The current standard mechanism for reporting toxicities in cancer research is clinician-only', 'reporting using items from the National Cancer Institute (NCI) CTCAEs. In multiple studies,', 'PRO measures have improved the predictive accuracy of clinician CTCAE reporting. In a', ""prospective study including lung cancer patients' PRO measurements of toxicities better"", ""reflected patients' underlying state and functional status than clinician's evaluation 47 Although"", 'PROs have been well validated 48,49,50,51 these examinations have been minimally evaluated for', 'feasibility and accuracy in an older patient group and will meaningfully add to the data collection', 'on this study.', '12', 'NCIVersion Date: 5/29/2020', 'Update 5']"
12,page_13,"['Alliance A171601', 'We will focus our PROs on side effects most commonly reported in prior studies with', 'palbociclib and hormonal therapy and which of are of most interest, including all symptoms', 'listed in Appendix VI.', 'All surveys will be given to patients on paper, at the same time points as in-clinic evaluations', 'through cycle 6, unless patients come off study prior to cycle 6. We will use the PRO-CTCAE', 'items developed by the National Cancer Institute in order to allow patients to self-report the', 'above symptomatic adverse events. The primary purpose of the inclusion of PRO-CTCAE is to', 'evaluate the performance and agreement of patient-reported outcomes with those collected as', 'linician-reported CTCAEs.', '2.0', 'OBJECTIVES', '2.1', 'Primary Objective', 'To estimate the safety and tolerability (adverse event rate) of the combination of palbocic lib and', 'letrozole or fulvestrant in adults age 70 or older with estrogen receptor-positive, HER2-negative', 'metastatic breast cancer.', '2.2', 'Secondary objectives', '2.2.1 To describe the full toxicity profile inc cluding all grade 2 and higher adverse events (per NCI', 'CTCAE v.5.0), specifically estimating the rate of grade 2 and higher myelosuppression', '(neutropenia, leukopenia, thrombocytopenia, and anemia), neutropenic fever, GI side effects', '(nausea, diarrhea, decreased appetite, vomiting, mucositis-oral), fatigue, neuropathy, and', 'thromboembolism.', '2.2.2 To describe rates of dose reductions, dose holds, and hospitalizations.', '2.2.3 To estimate median time to treatment failure, including progression free survival and overall', 'survival.', '2.2.4 To estimate the rate of adherence to palbociclib, letrozole and fulvestrant.', '2.2.5 To explore factors other than chronologic age that can affect toxic ity rates as identified using', 'a cancer-specific geriatric assessment.', '2.2.6 To describe the results of the Was It Worth It (WIWI) Questionnaire and the Overall', 'Treatment Utility (OTU).', '2.2.7 To determine the degree of agreement between patient-reported AEs using PRO-CTCAE', 'measures and those reported using traditional collections for AEs.', '2.2.8 Toexamine the association between sarc openia and the development of toxicity and adverse', 'events.', '2.3', 'Correlative science objectives', '2.3.1 To explore the association between baseline chronic inflammatory mediator levels and', 'development of adverse events.', '2.3.2 To explore the association between baseline chronic inflammatory mediator levels and', 'treatment modification.', '2.3.3 To explore the association between baseline chronic inflammatory mediator levels and', 'baseline physical function as assessed by the cancer-specific geriatric assessment.', '13', 'NCI Version Date: 5/29/2020', 'Update 5']"
13,page_14,"['Alliance A171601', '2.3.4 To explore the association between baseline chronic inflammatory mediator levels and', 'decline in physical function as assessed by the cancer-specific geriatric assessment.', '2.3.5 To explore the correlation between inherited single nucleotide polymorphisms (SNPs) in', 'cell cycle pathway genes and in genes that metabolize palbociclit and treatment efficacy', 'and toxicity (clinical outcomes) in elderly patients undergoing combined endocrine therapy', 'plus palbociclib for estrogen receptor positive, HER2 negative metastatic breast cancer.', '2.3.6 To explore whether genes in CYP19A, CYP2A6 and ESRI will also correlate with treatment', 'efficacy and toxicity (clinical outcomes) in elderly patients undergoing combined endocrine', 'therapy plus palbociclib for estrogen receptor positive, HER2 negative metastatic breast', 'cancer.', '2.3.7 To refine a population pharmacokine model using NONMEM for palbociclit based on', 'that of Sun and Wang (ESMO Poster Presentation 462P 2014) taking account of relevant', 'intrinsic and extrinsic factors.', '2.3.8 To determine the intrapatient and interpatient variability of palbociclib exposure (AUC) in', 'older breast cancer patients receiving palbociclib plus letrozole/fulvestrant.', '2.3.9 To explore the exposure (AUC/Cmux) toxicity (neutropenia, thrombocytopenia) relationship', 'for palbociclib when combined with letrozole/fulvestrant in older breast cancer patients.', '14', 'NCIVersion Date: 5/29/2020', 'Update 5']"
14,page_15,"['Alliance A171601', '3.0', 'PATIENT SELECTION', 'For questions regarding eligibility criteria, see the Study Resources page. Please note that the', 'Study Chair cannot grant waivers to eligibility requirements.', '3.1', 'On-Study Guidelines', 'This clinical trial can fulfill its objectives only if patients appropriate for this trial are enrolled.', 'All relevant medical and other considerations should be taken into account when deciding', 'whether this protocol is appropriate for a particular patient. Physicians should consider the risks', 'and benefits of any therapy, and therefore only enroll patients for whom this treatment is', 'appropriate.', 'Physicians should consider whether any of the following may render the patient inappropriate', 'for this protocol:', 'Psychiatric illness which would prevent the patient from giving informed consent.', 'Medical condition such as uncontrolled infection (including HIV), uncontrolled', 'diabetes mellitus or cardiac disease which, in the opinion of the treating physician,', 'would make this protocol unreasonably hazardous for the patient.', 'Concomitant medications:', 'Chronic concomitant treatment with strong inhibitors of CYP3A is strongly discouraged', 'on this study. Patients on strong CYP3A inhibitors must discontinue the drug prior to', 'registration on the study. See section 8.1.10 for more information.', 'Chronic concomitant treatment with strong CYP3A inducers is strongly discouraged', 'Patients must discontinue the drug prior to the start of study treatment. See section', '8.1.11 for more information.', 'Chronic concomitant treatment with CYP2A6 substrates is strongly discouraged for', 'patients who are being treated with letrozole. Patients must discontinue the drug prior', 'to the start of study treatment. See section 8.1.12 for more information.', 'Life expectancy of less than 6 months', '15', 'NCIVersion Date: 5/29/2020', 'Update 5']"
15,page_16,"['Alliance A171601', '3.2', 'Eligibility Criteria', ""Use the spaces provided to confirm a patient's eligibility by indicating Yes or No as appropriate."", 'It is not required to complete or submit the following page(s).', 'When calculating days of tests and measurements, the day a test or measurement is done is', 'considered Day 0. Therefore, if a test were done on a Monday, the Monday one weeklater would', 'be considered Day 7.', '3.2.1', 'Documentation of Disease: Estrogen receptor positive and/or progesterone', 'receptor (PR) positive, HER2 negative metastatic breast cancer. Histologic', 'confirmation is required.', '3.2.2', 'Measurable disease or non-measurable disease (see Section 11.3)', '3.2.3', 'Planning to begin palbociclib for metastatic disease. One prior line of', 'endocrine therapy and/or chemotherapy for metastatic disease is allowed.', 'Patients may begin or have already begun endocrine therapy before they start palbociclib', 'treatment, but no more than two weeks prior to registration.', '3.2.4', 'No prior therapy with a CDK inhibitor.', '3.2.5', 'Resolution of all acute toxic effects of prior therapy or surgical procedures to', 'CTCAE Grade 1 (except alopecia) or to baseline toxicities prior to previous therapy', 'or surgical procedures, prior to registration.', '3.2.6', 'No untreated brain metastases. Patients with treated brain metastases must have', 'completed treatment with steroids to be eligible.', '3.2.7', 'No known interstitial lung disease.', '3.2.8. No second malignancies other than non-melanoma skin cancers or cervical', 'carcinoma in situ. However, patients are not considered to have a ""currently active""', 'malignancy if they have completed therapy and are free of disease for > 3 years.', '3.2.9', 'No active infection requiring treatment with antibiotics.', '3.2.10', 'Patients must be able to swallow and retain oral medication.', '3.2.11', 'Patient Age: > 70 years', '3.2.12', 'ECOG Performance Status 0, 1 or 2.', '3.2.13', 'Patients must be able to read and comprehend English or Spanish.', '3.2.14', 'Required Initial Laboratory Values:', 'Absolute neutrophil count > 1500/mm³ (1.5 X 109/L)', '(ANC)', 'Platelet count: > 100,000/mm³ (100x 109/L)', 'Creatinine clearance:', '30 ml/min*', 'Total serum bilirubin', ""VI 1.5 ULN (<3 ULN if Gilbert's disease)"", 'AST and/or ALT VI 3 X ULN ( 5.0 X ULN if liver metastases', 'present)', 'Alkaline phosphatase < 2.5 X ULN (< 5 X ULN if bone or liver', 'metastases present)', '* Calculated using the Cockcroft-Gault formula', '16', 'NCIVersion Date: 5/29/2020', 'Update 5']"
16,page_17,"['Alliance A171601', '4.0', 'PATIENT Registration', '4.1', 'Investigator and Research Associate Registration with CTEP', 'Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy', 'require all individuals contributing to NCI-sponsored trials to register and renew their', 'registration annually. To register, all individuals must obtain a Cancer Therapy Evaluation', 'Program (CTEP) Identity and Access Management (IAM) account', 'at', 'In addition, persons with a registration type of Investigator', '(IVR), Non-Physician Investigator (NPIVR), or Associate Plus (AP) must complete their annual', ""registration using CTEP's web-based Registration and Credential Repository (RCR) at"", 'RCR utilizes five person registration types.', 'IVR - MD, DO, or international equivalent;', 'NPIVR - advanced practice providers (e.g., NP or PA) or graduate level', 'researchers (e.g., PhD);', 'AP - clinical site staff (e.g., RN or CRA) with data entry access to CTSU', 'applications such as the Roster Update Management System [RUMS], OPEN,', 'Rave, acting as a primary site contact, or with consenting privileges;', 'Associate (A) - other clinical site staff involved in the conduct of NCI-', 'sponsored trials; and', 'Associate Basic (AB) - individuals (e.g., pharmaceutical company', 'employees) with limited access to NCI-supported systems.', 'RCR requires the following registration documents:', 'Documentation Required', 'IVR', 'NPIVR', 'AP', 'A', 'AB', 'FDA Form 1572', 'Financial Disclosure Form', 'NCI Biosketch (education, training, employment,', 'license, and certification)', 'GCP training', 'Agent Shipment Form (if applicable)', 'CV (optional)', 'An active CTEP-IAM user account and appropriate RCR registration is required to access all', 'CTEP and Cancer Trials Support Unit (CTSU) websites and applications. In addition, IVRs and', 'NPIVRs must list all clinical practice sites and Institutional Review Boards (IRBs) covering', 'their practice sites on the FDA Form 1572 in RCR to allow the following:', 'Addition to a site roster;', 'Assign the treating, credit, consenting, or drug shipment (IVR only) tasks in', 'OPEN;', 'Act as the site-protocol Princ ipal Investigator (PI) on the IRB approval; and', '17', 'NCIVersion Date: 5/29/2020', 'Update 5']"
17,page_18,"['Alliance A171601', 'Assign the Clinical Investigator (CI) role on the Delegation of Tasks Log', '(DTL).', 'In addition, all investigators acting as the Site-Protocol PI (investigator listed on the IRB', 'approval), consenting/treating/drug shipment investigator in OPEN, or as the CI on the DTL', 'must be rostered at the enrolling site with a participating organization.', 'Additional', 'information', 'is', 'located', 'on', 'the', 'CTEP', 'website', 'at', 'For questions, please contact the', 'RCR Help Desk by email at', '.', '4.2', 'CTSU Registration Procedures', 'Permission to view and download this protocol and its supporting documents is restricted and is', 'based on person and site roster assignment housed in the CTSU Regulatory Support System', '(RSS).', 'This study is supported by the NCI Cancer Trials Support Unit (CTSU).', 'IRB Approval', 'For CTEP and Division of Cancer Prevention (DCP) studies open to the National Clinical Trials', 'Network (NCTN) and NCI Community Oncology Research Program (NCORP) Research Bases', 'after March 1, 2019, all U.S.-based sites must be members of the NCI Central Institutional', 'Review Board (NCI CIRB). In addition, U.S.-based sites must accept the NCI CIRB review to', 'activate new studies at the site after March 1, 2019. Local IRB review will continue to be', 'accepted for studies that are not reviewed by the CIRB, or if the study was previously open at', 'the site under the local IRB. International sites should continue to submit Research Ethics Board', '(REB) approval to the CTSU Regulatory Office following country-specific regulations.', 'Sites participating with the NCI CIRB must submit the Study Specific Worksheet for Local', 'Context (SSW) to the CIRB using IRBManager to indicate their intent to open the study locally.', ""The NCI CIRB's approval of the SSW is automatically communicated to the CTSU Regulatory"", 'Office, but sites are required to contact the CTSU Regulatory Office at', 'to establish site preferences for applying NCI CIRB approvals', 'across their Signatory Network. Site preferences can be set at the network or protocol level.', 'Questions about establishing site preferences can be addressed to the CTSU Regulatory Office', 'by email or calling', 'Sites using their local IRB or REB, must submit their approval to the CTSU Regulatory Office', 'using the Regulatory Submission Portal located in the Regulatory section of the CTSU website.', 'Acceptable documentation of localIRB/REB approval includes:', 'Local IRB documentation;', 'IRB-signed CTSUIRB Certification Form; and/or', 'Protocol of Human Subjects Assurance Identification/IRB Certification/Declaration of', 'Exemption Form.', 'In addition, the Site-Protocol Principal Investigator (PI) (i.e. the investigator on the IRB/REB', 'approval) must meet the following criteria in order for the processing of the IRB/REB approval', 'record to be completed:', 'Holds an active CTEP status;', 'Rostered at the site on the IRB/REB approval (applies to US and Canadian', 'sites only) and on at least one participating roster;', 'If using NCI CIRB, rostered on the NCI CIRB Signatory record;', '18', 'NCIVersion Date: 5/29/2020', 'Update 5']"
18,page_19,"['Alliance A171601', 'Includes the IRB number of the IRB providing approval in the Form FDA 1572', 'in the RCR profile; and', 'Holds the appropriate CTEP registration type for the protocol.', 'Additional Requirements:', 'Additional requirements to obtain an approved site registration status include:', 'An active Federal Wide Assurance (FWA) number;', 'An active roster affiliation with the Lead Protocol Organization (LPO) or a', 'Participating Organization (PO); and', 'Compliance with all protocol-specific requirements (PSRs).', '4.2.1 Protocol Specific Requirements for A171601 Site Registration', 'Evidence of Geriatric Assessment Training, as described in Section 15.0', 'IROC credentialing:', 'This is a study with a radiation and/or imaging (RTI) component and the enrolling site must', 'be aligned to an RTI provider. To manage provider associations or to add or remove', 'associated providers, access the Provider Association page from the Regulatory section on', ""the CTSU members' website at"", 'Sites', 'must be linked to at least one Imaging and Radiation Oncology Core (IROC) provider to', 'participate on trials with an RTI (component. Enrolling sites areresponsible for ensuring that', 'the appropriate agreements and IRB approvals are in place with their RTI provider. An', 'individual with a primary role on any roster is required to update provider associations,', 'though all individuals at a site may view provider associations. To find who holds primary', 'roles at your site, view the Person Roster Browser under the RUMS section on the CTSU', 'website.', '4.2.2 Downloading Site Registration Documents', 'Download the site registration forms from the protocol-specific page located on the CTSU', ""members' website. Permission to view and download this protocol and its supporting"", 'documents is restricted based on person and site roster assignment. To participate, the', 'institution and its associated investigators and staff must be associated with the LPO or a', 'Protocol Organization (PO) on the protocol. One way to search for a protocol is listed', 'below.', ""Log in to the CTSUmembers' website"", 'using your CTEP-IAM', 'username and password;', 'Click on Protocols in the upper left of the screen', 'Enter the protoco number in the search field at the top of the protocol tree;', 'or', 'Click on the By Lead Organization folder to expand, then select [Alliance],', 'and protocol number [A171601].', 'Click on Documents, select Site Registration, and download and complete the forms', 'provided. (Note: For sites under the CIRB, IRB data will load automatically to the', 'CTSU.)', '19', 'NCIVersion Date: 5/29/2020', 'Update 5']"
19,page_20,"['Alliance A171601', '4.2.3 Submitting Regulatory Requirements', 'Submitrequired forms and documents to the CTSURegulatory Officeusing the Regulatory', 'Submission Portal on the CTSU website.', ""To access the Regulatory Submission Portal log in to the CTSU members' website, go to"", 'the Regulatory section and select Regulatory Submission.', 'Institutions with patients waiting that are unable to use the Regulatory Submission Portal', 'should alert the CTSU Regulatory Office immediately at', 'in order to', 'receive further instruction and support.', ""4.2.4 Checking Your Site's Registration Status"", ""Site registration status may be verified on the CTSUmembers' website."", 'Click on Regulatory at the top of the screen;', 'Click on Site Registration; and', 'Enter the sites 5-character CTEP Institution Code and click on Go.', 'Additional filters are available to sort by Protocol, Registration Status,', 'Protocol Status, and/or IRB Type.', 'Note: The status shown only reflects institutional compliance with site registration', 'requirements as outlined within the protocol. It does not reflect compliance with protocol', ""requirements for individuals participating on the protocol or the enrolling investigator's"", 'status with NCI or their affiliated networks.', '4.2.5 Credentialing', 'See Section 15.0 for credentialing requirements for Geriatric Assessment Training.', '4.3', 'Patient Registration Requirements', 'Informed consent: The patient must be aware of the neoplastic nature of his/her disease and', 'willingly consent after being informed of the procedure to be followed, the experimental nature', 'of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts. Current', 'human protection committee approval of this protocol and a consent form is required prior to', 'patient consent and registration.', 'Patient completed booklets: Patient questionnaire booklets are to be ordered prior to the', 'registration of any patients. Patient completed booklets in English and Spanish can be ordered', 'by downloading and completing the CTSU supply request form (located under the site', 'registration section of the CTSU protocol specific website) and submitting the form through the', 'CTSU regulatory portal. Samples of the booklets in English are found in Appendices II-VII and', 'electronic versions of the booklets in Spanish are available on the Alliance and CTSU web sites.', 'These are to be used for reference and IRB submission only. They are not to be used for patient', 'completion.', 'Protected Health Information: Whole blood samples collected for the pharmacokinetics sub-', 'study A171601-PP1 will be sent directly to the University of Pittsburgh Cancer Center. These', 'samples will be labeled with patient initials, study ID and collection date/time.', '4.4', 'Patient Registration/Randomization Procedures', 'The Oncology Patient Enrollment Network (OPEN) is a web-basedregistration system available', 'on a 24/7 basis. OPEN is integrated with CTSU regulatory and roster data and with the LPOs', '20', 'NCIVersion Date: 5/29/2020', 'Update 5']"
20,page_21,"['Alliance A171601', 'registration/randomization systems or the Theradex Interactive Web Response System (IWRS)', 'for retrieval of patient registration/randomization assignment. OPEN will populate the patient', ""enrollment data in NCI's clinical data management system, Medidata Rave."", 'Requirements for OPEN access:', 'A valid CTEP-IAM account;', 'To perform enrollments or request slot reservations: Must be on an LPO roster, ETCTN', 'corresponding roster, or participating organization roster with the role of Registrar.', 'Registrars must hold a minimum of an Associate Plus (AP) registration type;', 'If a Delegation of Tasks Log (DTL) is required for the study, the registrars must hold', 'the OPEN Registrar task on the DTL for the site; and', 'Have an approved site registration for the protocol prior to patient enrollment.', 'To assign an Investigator (IVR) or Non-Physician Investigator (NPIVR) as the treating,', 'crediting, consenting, drug shipment (IVR only), or receiving investigator for a patient transfer', ""in OPEN, the IVR or NPIVR must list the IRB number used on the site's IRB approval on their"", 'Form FDA 1572 in RCR. If a DTL is required for the study, the IVR or NPIVR must be assigned', 'the appropriate OPEN-related tasks on the DTL.', 'Prior to accessing OPEN, site staff should verify the following:', 'Patient has met all eligibility criteria within the protocol stated timeframes; and', 'All patients have signed an appropriate consent form and HIP. AA authorization form (if', 'applicable).', 'Site staff have completed the Geriatric Assessment training described in Section 15.0.', 'Note: The OPEN system will provide the site with a printable confirmation of registration and', 'treatment information. You may print this confirmation for your records.', 'Access OPEN at', ""or from the OPEN link on the CTSU members' website."", 'Further instructional information is in the OPEN section of the CTSU website at', 'For any additional questions, contact the CTSU', 'Help Desk at', 'To receive site reimbursement for specific tests and/or bio-specimen submissions, completion', 'dates must be entered in the OPENFunding screen postregistration Pleaserefer to the protocol-', ""specific funding page on the CTSU members' website for additional information. Timely entry"", 'of completion dates is recommended as this will trigger site reimbursement.', '4.5', 'Registration to Correlative and Companion Studies', '4.5.1 Registration to Sub studies described in Section 14.0', 'There are 3 sub studies within Alliance A171601. These studies must be offered to all', 'patients enrolled on Alliance A171601 (although patients may opt to not participate). These', 'sub studies do not require separate IRB approval. The sub studies included within Alliance', 'A171601 are:', 'Circulating markers of inflammation as potential markers predictive of toxicity among', 'elderly patients enrolled to Alliance A171601: Alliance A171601-ST1 (Section 14.1)', 'Genetic determinants of Palbociclib Efficacy and toxicity in the elderly: Alliance', 'A171601-ST 2 (Section 14.2)', 'Population Pharmacokinetics of Palbociclib: Alliance A171601-PP1 (Section 14.3)', '21', 'NCIVersion Date: 5/29/2020', 'Update 5']"
21,page_22,"['Alliance A171601', 'If a patient answers ""yes"" to ""I agree to have my specimen collected and I agree that my', 'specimen sample(s) and related information may be used for the laboratory studies described', ""above.,' Question #1 in the model consent, they have consented to participate in the sub"", 'studies described in Section 14.1, , Section 14.2 and Section 14.3. The patient should be', 'registered to Alliance A171601 -ST1, A171601-ST2 and A171601-PP1 at the same time', 'they are registered to the treatment trial (A171601). Samples should be submitted per', 'Section 6.2.', '4.6', 'Grouping Factor', '4.6.1 Age 70-74 vs.>75', '22', 'NCIVersion Date: 5/29/2020', 'Update 5']"
22,page_23,"['Alliance A171601', '5.0', 'STUDY CALENDAR', 'The pre-study testing intervals are guidelines only. Laboratory and clinical parameters during', 'treatment are to be followed using individual institutional guidelines and the best clinic: al judgment', 'of the responsible physician. It is expected that patients on this study will be cared for by physic ians', 'experienced in the treatment and supportive care of patients on this trial.', 'Pre-Study Testing Intervals:', 'To be completed 14 DAYS before registration: All laboratory studies, history and physical,', 'concomitant medications and baseline adverse event assessment.', 'To be completed< 42 DAYS before registration: CT and bone scan, or PET scan', 'Prior to', 'Cycles and 2', 'Day 1 of every cycle starting', 'Every 3 mths from', 'At end of', 'registrati', 'with Cycle 3 for year 1 of', 'year 2 untilend of', 'protocol', 'on', 'Day 1*', 'Day 15*', 'treatment*', 'treatment(+/-8 days)', 'treatment', 'Tests and Observations', 'History and Physical', 'X', 'X', 'X', 'X', 'Adherenceevaluation', 'A', 'B', 'X', 'Adverse Event Reporting', 'X', 'X', 'X', 'X', 'X', 'PRO-CTCAE', 'X', 'X', 'X(1)', 'X(2)', 'Concomitant medications', 'X', 'X', 'X', 'X', 'Geriatric Assessment', 'C', 'B', 'X(2)', 'EQ-5D-3L', 'X', 'X(1)', 'X(2)', 'Was It WorthIt and Overall', 'X', 'Treatment Utility', 'Laboratory Studies', 'CBC, Differential, Platelets', 'X', 'X**', 'X', 'X', 'X', 'CMP*', 'X', 'X**', 'X', 'X', 'X', 'Staging', 'CT chest/abd+/-pelvis - or PET', 'X', 'D', 'X', 'Bone Scan, Whole Body', 'X(3)', 'D', 'X', 'Correlative studies for patients who consent to participate', 'Whole Blood and Plasma', 'To be collected at the timepoints described in Section 6.2', '*', '+/- 2 days. 1 cycle = 28 days. (All Day 1 baseline assessments may be completed any time after registration but before', 'treatment. H&P neednot be repeated for Day 1 if done within a 30 day window prior to Day 1 of Cycle 1.)', 'Need not be repeated if done within the last 7 days', 'CMP includes electrolytes (sodium, potassium, chloride, bicarbonate), renal function (bloodurea nitrogen ndcreatinine) liver', 'function tests (AST, ALT, alk. phos., total bilirubin, direct bilirubin only if clinically indicated), total protein, albumin, and calcium', '+', 'At the end of protocol treatment patients will complete the Geriatric Assessment and the end of treatment booklet. Patients will', 'then be followed every year for survival only, up to 5 years', '1', 'PRO-CTCAE and EQ-5L-3D required only for the first 6 cycles of protocol therapy during the first year of treatment', '2', 'Does not need to be repeated if done within the last 30 days.', '3', 'Radionuclide bone scan is not required if baseline PET scan was done. Bone scan after baseline is required only if indicative', 'of metastases at baseline or if signs or symptoms suggestive of metastases development.', 'A', 'End of cycle 1 and 2', 'B', 'Day 1, Cycle 4 only', 'C', 'Cycle 1 only', 'D', 'Day 1 of Cycle 4 (+/-2 weeks), then every 12 weeks (+/-2 weeks) until end of treatment. Response assessment should include', 'assessment of all sites of disease and use the same imaging method as was used at baseline. See Section 6.3 for instructions on', 'submission of images.', '23', 'NCI Version Date: 5/29/2020', 'Update 5']"
23,page_24,"['Alliance A171601', '6.0', 'DATA AND SPECIMEN SUBMISSION', '6.1', 'Data Collection and Submission', '6.1.1 Data submission schedule:', 'A Schedule of Forms is available on the Alliance study webpage, within the Case Report', 'Forms section. The Schedule of Forms is also available on the CTSUsite within the Case', 'Report Forms tab.', '6.1.2 Medidata Rave', 'Medidata Rave is a clinical data management system being used for data collection for this', 'trial/study. Access to the trial in Rave is controlled through the CTEP-IAM system and', 'role assignments.', 'Requirements to access Rave via iMedidata:', 'A valid CTEP-IAM account; and', 'Assigned a Rave role on the LPO or PO roster at the enrolling site of: Rave CRA, Rave', 'Read Only, Rave CRA (LabAdmin), Rave SLA, or Rave Investigator.', 'Rave role requirements:', 'Rave CRA or Rave CRA (Lab Admin) role must have a minimum of an Associate', 'Plus (AP) registration type;', 'Rave Investigator role must be registered as an Non-Physician Investigator', '(NPIVR) or Investigator (IVR); and', 'Rave Read Only role must have at a minimum an Associates (A) registration type.', 'Refer to', 'for registration types', 'and documentation required.', 'Upon initial site registration approval for the study in Regulatory Support System (RSS),', 'all persons with Rave roles assigned on the appropriate roster will be sent a study invitation', 'e-mail from iMedidata. To accept the invitation, site staff must log in to the Select Login', 'using their CTEP-IAM username and password', 'and click on the accept link in the upper right-corner of the iMedidata page. Site staff will', 'not be able to access the study in Rave until all required Medidata and study specific', 'trainings are completed. Trainings will be in the form of electronic learnings (eLearnings)', 'and can be accessed by clicking on the link in the upper right pane of the iMedidata screen.', 'If an eLearning is required and has not yet been taken, the link to the eLearning will appear', 'under the study name in iMedidata instead of the Rave EDC link; once the successful', 'completion of the eLearning has been recorded, access to the study in Rave will be granted,', 'and a Rave EDC link will display under the study name.', 'Site staff that have not previously activated their iMedidata/Rave account at the time of', 'initial site registration approval for the study in RSS will receive a separate invitation from', 'iMedidata to activate their account. Account activation instructions are located on the', 'CTSU website in the Data Management section under the Rave resource materials', '(Medidata Account Activation and Study Invitation Acceptance). Additional information', ""on iMedidata/Rave is available on the CTSU members' website in the Data Management"", '> Rave section at', 'or by contacting the CTSU Help Desk at', '24', 'NCIVersion Date: 5/29/2020', 'Update 5']"
24,page_25,"['Alliance A171601', 'Patient-completed questionnaire booklets for this study are to be ordered prior to the', 'registration of any patients (see Section 4.3). Samples of the booklets in English are', 'found in Appendices II-VII and electronic versions of the booklets in Spanish are', 'available on the Alliance and CTSU web sites, for reference and IRB submission only.', 'They are not to be used for patient completion. Booklets must be given to patients to', 'complete and patients should be instructed to return the booklets to site staff either in', 'person or by mail and site staff will enter patient and caregiver responses into Rave.', '6.1.3 Data Quality Portal:', 'The Data Quality Portal (DQP) provides a central location for site staff to manage', 'unanswered queries and form delinquencies, monitor data quality and timeliness, generate', 'reports, and review metrics.', ""The DQP is located on the CTSU members' website under Data Management. The Rave"", 'Home section displays a table providing summary counts of Total Delinquencies and Total', 'Queries. DQP Queries, DQP Delinquent Forms and the DQP Reports modules are available', 'to access details and reports of unanswered queries, delinquent forms, and timeliness', 'reports. Review the DQP modules on a regular basis to manage specified queries and', 'delinquent forms.', 'The DQP is accessible by site staff that are rostered to a site and have access to the CTSU', 'website. Staff that have Rave study access can access the Rave study data using a direct', 'link on the DQP.', 'To learn more about DQP use and access, click on the Help icon displayed on the Rave', 'Home, DQP Queries, and DQP Delinquent Forms modules.', 'Note: Some Rave protocols may not have delinquent form details or reports specified on', 'the DQP. A protocolmust have the Calendar functionality implemented in Rave by the', 'Lead Protocol Organization for delinquent form details and reports to be available on the', 'DQP. Site staff should contact the LPO Data Manager for their protocol regarding', 'questions about Rave Calendaring functionality.', '6.1.4 Supporting documentation', 'This study requires supporting documentation for diagnosis, response, progression and', 'survival. Supporting documentation will include pathology and imaging reports and must', 'be submitted at the following time points:', 'Baseline: For patients with measurable disease only, pathology and imaging reports.', 'At Progression and response: Imaging reports and/or clinic notes, based on standard', 'RECIST criteria.', 'All supporting documentation should be de-identified according to institutional standards', 'prior to upload into RAVE.', '25', 'NCIVersion Date: 5/29/2020', 'Update 5']"
25,page_26,"['Alliance A171601', '6.2', 'Specimen collection and submission', 'For patients registered to substudy A171601-ST1, A171601-ST2 and A171601-PP1: All', 'participating institutions must ask patients for their consent to participate in the correlative', 'substudies planned for Alliance A171601-ST1, A171601-ST2 and A171601-PP1, although', 'patient participation is optional. Biomarker, pharmacogenetic studies and pharmac okinetic', 'studies will be performed. Rationale and methods for the scientific components of these studies', 'are described in Section 14.0. For patients who consent to participate, plasma and whole blood', 'will be collected at the following time points for these studies: Collection of plasma for toxicity', 'biomarker correlative studies will coincide with the Geriatric assessment on cycle 1 day 1, and', 'prior to cycle 4.', 'For all patients registered to A171601 ST1, A171601- - ST2 and A171601-PP1, submit the following:', 'Prior to', 'Cycles 1 & 2', 'Day 15 (Prior to', 'Storage/Shipping', 'Treatment', 'Prior to Cycle 4', 'Submit to:', 'conditions', 'treatment)', 'Whole Blood', '(EDTA/lavender', '10 mL', '10 mL', 'Cool pack/ship over', 'Mayo BAP', 'night', 'Freezer', 'top)', 'Whole Blood2', 'Cool pack/ship over', 'Mayo BAP', '(EDTA/lavender', '10 mL', 'night', 'Freezer', 'top)', 'Plasma from', 'Whole Blood³', 'University', '5 mL', '5 mL', 'Dry ice/ ship over', 'of', '(EDTA/lavender', 'night', 'Pittsburgh', 'top)', '1', 'Whole blood for Plasma to be used for biomarker analyses described in Section 14.1.', '2', 'Whole blood to be used for pharmacogenomic analyses described in Section 14.2.', '3', 'Pharmacokinetic analyses described in Section 14.3. Patients will be asked to complete a', 'pharmacokinetics questionnaire (Appendix ] IX) these visits (Baseline, Cycles 1 &2 Day', '15, prior to treatment). The questionnaire can be completed before or after the blood', 'draw. A copy of the questionnaire will be sent by site staff along with the samples to the', 'University of Pittsburgh. Questionnaire responses are to be entered into Rave by site', 'staff.', 'Note: Samples for A171601- PP1 substudy are only required for patients who are', 'registered (and consent to participate in the substudies) after Update 1. Patients enrolled', 'prior to the release of Update 1 will not be asked to provide additional samples.', '6.2.1 Specimen Submission Using the Alliance Biospecimen Management System', 'USE OF THE ALLIANCE BIOSPECIMEN MANAGEMENT SYSTEM (BioMS) IS', 'MANDATORY AND ALL SPECIMENS MUST BE LOGGED AND SHIPPED VIA THIS', 'SYSTEM.', 'BioMS is a web-based system for logging and tracking all biospecimens collected on', 'Alliance trials. Authorized individuals may access BioMS at the following URL:', 'using most standard web browsers', '(Safari, Firefox, Internet Explorer). For information on using the BioMS system, pleaserefer', 'to the ""Help\' links on the BioMS webpage to access the on-line user manual, FAQs, and', '26', 'NCI Version Date: 5/29/2020', 'Update 5']"
26,page_27,"['Alliance A171601', 'training videos. To report technical problems, such as login issues or application errors,', 'please contact:', 'For assistance in using', 'the application or questions or problems related to specific specimen logging, please', 'contact:', 'After logging collected specimens in BioMS, the system will create a shipping manifest.', 'This shipping manifest must be printed and placed in the shipment container with the', 'specimens.', 'All submitted specimens must be labeled with the protocol number (A171601), Alliance', ""patient number, patient's initials, date and type of specimen collected (e.g., serum, whole"", 'blood).', 'When specimens are time-sensitive, and/or are required for communication of test results', 'back to institutions and patients, they should be labeled with patient initials and date of', 'procurement, in addition to protocol 1number, Alliance patient number and specimen type.', 'Specimens that are not time-sensitive, and/or are not submitted for the purpose of', 'performing an integral test that will be reported back to patients, should not include patient', 'initials or date of procurement.', 'A copy of the Shipment Packing Slip produced by BioMS must be printed and placed in the', 'shipment with the specimens.', 'Instructions for the collection of samples are included below. Please be sure to use a method', 'of shipping that is secure and traceable. Extreme heat precautions should be taken when', 'necessary.', 'Specimens for the A171601-ST1 and A171601-ST2 sub-studies should be shipped Monday', 'through Friday marked for Saturday delivery. Shipping by overnight service to assure', 'receipt is encouraged. Do not ship specimens on Saturdays.', 'Specimens for the A171601-PP1 substudy should be sent to the following address:', 'All other specimens should be sent to the following address:', '6.2.2 Whole Blood sample submission for plasma (A171601-ST1)', 'For patients who consent to participate, whole blood collected for plasma samples will be', 'used for the biomarker analyses described in Section 14.1.', 'For EDTA plasma, collect 10 mL of whole blood by standard venous phlebotomy into the', 'EDTA tube, prior to treatment and prior to cycle 4. The tube should be inverted several', '27', 'NCI Version Date: 5/29/2020', 'Update 5']"
27,page_28,"['Alliance A171601', 'times to mix the EDTA and refrigerated until shipped on cool pack by overnight mail to the', 'Alliance Biorepository (Mayo BAP). The samples should be shipped the same day that the', 'blood is drawn per Section 6.2.1.', 'Label samples with the following identification:', '1)', 'Procurement date/time of collection', '2)', 'Alliance patient number', '3)', 'Patient initials', '4)', 'Alliance study number (i.e., A171601-ST1)', '5)', 'Specimen type', 'The 10ml of blood can be collected in one 10ml tube, or two 5ml tubes or three 3ml tubes,', 'as long as the final volume is - -10ml.', '6.2.3 Whole blood submission for pharmacogenomic studies (A171601-ST2)', 'For patients who consent to participate, whole blood samples will be used for the', 'pharmacogenomic studies described in Section 14.2. This sample should be collected prior', 'to the initiation of protocol treatment.', 'The following bio specimens will be collected at baseline:', 'Collect 10 mL of whole blood by standard venous phlebotomy into the EDTA tube. The', 'tube should be inverted several times to mix the EDTA and refrigerated until shipped on', 'cool pack by overnight shipping to the Alliance Biorepository (Mayo BAP). The samples', 'should be shipped the same day that the blood is drawn per Section 6.2.1.', 'Label samples with the following identification:', '1) Procurement date/time of collection', '2) Alliance patient number', '3) Patient initials', '4) Alliance study number (i.e., A171601-ST2)', '5) Specimen type', 'The 10ml of blood can be collected in one 10ml tube, or two 5ml tubes or three 3ml tubes,', 'as long as the final volume is - 10ml.', '6.2.4 Plasma submission for pharmacokinetic studies (A171601-PP1)', 'For patients who consent to participate, blood samples will be used for the pharmacokinetic', 'analyses described in Section 14.3.', 'Plasma from Whole Blood in EDTA Lavender Top Tube:', 'Prior to receiving protocol therapy on Cycle 1 day 1, Cycle 1 Day 15, and Cycle 2 Day 15,', 'patients consented to the A171601-PP1 substudy will be asked to complete a Patient', 'Pharmacokinetics Form (see Appendix IX) which will provide information about the', 'previous 48-hours of palbocicl lib dosing (i.e. details on dose and time). After completion,', 'the form should be collected, and the data should be reported in Rave on the Specimen', 'Submission Form for A171601-PP1. Collect 1 X 5 mL of peripheral venous blood in a', 'lavender top (EDTA) tube prior to the patient receiving the daily dosage of palbocic lib on', 'Cycle 1 Day 1 and Day 15, and Cycle 2 Day 15. Invert the tubes approximately 8-10 times', 'to mix the EDTA, and then centrifuge at room temperature for 10 minutes at 1500g. Aliquots', 'of plasma will then be placed in labelled polypropylene tubes (1 mL in each of two tubes)', 'and stored at - 70 to - 80°C until shipped on dry ice.', '28', 'NCI Version Date: 5/29/2020', 'Update 5']"
28,page_29,"['Alliance A171601', 'Label all plasma samples with the following identification information:', '1) Date of Collection', '2)', 'Time of Collection (i.e. actual time the blood sample was obtained)', '3) Alliance Patient ID Number', '4) Patient Initials', '5) Alliance Study Number (i.e. A171601-PP1)', '6) Sample Type (e.g. Plasma)', 'If labels are used, please ensure labels are carefully attached to the tubes and are not likely', 'to fall off when frozen or during shipping.', 'Ship specimens and copies of the completed Pharmacokinetics questionnaires to the', 'Alliance Laboratory at the University of Pittsburgh (See Section 6.2.1) with Priority', 'Overnight on Monday through Thursday for next day delivery. Do not ship specimens the', 'day before a holiday. The University of Pittsburgh does not accept Saturday deliveries.', '6.3', 'Digital Image Submission Using TRIAD', ""Transfer of Images and Data (TRIAD) is the American College of Radiology's (ACR) image"", 'exchange application. TRIAD provides sites participating in clinical trials a secure method to', 'transmit images. TRIAD anonymizes and validates the images as they are transferred.', '6.3.1 TRIAD Access Requirements', 'A valid CTEP-IAM account.', 'Registration and Credential Repository (RCR) registration type of: Associate (A),', 'Associate Plus (AP), Non-Physician Investigator (NPIVR), or Investigator (IVR)', 'registration type. Refer to the CTEP Registration Procedures section for instructions on', 'how to request a CTEP-IAM account and complete registration in RCR.', 'TRIAD Site User role on an NCTN or ETCTN roster.', 'All individuals on the Imaging and Radiation Oncology Core provider roster have access to', 'TRIAD and may submit images for credentialing purposes, or for enrollments to which the', 'provider is linked in OPEN.', '6.3.2 TRIAD Installations', 'To submit images, the individual holding the TRIAD Site User role will need to install the', 'TRIAD application on their workstation. TRIAD installation documentation is available at', 'This process can be done in parallel to obtaining your CTEP-IAM account and RCR', 'registration.', 'For questions, contact TRIAD Technical Support staff via email', '6.3.3 Procedures for Data Submission via TRIAD', 'Collection of CT/PET-CT and Bone images is required. Images will be collected digitally', 'for archival and retrospective purposes at the following time points:', 'Baseline (within 28 days prior to patient registration)', '29', 'NCIVersion Date: 5/29/2020', 'Update 5']"
29,page_30,"['Alliance A171601', 'Restaging (Day 1 of Cycle 4 (+2weeks) then every 12 weeks until end of treatment)', 'The complete CT/PET-CT and Bone scan imaging data in digital DICOM format will be', 'submitted electronically to the Imaging and Radiation Oncology Core at Ohio (IROC Ohio)', 'within no more than 3 business days upon patient enrollment (at baseline) or upon the', 'image acquisition completeness (at follow-ups). BMP files, JPG files, or hard copies (films)', 'are not acceptable.', 'Imaging data should be submitted electronically to IROC Ohio via TRIAD. The standard', 'TRIAD based data transfer approach will be provided separately through IROC efforts via', 'the specific trial e-mail', 'per the request by participating', 'sites before their first data submission.', 'If TRIAD approach is not achievable at site, alternatively site needs to de-identify the patient', 'data using institutional procedures to remove patient name and medical record number while', 'preserving the Alliance patient ID number (e.g., 112136) and protocol number (e.g.,', 'A171601), and use the following electronic approaches for data submission:', '1) Web Transfer', 'Any PCs with internet access and web browser (e.g., Internet Explorer, Mozilla Firefox) can', 'be used to web transfer DICOM images and other required files to IROC Ohio. The standard', 'Web Transfer information will be provided separately through the specific trial e-mail', 'per the request by participating sites before their first data', 'submission.', '2) FTP Transfer', 'Any FTP software can be used to initiate access to the secure FTP Server of IROC Ohio.', 'The standard FTP access information will be provided separately through the specific trial', 'e-mail', 'per the request by participating sites before their', 'first data submission.', 'Mail/CD Shipment', 'Only if electronic data transfer approaches cannot be achieved, the de-identified images in', 'digital DICOM format can be burned to a CD and mailed to IROC Ohio. Submit only one', ""patient's images per CD, with the patient's Alliance ID number, study type, date of scans,"", 'and name of submitting institution. Submit these data to:', 'Once the imaging data submission is done, send an e-mail to IROC Ohio at the specific trial', 'email', 'to inform that the study has been submitted from the', 'institution. Please include the basic information of submitted data sets as follows:', '1)', 'Alliance patient ID number', '2)', 'Scan time point (i.e., baseline)', '3)', 'Date of scans', '30', 'NCI Version Date: 5/29/2020', 'Update 5']"
30,page_31,"['Alliance A171601', '4)', 'Institution name', 'IROC Ohio will notify site within 2 business days of the data receipt, and then, within 3', 'business days following the data receipt, of the quality check report.', 'Any questions or problems about the data submission to IROC Ohio, call IROC Ohio at', 'for help', '7.0', 'TREATMENT PLAN/INTERVENTION', 'Protocol treatment is to begin within 14 days of registration.', 'For questions regarding treatment, please see the protocol contacts on page 2.', 'It is acceptable for protocol treatment to be delivered within a 24-hour (business day) window', 'before and after the protocol-defined date for Day 1 of a new cycle. For example, if the treatment', 'due date is a Friday, the window for treatment includes the preceding Thursday through the', 'following Monday. In addition, patients are permitted to have a new cycle of protocol treatment', 'delayed up to 7 days for major life events (e.g., serious illness in a family member, major holiday,', 'vacation that cannot be rescheduled) without this being considered a protocol violation.', 'Documentation to justify this delay should be provided.', 'The study will be an open label, single arm, phase II safety and tolerability study of the combination', 'of palbocio lib and letrozole or fulvestrant in patients age 70 or over with hormone-receptorpositive', 'HER2-negative metastatic breast cancer. All patients who begin study treatment will be included', 'in the analysis of all clinical endpoints.', 'Agent', 'Starting', 'Route of', 'Frequency of Administration', 'Dose', 'Administration', 'Palbociclib', '125 mg/day', 'Once daily on Days 1-21 of each 28-day', 'Orally', 'cycle', 'Once daily on Days 1-28 of each 28 day', 'Letrozole', '2.5 mg', 'Orally', 'cycle', 'OR', 'Palbociclib', '125 mg/day', 'Once daily on Days 1-21 of each 28-day', 'Orally', 'cycle', 'Day 1 and Day 15 of Cycle 1, then Day 1', 'Fulvestrant', '500 mg', 'IM injection', 'of every subsequent cycle', 'Treatment will continue until disease progression or unacceptable toxicity.', '7.1 Palbociclib', 'A cycle will be four weeks (28 days) in duration. Treatment will be administered in an outpatient', 'setting. Palbociclib will be administered per the following schedule:', '1. 21 consecutive days of 125 mg palbociclib, taken orally with food and taken at', 'approximately the same time each day.', '2. Following the 21 consecutive days, there will be 7 days off treatment to comprise a', 'complete cycle of 28 days.', '31', 'NCI Version Date: 5/29/2020', 'Update 5']"
31,page_32,"['Alliance A171601', 'If a patient vomits or misses a dose, an additional dose should not be taken that day. The next', 'prescribed dose should be taken at the usual time. Missed doses will not be made up and cycle', 'length stays the same. Palbociclib capsules should be swallowed whole and should be taken in', 'combination with endocrine therapy (if taking letrozole).', '7.2', 'Letrozole', 'Letrozole will be prescribed and administered per MD discretion and dosing should follow the', 'package insert guidelines. The recommended dose is 2.5 mg daily. Doses missed for toxicity', 'will not be made up. Dosing interruption and/or dose reductions are recommended based on', 'individual safety and tolerability.', '7.3 Fulvestrant', 'Fulvestrant will be prescribed and administered per MD discretion and dosing should follow the', 'package insert guidelines. The recommended dose is 500 mg given IM on Days 1 and 15 of', 'Cycle 1, and then given every 28 days. Doses missed for toxicity will not be made up. Dosing', 'interruption and/or dosereductions rerecommended based on individual safety and tolerability.', '7.4', 'Adherence, Geriatric Assessment, and Patient Perspective', 'Pill diaries will be collected at the end of cycles 1-3 of treatment to ascertain dose delivered', 'adherence to palbociclib. Adherence to palbociclib will be measured by patient self-report in', 'dedicated patient diaries at the end of the first 3 cycles.', 'A cancer specific geriatric assessment will be captured pre-treatment, after 3 cycles, and at the', 'end of treatment. See Section 11.0.', ""To further assess the patient's perception of treatment efficacy of palbociclib in addition to"", 'endocrine therapy, we will ask our participants to complete the following questionnaires at the', 'end of treatment: Was It Worth It (Appendix III) and Overall Treatment Utility (Appendix IV),', 'the EQ-5D-3L (Appendix V) and PRO-CTCAE questionnaire (Appendix VI). These', ""questionnaires will provide a better understanding of the patient's perspectives regarding the"", 'benefits and side effects of treatment, in combination with an assessment of treatment efficacy', 'and toxicity. See Section 11.0.', '32', 'NCIVersion Date: 5/29/2020', 'Update 5']"
32,page_33,"['Alliance A171601', '8.0', 'DOSEAND TREATMENT MODIFICATIONS', '8.1 Ancillary Therapy, Concomitant Medications, and Supportive Care', '8.1.1 Patients should not receive any other agent which would be considered treatment for', 'the primary neoplasm or impact the primary endpoint.', '8.1.2 Patients should avoid immunizations with live virus vaccines.', '8.1.3 Patients should receive full supportive care while on this study. This includes blood', 'product support, antibiotic treatment, and treatment of other newly diagnosed or concurrent', 'medical conditions. All blood products and conc omitant medications such as antidiarrheals,', 'analgesics, and/or antiemetics received from the first day of study treatment administration', 'until 30 days after the final dose will be recorded in the medical records.', '8.1.4 Treatment with hormones for breast cancer treatment or other chemotherapeutic', 'agents may not be administered.', '8.1.5 Antiemetics may be used at the discretion of the attending physician, with the exception of', 'steroids above.', '8.1.6 Diarrhea management is per the discretion of the treating physician. Diarrhea could be', 'managed conservatively with medications such as loperamide.', 'Patients with severe diarrhea should be assessed for intravenous hydration and correction of', 'electrolyte imbalances.', '8.1.7 Palliative radiation therapy may not be administered.', 'Patients who require radiation therapy during protocol treatment will be removed from', 'protocol therapy due to disease progression.', '8.1.8 Alliance Policy Concerning the Use of Growth Factors', 'Blood products and growth factors should be utilized as clinically warranted and following', 'institutional policies and recommendations.', 'The use of colony stimulating factors, filgrastim (G-CSF), pegfilgrastim and sargramostim', '(GM-CSF) is discouraged but may be used in patients who have prognostic factors that are', 'predictive of clinical deterioration such as pneumonia, hypotension, multi-organ', 'dysfunction (sepsis syndrome) or fungal infection, as per ASCO guidelines Investigators', 'should use their own discretion in using the CSFs in this setting which must be documented', 'and reported on forms.53', '8.1.9 Hypersensitivity/infusionreactions', 'Treat hypersensitivity and infusion reactions to (drug as per institutional standards.', '8.1.10 CYP3A Inhibitors', 'Chronic concomitant treatment with strong inhibitors of CYP3A is strongly discouraged', 'while on this trial. The following drugs are EXAMPLES of strong inhibitors of CYP3A and', 'are not allowed during treatment with palbociclib.', 'Indinavir', 'Clarithromycin', 'Ketoconazole', 'Grapefruit juice', '33', 'NCIVersion Date: 5/29/2020', 'Update 5']"
33,page_34,"['Alliance A171601', 'Because lists of these agents are constantly changing, please consult and review any drugs', 'for their potential to inhibit CYP3A. Examples of resources that may be utilized include the', 'product information for the individual concomitant drug in question, medical reference texts', ""such as the Physicians' Desk Reference, the FDA website, or your local institution's"", 'pharmacist.', '8.1.11 CYP3A Inducers', 'Chronic concomitant treatment with strong inducers of CYP3A is strongly discouraged', 'while on this trial. The following drugs are EXAMPLES of strong inducers of CYP3A and', 'are not allowed during treatment with palbociclib.', 'Rifampin', 'Carbamazepine', 'Because lists of these agents are constantly changing, please consult and review any drugs', 'for their potential to induce CYP3A. Examples of resources that may be utilized inc lude the', 'product information for the individual concomitant drug in question, medical reference texts', ""such as the Physicians' Desk Reference, the FDA website, or your local institution's"", 'pharmacist.', '8.1.12 CYP2A6 Substrates', 'Chronic concomitant treatment with substrates of CYP2A6 is strongly discouraged while', 'on this trial. The following drugs are EXAMPLES of CYP2A6 substrates and are not', 'allowed during treatment with letrozole.', 'Dexmedetomidine', 'Tegafur', 'Because lists of these agents are constantly changing, please consult and review any drugs', 'for their potential to induce CYP2A6. Examples of resources that may be utilized include', 'the product information for the individual concomitant drug in question, medical reference', ""texts such as the Physicians' Desk Reference, the FDA website, or your local institution's"", 'pharmacist.', '34', 'NCIVersion Date: 5/29/2020', 'Update 5']"
34,page_35,"['Alliance A171601', '8.2', 'Dose Modifications', 'Palbociclib cycle length will remain 28 days ( 2 days) (despite a delay in initiating a new cycle', 'of palbociclib); endocrine therapy may continue to be administered per the preplanned schedule.', 'Dose holds/reductions of letrozole or fulvestrant will occur per the package insert and the', ""treating investigator's discretion."", 'Dose escalation will not be permitted in this study.', 'Palbociclib doses missed for toxicity will not be made up.', 'The initiation of a new cycle may be delayed for up to 7 days', 'CTEP - AERS reporting may be required for some adverse events. See Section 9.0.PRO-', 'CTCAE data should not be used for dose modifications.', '8.2.1 Dose Levels', 'Dose Level', 'Palbociclib Dose', 'Starting Dose', '125 mg/day', '-1', '100 mg/day', '-2', '75 mg/day', '8.2.2 Hematologic adverse events (except lymphopenia, unless associated with clinical', 'events, e.g., opportunistic infections):', 'Monitor complete blood counts prior to the start of palbocic lib therapy and at the beginning', 'of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated.', 'For patients who experience a maximum of Grade 1 or 2 neutropenia in the first 6 cycles,', 'monitor complete blood counts for subsequent cycles every 3 months, prior to the beginning', 'of a cycle and as clinically indicated.', 'For grade 3 events:', 'Day 1 of cycle:', 'Omit palbociclib repeat complete blood count monitoring within 1 week. Upon recovery to', 'Grade 2, start the next cycle at the same (previous) dose.', 'Day 15 of first 2 cycles:', 'If Grade 3 on Day 15, continue palbociclib at current dose to complete cycle and', 'repeat complete blood count on Day 22.', 'If Grade 4 on Day 22, see Grade 4 dose modification guidelines below.', 'Consider dose reduction in cases of prolonged (>1 week) recovery from Grade 3', 'neutropenia or recurrent Grade 3 neutropenia on Day 1 of subsequent cycles.', 'For grade 3 neutropenia with fever >38.5 °C and/orinfection, and Grade 4 events:', 'Omit palbociclib until recovery to Grade 2.', 'Resume at the next lower dose.', '35', 'NCIVersion Date: 5/29/2020', 'Update 5']"
35,page_36,"['Alliance A171601', '8.2.3 Non Hematologic adverse events:', 'For all grade 3 and higher events related to palbociclib, omit palbociclib until recovery', 'to Grade 1, or Grade <2 (if not considered a safety risk for the patient).', 'Resume palbocicl lib at thenext lower dose at the discretion of the treating physician.', 'Permanently discontinuing palbociclib is recommended in patients experiencing', 'severe Interstitial Lung Disease/pneumonitis.', '9.0', 'ADVERSE EVENTS', 'The promptreporting of adverse events is the responsibility of each investigator engaged in clinical', 'research, as required by Federal Regulations. Adverse events must be described and graded using', ""the terminology and grading categories defined in the NCI's Common Terminology Criteria for"", 'Adverse', 'Events', '(CTCAE),', 'Version', '5.0.', 'The', 'CTCAE', 'is', 'available', 'at', 'Attribution to protocol', 'treatment for each adverse event must be determined by the investigator and reported on the', 'required forms. Pleaserefer the NCI Guidelines: Adverse Event Reporting Requirements for fur ther', 'details on AE reporting procedures.', 'To complement CTCAE reporting, patients will self-report their side effects using the PRO-', 'CTCAE. The specific PRO-CTCAE items for this protocol can be found in Appendix VI. PRO-', 'CTCAE should not be used for determining attribution or reporting of serious adverse events.', '9.1', 'Routine Adverse Event Reporting', 'Adverse event data collection and reporting, which are required as part of every clinical trial are', 'done to ensure the safety of patients enrolled in the studies as well as those who will enroll in', 'future studies using similar agents. Adverse events are reported in a routine manner at scheduled', 'times according to the study calendar in Section 5.0. For this trial, the Adverse Event Solicited', 'form is used for routine AE reporting in Rave.', 'Solicited Adverse Events: The following adverse events are considered ""expected"" and their', 'presence/absence should be solicited, and severity graded, at baseline and for each cycle of', 'treatment by CTCAE, PRO-CTCAE, or both.', 'PRO-CTCAE V. 1.0', 'CTCAE v.5.0 System Organ', 'CTCAE v. 5.0 Term', 'Term', 'Class (SOC)', 'Neutrophil count decreased', 'Investigations', 'Platelet count decreased', 'Investigations', 'White Blood cell count', 'decreased', 'Investigations', 'Anemia', 'Blood and lymphatic system', 'disorders', 'Blood and lymphatic system', 'Febrile Neutropenia', 'disorders', 'Nausea', 'Nausea', 'Gastrointestinal Disorders', 'Metabolism and Nutritional', 'Anorexia', 'Decreased Appetite', 'Disorders', 'Diarrhea', 'Diarrhea', 'Gastrointestinal disorders', '36', 'NCIVersion Date: 5/29/2020', 'Update 5']"
36,page_37,"['Alliance A171601', 'Vomiting', 'Vomiting', 'Gastrointestinal disorders', 'Mucositis oral', 'Mouth/throat sores', 'Gastrointestinal disorders', 'Fatigue', 'Fatigue', 'General disorders', 'Peripheral Sensory', 'Numbness and Tingling', 'General disorders', 'Neuropathy', 'Thromboembolic event', 'Vascular disorders', 'Upper Respiratory Infection', 'Infections and Infestations', 'Urinary Tract Infection', 'Infections and Infestations', '9.2', 'CTCAE Routine Reporting Requirements', 'In addition to the solicited adverse events listed in Section 9.1, the following table outlines the', 'combinations of time points, grades and attributions of AEs that require routine reporting to the', 'Alliance Statistics and Data Center. Questions about routine reporting should be directed to the', 'Data Manager. PRO-CTCAE data should not be used for determining attribution, dose', 'modifications, or reporting of serious adverse events.', 'Combinations of CTCAE Grade & Attribution Required for Routine AE Data', 'Submission on Case Report Forms (CRFs)', 'Attribution', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Grade 5', 'Unrelated', 'a', 'a', 'a', 'a', 'Unlikely', 'a', 'a', 'a', 'a', 'Possible', 'a', 'a, b', 'a, b', 'a, b', 'Probable', 'a', 'a, b', 'a, b', 'a, b', 'Definite', 'a', 'a, b', 'a, b', 'a, b', 'a)', 'Adverse Events: Other CRF - Applies to AEs occurring between registration and', ""within 30 days of the patient's last treatment date, or as part of the Clinical Follow - Up"", 'Phase.', 'b) Adverse Events: Late CRF - Applies to AEs occurring greater than 30 days after', ""the patient's last treatment date."", '9.3', 'Expedited Adverse Event Reporting (CTEP-AERS)', 'Investigators are required by Federal Regulations to report serious adverse events as defined in', 'the table below. Alliance investigators are required to notify the Alliance Central Protocol', 'Operations Program, the Study Chair, and their Institutional Review Board if a patient has a', 'reportable serious adverse event. The descriptions and grading scales found in the NCI Common', 'Terminology Criteria for Adverse Events (CTCAE) version 5 will be utilized for AE reporting.', 'The', 'CTCAE', 'is', 'identified', 'and', 'located', 'on', 'the', 'CTEP', 'website', 'at:', 'All', 'appropriate', 'treatment areas should have access to a copy of the CTCAE. All reactions determined to be', '""reportable"" in an expedited manner must be reported using the Cancer Therapy Evaluation', 'Program Adverse Event Reporting System (CTEP-AERS).', '37', 'NCI Version Date: 5/29/2020', 'Update 5']"
37,page_38,"['Alliance A171601', 'For further information on the NCI requirements for SAE reporting, please refer to the ""NCI', ""Guidelines for Investigators: Adverse Event Reporting Requirements' document published by"", 'the NCI.', 'Note: All deaths on study require both routine and expedited reporting regardless of causality.', 'Attribution to treatment or other cause should be provided.', '38', 'NCIVersion Date: 5/29/2020', 'Update 5']"
38,page_39,"['Alliance A171601', '9.3.1 Alliance A171601 Reporting Requirements', 'Expedited reporting requirements for adverse events that occuron studies under an IND/IDE', '< 30 Days of the last administration of the investigational agent/intervention 1,2', 'FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSEI EVENTS (21 CFR Part 312)', 'NOTE: Investigators MUST immediately report to the sponsor (NCI) ANYSerious Adverse Events, whetherornot', 'they are considered: related to the investigational agent(s)/intervention CFR 312.64)', 'An adverse event is considered serious if it results in ANYofthefollowingoutcomes:', '1) Death', '2)', 'A life-threatening adverse event', '3) An adverse event that results in inpatient hospitalization or prolongation ofexis ting hospitalization for > 24', 'hours', '4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions', '5) A congenital anomaly/birth defect.', '6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may', 'be considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may', 'require medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR', '312.32; ICH E2A and ICHE6).', 'ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the', 'NCI via CTEP-AERS within the timeframes detailed in the table below.', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4 & 5', 'Hospitalization', 'Timeframes', 'Timeframes', 'Timeframes', 'Timeframes', 'Resulting in', 'Hospitalization 24 hrs', '10 Calendar Days', '24-Hour;', 'Not resulting in', '5 Calendar Days', 'Not required', '10 Calendar Days', 'Hospitalization > 24 hrs', 'NOTE Protocol specific exceptions to expeditedreporting of serious adverse events are found in the', 'Specific Protocol Exceptions to Expedited Reporting (SPEER) portion ofthe CAEPR', 'Expedited AE reporting timelines are definedas:', '""24-Hour; 5 Calendar Days"" - The AEmust initially be reported via CTEP-AERS < 24 hours of', 'learning of the AE, followed by a complete expeditedreport <5 calendar days of the initial 24-hour', 'report.', '""10 Calendar Days"" - A complete expedited report on the AEmust be submitted < 10 calendar days', 'of learning of the AE.', '1 Serious adverse events that occur more than 30 days after the last administration of investigational', 'agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:', 'Expedited 24-hour notification followed by complete report <5 calendar days for:', 'All Grade 4, and Grade 5 AEs', 'Expedited 10 calendar day reports for:', 'Grade 2 adverseevents resulting in hospitalization orprolongation of hospitalization', 'Grade 3 adverseevents', '2', 'Forstudies using PET or SPECT IND agents, the AEreporting period is limited to 10 radioactive half-lives,', 'rounded UP to the nearest whole day, after theagent/interventionwas lastadministered Footnote ""1"" above', 'applies after this reporting period.', '39', 'NCIVersion Date: 5/29/2020', 'Update 5']"
39,page_40,"['Alliance A171601', '9.3.2 Expedited AE reporting timelines defined', '""24 hours; 5 calendar days"" - The investigator must initially report the AE via CTEP-AERS', 'VI 24 hours of learning of the event followed by a complete CTEP-AERS report 5 calendar', 'days of the initial 24-hour report.', '""10 calendar days"" - A complete CTEP-AERS report on the AE must be submitted VI 10', 'calendar days of the investigator learning of the event.', 'Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipitates hospitalization', '(or prolongation of existing hospitalization) must be reported regardless of attribution and', 'designation as expected or unexpected with the exception of any events identified as', 'protocol-specific expedited adverse event reporting exclusions (see below).', 'Use the NCI protocol number and the protocol-specific patient ID provided during trial', 'registration on all reports.', '9.3.3', 'Additional Instructions or Exclusion to CTEP-AERS Expedited Reporting', 'Requirements', 'All adverse events reported via CTEP-AERS (i.e., serious adverse events) should', 'also be forwarded to your localIRB.', 'Grade 3/4 hematosuppression and hospitalization resulting from such do not', 'require CTEP-AERS, but should be submitted as part of study results. All other grade', '3, 4, or 5 adverse events that precipitate hospitalization or prolong an existing', 'hospitalization must be reported via CTEP-AERS.', 'Reporting of cases of secondary AML/MDS is to be done using the NCI/CTEP', 'Secondary AML/MDS Report Form. New primary malignancies should be reported in', 'Rave.', 'Death due to progressive disease should be reported as Grade 5 ""Disease', 'progression"" in the system organ class (SOC) ""Generaldisorders and administration site', ""conditions.' Evidence that the death was a manifestation of underlying disease (e.g.,"", 'radiological changes suggesting tumor growth or progression: clinical deterioration', 'associated with a disease process) should be submitted.', 'Any death occurring within 30 days of the last dose, regardless of attribution to the', 'investigational agent/intervention requires expedited reporting within 24 hours.', 'Any death occurring greater than 30 days after the last dose of the investigational', 'agent/intervention requires expedited reporting within 24 hours only if it is possibly,', 'probably, or definitely related to the investigational agent/intervention.', 'All new malignancies must be reported via CTEP-AERS whether or not they are', 'thought to be related to either previous or current treatment. All new malignancies', 'should be reported, i.e. solid tumors (including non-melanoma skin malignancies),', 'hematologic malignancies, myelodysplastic syndrome/acute myelogenous leukemia,', 'and in situ tumors. In CTCAE version 5.0, the new malignancies (both second and', 'secondary) may be reported as one of the following: (1) Leukemia secondary to', 'oncology chemotherapy, (2) Myelodysplastic syndrome, (3) Treatment-related', 'secondary malignancy, or (4) Neoplasms benign, malignant and unspecified-other.', 'Whenever possible, the CTEP-AERS reports for new malignancies should include', 'tumor pathology, history or prior tumors, prior treatment/current treatment including', 'duration, any associated risk factors or evidence regarding how long the new', 'malignancy may have been present, when and how the new malignancy was detected,', '40', 'NCIVersion Date: 5/29/2020', 'Update 5']"
40,page_41,"['Alliance A171601', 'molecular characterization or cytogenetics of the original tumor (if available) and of', 'any new tumor, and new malignancy treatment and outcome, if available.', 'Treatment expected adverse events inc lude those listed in Section 10.0 and in the', 'package insert.', 'Grade 1-3 nausea or vomiting and hospitalization resulting from such do not require', 'AERS reporting, but should be reported via routine AE reporting', 'Grade 3 or 4 nausea or vomiting does not require AERS reporting, but should be', 'reported via routine AE reporting.', 'Grade 1-3 fatigue and hospitalization resulting from such do not require AERS', 'reporting, but should be reported via routine AE reporting.', 'Grade 3 or 4 fatigue does not require AERS reporting, but should be reported via', 'routine AE reporting', 'Grade 1-3 diarrhea does not require AERS reporting, but should be reported via', 'routine AE reporting', 'Grade 3 or 4 diarrhea and hospitalization resulting from such do not require AERS', 'reporting, but should be reported via routine AE reporting.', 'Grade 3 neutropenic fever and hospitalization resulting from such do not require', 'AERS reporting, but should be reported via routine AE reporting.', 'CTEP-AERS reports should be submitted electronically.', '41', 'NCIVersion Date: 5/29/2020', 'Update 5']"
41,page_42,"['Alliance A171601', '9.4 CAEPR', 'Revised Palbociclib CAEPR - Version 2.4, September 13, ,2019', 'Comprehensive Adverse Events and Potential Risks list (CAEPR)', 'for', 'Palbociclib (PD-0332991, NSC 772256)', 'The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of reported and/or', 'potential adverse events (AE) associated with an agentusing a unifompresentation of events by bodys system In', 'addition to the comprehensive list, a subset, the Specific Protocol Exceptions to Expedited Reporting (SPEER),', 'appears in a separate column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of', 'events that are protocol specific exceptions to expeditedreporting to NCI (except as noted below). Refer to the', ""'CTEP, NCI Guidelines: Adverse Event Reporting Requirements'"", 'for further clarification.', 'Frequency is provided basedon 1751 patients. Belowis the CAEPR for Palbociclib (PD-0332991).', 'NOTE: Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses next to the AE in the', 'SPEER. If this CAEPR is part ofa combination protocol using multiple investigational agents and has an AE', 'listed on different SPEERs, use the lower of the grades to determine if fexpedit ed reporting is required.', 'Version 2.4, September 13, 2019¹', 'Specific Protocol Exceptions to', 'Adverse Events with Possible', 'Relations hipto Palbociclib(PD 0332991)', 'Expedited Reporting', '(CTCAE 5.0 Term)', '(SPEER)', '[n= 1751]', 'Likely (>20%)', 'Less Likely (<=20%)', 'Rare but Serious (<%%)', 'BLOOD ANDLYMPHATIC SYSTEM DISORDERS', 'Anemia', 'Anemia (Gr 2)', 'Febrile neutropenia', 'EYE DISORDERS', 'Blurred vision', 'Dry eye', 'Wateringeyes', 'GASTROINTESTINAL DISORDERS', 'Constipation', 'Constipation (Gr 2)', 'Diarrhea', 'Diarrhea (Gr 2)', 'Mucositis oral', 'Mucositis oral (Gr 2)', 'Nausea', 'Nausea (Gr 2)', 'Vomiting', 'Vomiting (Gr 2)', 'GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS', 'Fatigue', 'Fatigue (Gr 2)', 'Fever', 'INFECTIONS ANDINFESTATIONS', 'Infection2', 'Infection² (Gr 2)', 'INVESTIGATIONS', 'Alanine aminotransferase', 'increased', 'Aspartate aminotransferase', 'increased', 'Lymphocyte count decreased', 'Lymphocyte count decreased (Gr 2)', 'Neutrophil count', 'Neutrophil count decreased (Gr 2)', 'decreased', 'Platelet count decreased', 'Platelet count decreased (Gr', '42', 'NCIVersion Date: 5/29/2020', 'Update 5']"
42,page_43,"['Alliance A171601', 'Adverse Events with Possible', 'Specific Protocol Exceptions to', 'Relationshipto Palbociclib (PD-0332991)', 'Expedited Reporting', '(CTCAE 5.0 Term)', '(SPEER)', '[n= 1751]', 'Likely (>20%)', 'Less Likely (<=20%)', 'Rare but Serious (<%%)', 'White blood cell', 'White blood cell decreased (Gr 2)', 'decreased', 'METABOLISM AND NUTRITION DISORDERS', 'Anorexia', 'Anorexia (Gr2)', 'NERVOUS SYSTEM DISORDERS', 'Dysgeusia', 'Headache³', 'RESPIRATORY, THORACIC AND MEDLASTINALDISORDER', 'Epistaxis', 'Pneumonitis', 'SKIN AND SUBCUTANEOUS TISSUE DISORDERS', 'Alopecia', 'Alopecia (Gr 2)', 'Dry skin', 'Skin and subcutaneous tissue', 'disorders - Other (rash4', 'This table will be updatedas the toxicity profile of the agent is revised. Updates will be distributed to all Principal', 'Investigators at thetime ofrevision. The current version canbe obtained by contacting', 'Yourname, the name of the investigator, the protocol and the agent should be included', 'in the e-mail.', '2Infection includes all 75 infection sites under the INFECTIONS AND INFESTATIONS SOC.', 'Headachehas been observed in trials using Palbociclib (PD-0332991) in combination with fulvestrant.', '4Rash includes rash, rashmaculo-papular, erythema, erythematous rash, erysipelas, rashpruritic, rash papular,', 'generalized rash, exanthema, allergic dermatitis, dermatitis acneiform, and dermatitis.', 'Peripheral neuropathy includes both peripheral motor neuropathy and peripheral sensory neuropathy under the', 'NERVOUS SYSTEM DISORDERS SOC.', 'Adverse events reported on palbociclib (PD-0332991) trials, but for which there is ins ufficient evidence to', 'suggest that there was a reasonable possibility that palbociclib (PD-0332991) caus edthe adverse event:', 'BLOOD AND LYMPHATIC SYSTEM DISORDERS - Bone marrow hypocellular; Blood and lymphatic system', 'disorders - Other (pancytopenia)', 'CARDIAC DISORDERS - Atrial fibrillation; Cardiac arrest; Cardiac disorders - Other (paroxysmal atrial', 'fibrillation with rapid ventricular response); Palpitations; Pericarditis; Sinus bradycardia; Supraventricular', 'tachycardia', 'EYE DISORDERS - Cataract: Eye disorders - Other (retinalhemorhage)', 'GASTROINTESTINAL DISORDERS - Abdominal distension; Abdominalpain; Ascites; Colitis; Colonic', 'perforation; Dry mouth; Dyspepsia; Dysphagia; Esophageal stenosis; Flatulence; Gastric hemorhhage;', 'Gastrointestinal disorders - Other (gas strointestinal hemorrhage); Intra-abdominalhemorhage;Lower', 'gastrointestinal hemorrhage; Small intestinal obstruction; Small intestinalperforation; Upper gastrointestinal', 'hemorrhage', 'GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Chills: Death NOS; Edema limbs;', 'Localized edema; Malaise; Non-cardiac chestpain; Pain; SuddendeathNOS', '43', 'NCIVersion Date: 5/29/2020', 'Update 5']"
43,page_44,"['Alliance A171601', 'HEPATOBILIARY DISORDERS - Hepatic failure; Hepatobiliary disorders - Other (bile duct obstruction);', 'Hepatobiliary disorders- - Other (jaundice)', 'IMMUNE SYSTEM DISORDERS - Allergic reaction', 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Fall; Fracture', 'INVESTIGATIONS - Alkaline phosphatase increased; Bloodbilirubin increased; CPK increased; Creatinine', 'increased; Ejection fraction decreased; GGT increased; INR increased Weightloss', 'METABOLISM AND NUTRITION DISORDERS - Dehydration; Hypercalcemia; Hyperglycemia;', 'Hyperkalemia; Hypermagnesemia; Hyperuricemia; Hypoalbuminemia; Hypocalcemia; Hypokalemia;', 'Hyponatremia; Hypophosphatemia; Metabolismand nutrition dis sorders - Other (failure to thrive)', 'MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Arthralgia; Backpain; Flankpain;', 'Generalized muscle weakness; Muscle cramp; Musculoskeletal and connective tissuedisorder -Other -', '(osteomyelitis); Myalgia; Neckpain; Osteonecrosis; Pain in extremity', 'NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL. CYSTS AND POLYPS) - Treatment', 'related secondary malignancy', 'NERVOUS SYSTEM DISORDERS - Dizziness; Dysesthesia; Dysphasia; Intracranial hemorrhage; Nervous', 'systemdisorders - Other (peripheralneuropathy) Syncope', 'PSYCHIATRIC DISORDERS - Confusion; Insomnia; Psychiatric disorders - Other (altered mental status)', 'RENAL AND URINARY DISORDERS - Acute kidney injury; Hematuria', 'RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Cough; Dyspnea; Hypoxia;', 'Oropharyngealpain; Pleuraleffusion; Postnasal drip; Pulmonary edema; Pulmonary hypertension', 'SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Hyperhidrosis; Pruritus', 'VASCULAR DISORDERS - Hypertension; Hypotension', 'Note: Palbociclib (PD-0332991) in combination with other agents could cause an exacerbation of any adverse event', 'currently knownto be caused by the other agent, or the combinationma result in events never previously', 'associated with either agent.', '44', 'NCIVersion Date: 5/29/2020', 'Update 5']"
44,page_45,"['Alliance A171601', '10.0', 'DRUG INFORMATION', '10.1 General Considerations:', 'All study agents are to be administered at the registering institution.', '10.2 Palbociclib', 'IND Exempt: Palbociclib is IND exempt as used in this trial. This exemption has been', 'determined by attestation that neither the investigator nor sponsor intends to seek a new', 'indication for use or to support any other signific ant change in the labeling or product advertising', 'for Palbociclib; this investigation will use an approved route of administration and dosage of', 'Palbociclib and has no factors that increase the risk of the product; this investigation will be in', 'compliance with 21CFR parts 56, 50, and 312.7; and neither the investigator nor sponsor will', 'promote or represent that Palbociclib is safe or effective for the context that is under', 'investigation in this study.', 'Procurement', 'Palbociclib is a commercially available agent and filled with prescription.', 'Formulation', 'Palbociclib is supplied as a 125 mg, 100 mg, or 75 mg tablet. Palbociclib is a yellow to orange', 'powder and the 125mg capsule is an opaque hard gelatin, size 0 capsules with a caramel cap and', 'body, printed with white ink ""Pfizer"" on the cap, and ""PBC 125"" on the body. The 100 mg', 'capsules are opaque hard gelatin capsules, size 1, with caramel cap and light orange body,', 'printed with white ink ""Pfizer"" on the cap and ""PBC 100"" on the body. The 75 mg capsules are', 'opaque hard gelatin capsules, size 2, with light orange cap and body, printed with white ink', '""Pfizer"" on the cap and ""PBC 75"" on the body.', 'Inactive ingredients present in the capsule include: Microcrystalline cellulose, lactose', 'monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard', 'gelatin capsule shells', 'The light orange, light orange/caramel and caramel opaque capsule shells contain gelatin, red', 'iron oxide, yellow iron oxide, and titanium dioxide; and the printing ink contains shellac,', 'titanium dioxide, ammonium hydroxide, propylene glycol and simethicone', 'Storage and Stability', 'The intact bottles should be stored at 20°Cto 25°C (68°F to 77°F); excursions permitted between', '15 to 30°C (59 to 86°F)', 'Administration', 'Dose: 125mg of palbocic lib administered orally once a day around the same time every day for', '21 consecutive days followed by 7 days off to comprise a cycle of 28 days.', 'Route of Administration: Orally with meals and patients should be encouraged to take their dose', 'at approximately the same time each day. If a patient vomits or misses a dose, an additional dose', 'should not be taken that day. Instead the next prescribed dose should be taken at the usual time.', 'Palbociclib capsules should be swallowed whole (do not chew, crush, or open them prior to', 'swallowing). No capsule should be ingested if it is broken, cracked, or otherwise not intact.', 'Patients should avoid consumption of grapefruit or grapefruit juice.', '45', 'NCIVersion Date: 5/29/2020', 'Update 5']"
45,page_46,"['Alliance A171601', 'Drug Interactions', 'Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme', 'SULT2A1. Palbociclib interacts with CYP3A inhibitors and CYP3A inducers. Avoid', 'concurrent use of palbocic lib with strong CYP3A inhibitors or inducers.', 'Adverse Events', 'The following are common (> 10%) adverse events occurring in at least one patient who', 'received palbocic lib plus letrozole in clinical trials.', 'Infections and Infestations: Upper Respiratory Infection', 'Blood and Lymphatic System Disorders: Neutropenia, Leukopenia, Anemia, Thrombocytopenia', 'Metabolism and Nutrition Disorders: Decreased Appetite', 'Nervous System Disorders: Peripheral Neuropathy', 'Respiratory, Thoracic, and Mediastinal Disorders: Epistaxis', 'Gastrointestinal Disorders: Stomatitis, Nausea, Diarrhea, Vomiting', 'Skin and Subcutaneous Tissue Disorders: Alopecia', 'General Disorders and Administration Site Conditions: Fatigue, Asthenia', 'Nursing Guidelines', '1. Agent should be administered with food. Do not crush, break or open capsules prior to', 'administration.', '2. Monitor CBC w/diff as cytopenias are common and require dose reductions. Instruct', 'patients to report signs or symptoms of infection and/or any unusual bruising or', 'bleeding to the study team.', '3. GI symptoms are common, including nausea/vomiting, stomatitis and diarrhea. Treat', 'symptomatically and monitor for effectiveness. Some side effects may require dose', 'reductions.', '4. Patients should avoid grapefruit and grapefruit juice, due to possible increase in the', 'serum concentration of palbociclib.', '5. There are drug to drug interactions with CYP3A4 substrates. Obtain a complete list of', 'patient medications including OTC and herbal products. Instruct patients to report any', 'new mediations to the study team immediately.', '6. Warn patient of risk of thromboembolic events, specifically pulmonary embolism.', '7. Warn patients of possibility of alopecia.', '8. Patients may experience upper respiratory infection. Instruct patients to report URI', 'symptoms to study team.', '9. Rarely patients may experience peripheral neuropathy. Monitor patients closely who', 'may have preexisting CIPN from previous therapy.', '10.3 Fulvestrant', 'Please refer to the FDA-approved package insert for fulvestrant for product information,', 'extensive preparation instructions and a comprehensive list of adverse events.', 'Other names: Faslodex', '46', 'NCI Version Date: 5/29/2020', 'Update 5']"
46,page_47,"['Alliance A171601', 'Classification: Estrogen receptor antagonist', 'Molecular Formula: C32H47F5O3S', 'M.W.: 606.77', 'Approximate Solubility: Each injection contains as inactive ingredients alcohol, USP, benzyl', 'alcohol, NF, and benzyl benzoate, USP as co-solvents and castor oil, USP as a co-solvent and', 'release rate modifier.', 'The solution is a clear, colorless to yellow, viscous liquid.', 'Procurement', 'Fulvestrant is a commercially available agent and filled with prescription.', 'Storage:', 'The syringes of fulvestrant for all cycles of treatment should be stored in the original container', 'and refrigerated at 2° 8°C (36°-46°F).', 'Administration:', 'Routes of Administration: IM Injection', 'Method of Administration: Remove glass syringe barrel from tray and check that it is not', 'damaged. Peel open the safety needle (SafetyGlide™) outer packaging. Break the seal of the', 'white plastic cover on the syringe luer connector to remove the cover with the attached rubber', 'tip cap. Twist to lock the needle to the luer connector. Remove needle sheath. Remove excess', 'air from the syringe (a small gas bubble may remain).', 'For this study, fulvestrant will be administered at a dose of 500 mg (2 X 250 mg injections) IM', 'or as indicated per the package insert on Day 1 and Day 15 of Cycle 1 and then on Day 1 of', 'each cycle in each subsequent cycle. Administer intramuscularly slowly in the buttock. (NOTE:', '500 mg dose will require one 250 mg injection in each buttock.) Immediately activate needle', 'protection device upon withdrawal from patient by pushing lever arm completely forward until', 'needle tip is fully covered. Visually confirm that the lever arm has fully advanced and the needle', 'tip is covered. If unable to activate, discard immediately into an approved sharps container.', 'Toxicity:', 'The most common toxicities reported in trials of fulvestrant to date include gastrointestinal', 'symptoms, menopausal symptoms and injection site reactions. Nausea and vomiting have been', 'the primary GI symptoms, occurring in approximately 50% of patients in phase III trials. They', 'were generally of mild to moderate severity. Hot flashes were reported in approximately 20%', 'of patients. Injection site reactions inc lude pain, hemorrhage and inflammation. Such reactions', 'may be more frequent when fulvestrant is administered as 2 injections of 2.5 ml (125 mg) each,', 'as compared with 1 injection of 5 ml (250mg).', 'Potential Drug Interactions: In in vitro studies using human hepatocytes, fulvestrant was', 'metabolized predominantly by conjugation. The metabolites thus formed are thought to possess', 'no estrogenic activity and minimal anti-estrogenic activity. In studies using human liver', 'microsomes, fulvestrant inhibited the activity of CYP1A2, 2C9 and 3A4 minimally. CYP3A4', 'did metabolize fulvestrant in these studies, but the human hepatocyte studies noted above', 'indicate conjugation is a more important metabolic pathway. In addition, studies in healthy', 'volunteers indicate that fulvestrant metabolism is not significantly affected by inducers or', 'inhibitors of CYP3A4, nor does fulvestrant affect the metabolism of 3A4 substrates. Thus,', 'fulvestrant is not expected to be involved in significant drug interactions mediated by CYP3A4.', 'Nursing guidelines', '47', 'NCI Version Date: 5/29/2020', 'Update 5']"
47,page_48,"['Alliance A171601', '1', 'Rarely a blood-tinged vaginal discharge has been reported infrequently during therapy.', 'Advise patients that this is a possibility and that studies have shown no effects on vagina', 'or endometrium.', '2', ""Monitor LFT's based on protocol requirements. Report increased LFT's to treating"", 'physician.', '3', 'Hot packing the injection site for a short while after injection may prevent the possible', 'bruising, tenderness, and/or erythema at the IM injection site.', '4 Instruct patient to report any signs or symptoms of blood clots. Patients with calf', 'tenderness or burning, and/or chest pain (pulmonary embolus) should be evaluated by a', 'physician immediately.', '5', 'Warn patient of possible hot flashes. Assess severity and discuss non-hormonal', 'treatments with treating physician. Assess treatment for efficacy.', '6', 'May cause mild GI symptoms (nausea, anorexia, vomiting, constipation). Treat', 'symptomatically and monitor for effectiveness of intervention.', '10.4 Letrozole', 'Please refer to the FDA-approved package insert for letrozole for product information, and a', 'comprehensive list of adverse events.', 'Other name: FemaraR', 'Classification: Aromatase inhibitor', 'Molecular formula: C17H11N5', 'Procurement', 'Letrozole is commercially available and filled with prescription.', 'Formulation:', 'Letrozole is supplied as 2.5 mg, dark yellow, film-coated tablets in bottles of 30 tablets.', 'Storage and Stability', 'Intact bottles of letrozole should be stored at 25°C (77°F), excursions permitted to 15 to 30°C', '(59 to 86°F)', 'Administration', 'Letrozole will be taken orally, at a dose of 2.5 mg once daily without regard to meals.', 'Toxicities', 'The most common adverse events reported include arthralgia, flushing, asthenia, edema,', 'headache, dizziness, hypercholesterolemia, bone pain. Ofconcern, primarily with long-term use', 'of aromatase inhibitors including letrozole, are effects on lipid metabolism with subsequent', 'cardiovascular events and on bone resorption. Other less frequent adverse events include bone', 'and muscle pain.', 'Nursing guidelines', '1', 'Manage hot flashes with non-hormonal interventions (ie: venlafaxine XR 75 mg daily).', '2', 'Manage pain (arthralgias). Instruct patient to report unrelieved pain.', '3', 'May take with food if needed for nausea. Instruct patient to report unrelieved nausea or', 'vomiting.', '48', 'NCI Version Date: 5/29/2020', 'Update 5']"
48,page_49,"['Alliance A171601', '4', 'Assess for changes in bowel patterns. Manage diarrhea or constipation with non-', 'prescription drugs. Tell patients to report unrelieved diarrhea or constipation.', '5', 'If patient experiences difficulty breathing or sudden onset chest pain, instruct them to', 'seek emergency medical attention immediately.', '6', 'Monitor for signs of edema, instruct patient to report any swelling in legs, feet, or hands.', '11.0', 'MEASUREMENT OF EFFECT', '11.1 Patient reported outcome measures', '11.1.1 Geriatric assessment', 'A cancer-specific comprehensive geriatric assessment will be given at baseline, the first', 'restaging (i.e., after 3 cycles of treatment and prior to cycle 4), and at the end of treatment', '(see Appendix II for Geriatric Assessment Survey). The cancer-specific comprehensive', 'geriatric assessment includes an evaluation of functional status, co-morbidity, cognition,', 'psychologicalstatus, socialfunctioning and support, and nutritional status. 3 This assessment', 'has been piloted in the Alliance (in legacy Cancer and Leukemia Group B [CALGB]).', 'CALGB 360401 evaluated the feasibility of incorporating the Geriatric Assessment Tool', 'into oncology cooperative group trials. 52 Patients were eligible to participate if they were', 'age > 65 and had signed consent for a cooperative group treatment trial. The Geriatric', 'Assessment Tool was completed prior to initiation of the protocol-specified treatment.', 'Ninety-three patients enrolled in this study. The median time to complete the assessment', 'was 22 minutes, 88% of patients completed the patient portion without assistance, 88%', 'satisfied with the assessment length, 98% reported there were no upsetting items, and 95%', 'said the assessment was easy to comprehend. The Geriatric Assessment Tool met the', 'protocol specified feasibility criteria for incorporation in oncology cooperative group', 'trials.52', 'Several studies are emerging regarding the benefits of performing a comprehensive geriatric', 'assessment for older patients with cancer. Factors evaluated in a comprehensive geriatric', 'assessment can predict survival, predict toxicity to chemotherapy, and uncover problems', 'not detected by a routine history and physical in initial consultation and follow -up care. 53,', '54,55 Consensus guidelines recognize the benefits and recommend the inclusion of a geriatric', 'assessment as part of the evaluation of an older patient. 56', '11.1.2 Overall treatment utility', 'We will be including a measure of Overall Treatment Utility (OTU) to assess the ""objective', 'and subjective measures of tolerability and acceptability"". This is accomplished with an', 'analysis of clinical benefits in conjunction with an analysis of whether toxicity and serious', ""adverse events affect one's daily functions. This provides a way to quantify advantages and"", 'disadvantages from receiving treatment in this study, as well as an understanding of how', 'patients may respond to treatment. OTUis useful in answering the following hypothetical', 'question from the patient\'s perspective: ""With the benefit of hindsight, are you glad you', 'received treatment?"" By including the OTU in this study, researchers and oncologists will', 'be', ""able to better understand the patient's perspectives regarding the benefits and side effects"", 'of treatment, in combination with an assessment of treatment efficacy and toxicity.', 'OTU is a novel composite endpoint developed by investigators of the FOCUS2 trial to', 'assess the outcome of palliative chemotherapy57 The interpretation of clinical trials,', 'especially in the palliative setting, often requires subjective synthesis of object data.', 'Measures of efficacy are weighted against the toxic effects, convenience, and other variables', 'before deciding which treatment is best. OTU helps integrate these measures into a single', '49', 'NCI Version Date: 5/29/2020', 'Update 5']"
49,page_50,"['Alliance A171601', 'composite endpoint. OTU combines clinical efficacy (""Is my patient alive without disease', 'progression?""), clinical tolerability (""Did we avoid causing major harm""), and patient', 'opinion (""Was my treatment worthwhile and acceptable?""). In the original study using OTU,', 'the composite endpoint was found to be particularly useful when conventional outcomes', 'were divergent (Oxaliplatin improved response rates and progression free survival, yet', 'resulted in increased toxicity), and helped confirm the benefit of Oxaliplatin5 We will', 'measure OTU by assessing clinical benefit and tolerability/acceptability at the end of', 'treatment. (See Study calendar Section 5.0 and AppendixIV). OTU: is scored as Good OTU', '(clinical or radiographic evidence or disease progression, no major negative treatment', 'effects in terms of toxicity or patient acceptability), Intermediate OTU (either clinical', 'deterioration but no negative treatment effect, or a significant negative treatment effect but', 'no clinical deterioration), or Poor OTU (both clinical deterioration and a major negative', 'treatment effect, or death).', '11.1.3 Was it worth it questionnaire', 'The Was It Worth It instrument (Appendix III) was developed to learn more about the', 'experience of patients participating in clinical trials. It is comprised of four brief questions,', 'and it has also been called the ""Trial Satisfaction"" survey. 58 Although formal validity and', 'reliability data for this instrument are not yet available, multiple cooperative group studies', 'have used it to measure how satisfied patients end up with their decision to enroll on a', 'clinical trial. 59-63', '11.1.4. Quality of life', 'All participants-will be asked to fill out a short QOL survey and on paper at each provider', 'assessment visit at baseline through the start of cycle 6 (unless patients come off study', 'treatment before that time). Appendix V has the required EQ-5D-3L survey.)', '11.1.5 Adherence evaluation', 'Pill diaries will be collected at the end of each cycle of treatment to ascertain dose delivered', 'adherence to palbociclib for a maximum of three cycles from initiation of protocol', 'treatment. Adherence to palbociclib will be measured by patient self-report in dedicated', 'patient diaries. (Appendix VII). Patients will be asked to bring their pill diaries to every', 'clinic visit.', '11.2 Measurement of tumor response and schedule of evaluations', 'Response and progression will be evaluated in this study using the new international criteria', 'proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines', '(version 1.1).', 'Per the new RECIST criteria, as disease response is not the primary endpoint of this trial,', 'confirmatory scans following documentation of progression or response will not be required', 'Rather, progression/response will be determined based on results of the single scan.', 'Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the', 'short axis measurements in the case of lymph nodes are used in the RECIST guideline. 64', 'Schedule of Evaluations', 'For the purposes of this study, patients should be reevaluated for tumor response every 12 weeks.', 'While on study, a CT of the chest, abdomen, with or without pelvis (or PET-CT as above) will', 'be performed every 12 weeks (2 weeks). A bone scan will be done at restaging time points if', 'clinically indicated (or to confirm a complete response).', '50', 'NCIVersion Date: 5/29/2020', 'Update 5']"
50,page_51,"['Alliance A171601', 'Toxicity Evaluation', 'Toxicity evaluations will be performed Days 1 (2 days), 8 (+2 days), and 15 (=2 days) of Cycles', '1 and 2. For subsequent cycles, toxicity evaluations will be done on Day 1 (+2 days). Additional', 'adverse events captured in-between will also be recorded. (Please see study calendar Section', '5.0)', 'All toxicity related dose interruptions or reductions, hospitalizations, and adverse events will be', 'noted. Patients will be followed for toxicity outcomes for an additional 30 days after stopping', 'the drug and until resolution of all grade >2 toxicities. Any toxicities will be recorded in the', ""patient's medical record and highest grade of that toxicity will be reported on the case report"", 'forms.', '11.3 Definitions of Measurable and Non-Measurable Disease', '11.3.1 Measurable Disease', 'Measurable lesions are defined as those that can be accurately measured in at least one', 'dimension (longest diameter to be recorded) as > 10mm with conventional techniques (CT,', 'or caliper measurement). Lymph nodes greater than 15mm on short axis are considered', 'measurable as well. All tumor measurements must be recorded in millimeters (or decimal', 'fractions of centimeters).', 'Tumor lesions in a previously irradiated area are not considered measurable disease.', '11.3.2 Non-Measurable Disease', 'All other lesions (or sites of disease), are considered non-measurable disease.', 'Organomegaly, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis', 'cutis/pulmonis, inflammatory breast disease, and abdominal masses (not followed by CT', 'are all non-measurable.', 'Target lesions: All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions', 'in total, representative of all involved organs, should be identified as target lesions and', 'recorded and measured at baseline. Lymph nodes less than 15mm in the short axis cannot', 'be used as target lesions. Target lesions should be selected on the basis of their size (lesions', 'with the longest diameter) and their suitability for accurate repeated measurements (either', 'by imaging techniques or clinically). A sum of the longest diameter (LD) for all target', 'lesions will be calculated and reported as the baseline sum LD. The baseline sum LD will', 'be used as reference by which to characterize the objective tumor response.', 'Non-target lesions: All other lesions (or sites of disease) including any measurable lesions', 'over and above the 5 target lesions should be identified as non-targetlesions and should', 'also be recorded at baseline. Measurements of these lesions are not required, but the', 'presence or absence of each should be noted throughout follow-up', 'All other lesions (or sites of disease) are considered non-measurable disease, including', 'pathological nodes (those with a short axis > 1.0 to < 1.5cm). Bone lesions, leptomeningeal', 'disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory', 'breast disease, and abdominal masses (not followed by CT), are considered as non-', 'measurable as well.', 'Note: ""Cystic lesions\' thought to represent cystic metastases can be considered as', 'measurable lesions, if they meet the definition of measurability described above. However,', 'if non-cystic lesions are present in the same patient, these are preferred for selection as target', 'lesions. In addition, lymph nodes that have a short axis < 1.0 cm are considered non-', 'pathological (i.e., normal) and should not be recorded or followed.', '51', 'NCI Version Date: 5/29/2020', 'Update 5']"
51,page_52,"['Alliance A171601', '11.4 Guidelines for Evaluation of Measurable Disease', '11.4.1 Measurement Methods', 'All measurements should be recorded in metric notation (i.e., decimal fractions of', 'centimeters) using a ruler or calipers.', 'The same method of assessment and the same technique must be used to characterize each', 'identified and reported lesion at baseline and during follow-up. For patients having only', 'lesions measuring at least 1 cm to less than 2 cm must use CT imaging for both pre- and', 'post-treatment tumor assessments.', 'Imaging-based evaluation is preferred to evaluation by clinical examination when both', 'methods have been used at the same evaluation to assess the antitumor effect of a treatment.', '11.4.2 Acceptable Modalities for Measurable Disease', 'Conventional CT: This guideline has defined measurability of lesions on CT scan', 'based on the assumption that CT slice thickness is 5 mm or less. If CT scans have slice', 'thickness greater than 5 mm, the minimum size for a measurable lesion should be twice', 'the slice thickness.', ""PET-CT: If the site's protocol is to use a PET-CT, then a PET-CT with or without IV"", 'and oral contrast, can be used interchangeably with conventional CT in accurately', 'measuring cancer lesions over time.', 'Physical Examination: For superficial non-nodal lesions, physical examination is', 'acceptable, but imaging is preferable, if both can be done. In the case of skin lesions,', 'documentation by color photography, inc cluding a ruler to estimate the size of the lesion,', 'is recommended.', 'FDG-PET: FDG-PET scanning is allowed to complement CT scanning in assessment', 'of progressive disease [PD] and particularly possible \'new\' disease. A ""positive\' FDG-', 'PET scanned lesion is defined as one which is FDG avid with an update greater than', 'twice that of the surrounding tissue on the attenuation corrected image; otherwise, an', 'FDG-PET scanned lesion is considered ""negative. New lesions on the basis of FDG-', 'PET imaging can be identified according to the following algorithm:', 'Negative FDG-PET at baseline with a positive FDG-PET at follow-up is a sign of', 'PD based on a new lesion.', 'No FDG-PET at baseline and a positive FDG-PET at follow-up:', 'If the positive FDG-PET at follow-up corresponds to a new site of disease', 'confirmed by CT, this is PD.', 'If the positive FDG-PET at follow-up is not confirmed as a new site of disease on', 'CT at the same evaluation, additional follow-up CT scans (i.e., additional follow', '-', 'up scans at least 4 weeks later) are needed to determine if there is truly progression', 'occurring at that site. In this situation, the date of PD will be the date of the initial', 'abnormal PDG-PET scan.', 'If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease', 'on CT that is not progressing on the basis of the anatomic images, it is not classified', 'as PD.', '52', 'NCIVersion Date: 5/29/2020', 'Update 5']"
52,page_53,"['Alliance A171601', '11.4.3 Measurement at Follow-up Evaluation:', 'The cytological confirmation of the neoplastic origin of any effusion that appears or worsens', 'during treatment when the measurable tumor has met criteria for response or stable disease', 'is mandatory to differentiate between response or stable disease (an effusion may be a side', 'effect of the treatment) and progressive disease.', 'Cytologic and histologic techniques can be used to differentiate between PR and CR in rare', 'cases (e.g., residual lesions in tumor types such as germ cell tumors, where known residual', 'benign tumors can remain.)', '11.5 Measurement of Treatment/Intervention Effect', '11.5.1 Target Lesions & Target Lymph Nodes', 'Measurable lesions (as defined in Section 11.3.1) up to a maximum of 5 lesions in total,', 'representative of all involved organs, should be identified as ""Target Lesions"" and recorded', 'and measured at baseline. These lesions can be non-nodal or nodal (as defined in 11.3.1),', 'where no more than 2 lesions are from the same organ and no more than 2 malignant nodal', 'lesions are selected.', 'Note: If fewer than 3 target lesions and target lymph nodes are identified (as there often will', 'be), there is no reason to perform additional studies beyond those specified in the protocol', 'to discover new lesions.', 'Target lesions and target lymph nodes should be selected on the basis of their size, be', 'representative of all involved sites of disease, but in addition should be those that lend', 'themselves to reproducible repeated measurements. It may be the case that, on occasion,', 'the largest lesion (or malignant lymph node) does not lend itself to reproducible', 'measurements in which circumstance the next largest lesion (or malignant lymph node)', 'which can be measured reproducibly should be selected.', 'Baseline Sum of Dimensions (BSD): A sum of the longest diameter for all target lesions', 'plus the sum of the short axis of all the target lymph nodes will be calculated and reported', 'as the baseline sum of dimensions (BSD). The BSD will be used as reference to further', 'characterize any objective tumor response in the measurable dimension of the disease.', 'Post-Baseline Sum of the Dimensions (PBSD): A sum of the longest diameter for all target', 'lesions plus the sum of the short axis of all the target lymph nodes will be calculated and', 'reported as the post-baseline sum of dimensions (PBSD). If the eradiologist is able to provide', 'an actual measure for the target lesion (or target lymph node), that should be rec orded, even', 'if it is below 0.5 cm. If the target lesion (or target lymph node) is believed to be present and', 'is faintly seen but too small to measure, a default value of 0.5 cm should be assigned. If it', 'is the opinion of the radiologist that the target lesion or target lymph node has likely', 'disappeared, the measurement should be recorded as 0 cm.', 'The minimum sum of the dimensions (MSD) is the minimum of the BSD and the PBSD.', '11.5.2 Non-Target Lesions & Non-Target Lymph Nodes', 'Non-measurable sites of disease (Section 11.3.2) are classified as non-target lesions or non-', 'target lymph nodes and should also be recorded at baseline. These lesions and lymph nodes', 'should be followed in accord with 11.5.3.', '53', 'NCIVersion Date: 5/29/2020', 'Update 5']"
53,page_54,"['Alliance A171601', '11.5.3 Response Criteria', 'All target lesions and target lymph nodes followed by CT/PET-CT/physical examination', 'must be measured on re-evaluation at evaluation times specified in Section 11.2.', 'Specifically, a change in objective status to either a PR or CR cannot be done without re-', 'measuring target lesions and target lymph nodes.', 'Note: Non-target lesions and non-target lymph nodes should be evaluated at each', 'assessment, especially in the case of first response or confirmation of response. In selected', 'circumstances, certain non-target organs may be evaluated less frequently. For example,', 'bone scans may need to be repeated only when complete response is identified in target', 'disease or when progression in bone is suspected.', 'Evaluation of Target Lesions', 'Complete Response (CR): All of the following must be true:', 'Disappearance of all target lesions.', 'Each target lymph node must have reduction in short axis to < 1.0 cm.', 'Partial Response (PR): At least a 30% decrease in PBSD (sum of the longest diameter', 'for all target lesions plus the sum of the short axis of all the target lymph nodes at current', 'evaluation) taking as reference the BSD (see Section 11.5.1).', 'Progression (PD): At least one of the following must be true:', 'At least one new malignant lesion, which also includes any lymph node that was', 'normal at baseline(<1.0cm shortaxis) and increased to > 1.0 cm short axis during', 'follow-up.', 'At least a 20% increase in PBSD (sum of the longest diameter for all target lesions', 'plus the sum of the short axis of all the target lymph nodes at current evaluation)', 'taking as reference the MSD (Section 11.5.1). In addition, the PBSD must also', 'demonstrate an absolute increase of at least 0.5 cm from the MSD.', 'See Section 11.4.2 for details in regards to the requirements for PD via FDG-PET', 'imaging.', 'Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient', 'increase to qualify for PD taking as reference the MSD.', 'Evaluation of Non-Target Lesions & Non-target Lymph Nodes', 'Complete Response (CR): All of the following must be true:', 'Disappearance of all non-target lesions.', 'Each non-target lymph node must have a reduction in short axis to <1.0 cm.', 'Non-CR/Non-PD: Persistence of one or more non-target lesions or non-target lymph', 'nodes', 'Progression (PD): At least one of the following must be true:', 'At least one new malignant lesion, which also includes any lymph node that was', 'normal at baseline (<1.0cmshortaxis) and increased to > 1.0 cm short axis during', 'follow-up.', 'Unequivocal progression of existing non-target lesions and non-target lymph', 'nodes. (NOTE: Unequivocal progression should not normally trump target lesion', '54', 'NCIVersion Date: 5/29/2020', 'Update 5']"
54,page_55,"['Alliance A171601', 'and target lymph node status. It must be representative of overall disease status', 'change.)', 'See Section 11.4.2 for details in regards to the requirements for PD via FDG-PET', 'imaging.', '11.5.4 Overall Objective Status', ""The overall objective status for an evaluation is determined by combining the patient's status"", 'on target lesions, target lymph nodes, non-target lesions, non-target lymph nodes, and new', 'disease as defined in the following tables:', 'For Patients with Measurable Disease', 'Target Lesions &', 'Non-Target Lesions &', 'New', 'Overall Objective', 'Status', 'Target Lymph Nodes', 'Non-Target Lymph Nodes', 'Sites of Disease', 'CR', 'CR', 'No', 'CR', 'CR', 'Non-CR/Non-PD', 'No', 'PR', 'PR', 'CR', 'No', 'PR', 'Non-CR/Non-PD', 'CR/PR', 'Not All Evaluated*', 'No', 'PR', 'SD', 'CR', 'No', 'SD', 'Non-CR/Non-PD', 'Not All Evaluated*', 'Not all Evaluated', 'CR', 'No', 'Not Evaluated (NE)', 'Non-CR/Non-PD', 'Not All Evaluated*', 'PD', 'Unequivocal PD', 'Yes or No', 'PD', 'CR', 'Non-CR/Non-PD', 'Not All Evaluated*', 'CR/PR/SD/PD/Not all', 'Unequivocal PD', 'Yes or No', 'PD', 'Evaluated', 'CR/PR/SD/PD/Not all', 'CR', 'Yes', 'PD', 'Evaluated', 'Non-CR/Non-PD', 'Not All Evaluated*', '*', 'See Section 11.5.3', '55', 'NCIVersion Date: 5/29/2020', 'Update 5']"
55,page_56,"['Alliance A171601', 'For Patients with Non-Measurable Disease Only', 'Non-Target Lesions &', 'New', 'Overall', 'Non-Target Lymph Nodes', 'Sites of Disease', 'Objective Status', 'CR', 'No', 'CR', 'Non-CR/Non-PD', 'No', 'Non-CR/Non-PD', 'Not All Evaluated*', 'No', 'Not Evaluated (NE)', 'Unequivocal PD', 'Yes or No', 'PD', 'Any', 'Yes', 'PD', '*', 'See Section 11.5.3', '11.5.5 Symptomatic Deterioration', 'Patients with global deterioration of health status requiring discontinuation of treatment', 'without objective evidence of disease progression at that time, and not either related to study', 'treatment or other medical conditions, should be reported as PD due to ""symptomatic', 'deterioration."" Every effort should be made to document the objective progression even', 'after discontinuation of treatment due to symptomatic deterioration.', '11.6 Definitions of Analysis Variables', 'Formal definitions of variables used in analyses can be found in the Statistical Considerations', 'section of the protocol.', '12.0', 'END OF TREATMENT/INTERVENTION', '12.1 Duration of Treatment', 'Patients should continue protocol treatment until disease progression or unacceptable toxicity.', 'There are no minimum required cycles of therapy.', '12.2 Follow-up for patients who discontinue protocol therapy', '12.2.1 Disease Progression', 'Remove from protocol therapy any patient with disease progression. Document details,', 'including tumor measurements, on data forms.', 'After disease progression, patients should be followed for survival every year per the study', 'calendar (Section 5.0).', '12.2.2 Unacceptable toxicity', 'Patients who discontinue treatment for unacceptable toxicities should continue to be', 'followed for progression. Following progression, patients will be followed every year for', 'survival.', 'In', 'addition, patients who discontinue therapy within 1 year after registration will be', 'followed for toxicity outcomes for an additional 30 days after stopping the drug and until', 'resolution of all grade >2 toxicities. Resolution or stabilization of the adverse event will be', 'recorded even if disease progression has occurred.', '56', 'NCIVersion Date: 5/29/2020', 'Update 5']"
56,page_57,"['Alliance A171601', '12.2.3 Other reasons for discontinuation of protocol therapy', 'Patients who discontinue treatment for any other reason than progression or unacceptable', 'toxicity should continue to be followed for progression. Following progression, patients will', 'be followed every year for survival. The reason for disc ontinuation of protocol treatment', 'must be documented on the ""Off treatment"" form.', '12.2.4 Discontinuation of Geriatric Assessment and Specimen Submission', 'Geriatric Assessment: Patients will complete the geriatric assessment at the end of', 'treatment. If end of treatment occurs prior to the end of Cycle 3, the end of cycle 3', 'assessment need not be submitted. (That is, patients who discontinue protocol treatment', 'prior to the end of cycle 3 will have completed a geriatric assessment at baseline and at the', 'end of treatment.)', 'Specimen Submission: Patients who discontinue protocol treatment prior to the end of', 'Cycle 3 must still be asked to submit an end of treatment blood sample rather than the prior', 'to Cycle 4 blood sample listed in Section 6.2.', '12.3 Managing ineligible patients and registered patients who never receive protocol', 'intervention', 'Definition of ineligible patient', 'A study participant who is registered to the trial but does not meet all of the eligibility criteria', 'is deemed to be ineligible.', 'Follow-up for ineligible patients who continue with protocol treatment', 'Patients who are deemed ineligible after registering may continue protocol treatment, provided', 'the treating physician, study chair, and executive officer agree there are no safety concerns if', 'the patient continues protoco treatment. All scans, tests, and data submission are to continue as', 'if the patient were eligible. Notification of the local IRB may be necessary per local IRB', 'policies.', 'Follow-up for ineligible patients who discontinue protocol treatment', 'For patients who are deemed ineligible after registering to the trial, who start treatment, but then', 'discontinue study treatment, the same data submission requirements are to be followed as for', 'those patients who are eligible and who discontinue study treatment.', 'Follow-up for patients who are registered but who never start study treatment', 'For all study participants who are registered to the trial but who never receive study intervention', '(regardless of eligibility), the follow-up requirements are specified below.', 'Baseline and off-treatment notice data submission required. See the Data Submission Schedule', 'accompanying the All Forms Packet.', '12.4 Extraordinary Medical Circumstances', ""If, at any time the constraints of this protocol are detrimental to the patient's health and/or the"", 'patient no longer wishes to continue protocol therapy, protocol therapy shall be discontinued In', 'this event:', 'Document the reason(s) for discontinuation of therapy on data forms.', 'Follow the patient for protocol endpoints as required by the Study Calendar.', '57', 'NCIVersion Date: 5/29/2020', 'Update 5']"
57,page_58,"['Alliance A171601', '13.0', 'STATISTICAL CONSIDERATIONS', '13.1 Primary Endpoints:', 'The primary endpoint is the adverse event rate at 6 months, defined as the proportion of patients', 'with documentation of grade 3 - 5 toxicity (regardless of attribution using the NCICTCAE v.5.0', 'criteria).', '13.2 Primary Endpoint Analysis:', 'A 95% binomial confidence interval for single proportions will be constructed for the severe', 'toxicity rate occurring the first 6 months of treatment. Univariate relationships between the', 'primary endpoint and various pre-treatment patient characteristics such as anemia, self-assessed', ""functional status, or social support will be described via cross-tabulation and Fisher's exact"", 'testing. Exploratory logistic regression modeling, with limited generalizability due to the', 'modest sample size, will be used to assess the relative contributions of these variables impact', 'the likelihood of developing a severe toxicity during treatment. The strength of this association', 'will be expressed in terms of an odds ratio and its associated 95% confidence interval. As a', 'secondary analysis for this endpoint, we will also look at grade 3-5 toxicities occurring within', 'the first 6 months of treatment that are at least possibly related to palbociclib This analysis will', 'be conducted in a similar fashion as the primary endpoint. To explore the relationship between', 'the severe toxicity rate occurring within the first 6 months of treatment in this population and', 'the type of endocrine therapy used (letrozole VS. fulvestrant), we will conduct a chi-square test', ""or Fisher's exact test as appropriate."", '13.3 Secondary Endpoints:', 'All toxicities associated with the combinations as measured by NCI CTCAE v.5.0', 'Dose reductions, dose holds, and hospitalizations', 'Time to treatment failure (and reason for coming off study - toxicity, patient', 'preference, progression)', 'The percentage of doses of palbocic lib taken each cycle for the first 3 cycles', 'Results of the geriatric assessment, Was It Worth It (WIWI) Questionnaire, and', 'Overall Treatment Utility (OTU)', '13.4 Secondary Endpoint Analyses', '13.4.1 Palbociclib Tolerability', 'Conclusions concerning the tolerability of this regimen in elderly patients will take into', 'account the percentage of patients who develop grade 2 and higher toxicities including', 'febrile neutropenia, leukopenia, thrombocytopenia, and anemia, GI side effects (nausea,', 'diarrhea, decreased appetite, vomiting, stomatitis), fatigue, neuropathy, and', 'thromboembolism . the percentage of patients who require dose modifications and the', 'percentage of patients who refuse to continue on study treatment for any reason.', '13.4.2 Reasons for Dose Reduction, Dose Holds, and Hospitalizations', 'Summaries of reasons for dosereductions, doseholds, and hospitalizations will be prepared', 'Any dose reduction will be considered and reason for dose reduction will be noted. Since', 'palbociclib is given in combination with endocrine therapy as per standard of care, we are', 'evaluating clinical endpoints based on tolerability of the combination. In the case report', 'forms, we will capture whether the toxic ity is due to the endocrine therapy or the palbociclib.', '58', 'NCI Version Date: 5/29/2020', 'Update 5']"
58,page_59,"['Alliance A171601', '13.4.3 Time to Treatment Failure', 'Distributions time to treatment failure will be estimated using Kaplan-Meier methodology.', 'Treatment failure is defined as a severe adverse event, disease progression or patient refusal', 'to continue assigned treatment. We would inc lude any reason that treatment is discontinued', 'to time to treatment failure and not censor patients. The reason for treatment diso continuation', 'will be captured.', '13.4.4 Adherence to Palbociclib', 'Patients to be included in the analysis cohort will be those patients who have taken one or', 'more doses of the study treatment. Those patients will be considered adherent to study', 'treatment. For each of the first 3 cycles, an estimate of the proportion of patients who meet', 'the criteria for adherence and its corresponding 95% confidence interval will be determined.', '13.4.5 Response Rate as Determined by RECIST', 'The response rate is defined as the proportion of patients whose disease status met RECIST', 'criteria for complete response (CR) or partial response (PR) on 2 consecutive evaluations at', 'least 8 weeks apart. A 95% binomial confidence interval for the response rate will be', 'constructed.', '13.4.6 Progression Free Survival (PFS) and Overall Survival (OS)', 'Distributions of PFS and os times will be estimated using Kaplan-Meier methodology.', 'Progression free survival is defined as follows: ""the time from start of treatment to the first', 'of the following disease events: local/regional/distant recurrence, invasive contralateral', 'breast disease, second primary or death due to any cause"".', '13.4.7 Geriatric Assessment, WIWI Questionnaire, and OTU', 'Descriptive statistics will be provided for responses from the WIWI Questionnaire and the', 'OTU. General linear models and graphical methods will be used to explore factors as', 'identified by a cancer-specific geriatric assessment that may be predictive of toxicity/dose', 'reduction, dose holds, or hospitalizations. Repeated measures models and graphic almethods', 'will also be utilized in an exploratory fashion to assess the impact of the length of treatment', 'on the results of the geriatric assessment.', '13.4.8 Sarcopenia analysis', 'Abdominal or thoracic CT images performed as part of routine care for staging and disease', 'monitoring during the trial, (which is every 12 weeks - -See Study calendar Section 5.0) will', 'be acquired from study sites. Using the transverse section at the L3 level for abdominal', 'imaging (as most highly correlated with total body muscle mass [r2=0.86]65) or at L1 level', 'for thoracic imaging (as most highly correlated with L3), 66 skeletal muscle area (SMA) will', 'be quantified within a Hounsfield unit (HU) range of -29 to +150 HU using Slice-O-Matic', 'software .4.3;Tomovision, Montreal, Quebec, Canada). A Skeletal Muscle Index (SMI)', 'will then be calculated using the following formula: SMI = SMA (cm2) / patient height', '(m2). Estimated LBM will also be calculated using the following formula: [LBM (kg) =', '0.30 X [SMA (cm2)] + 6.06].1 15 Mean skeletal muscle density (SMD) will be derived by', 'averaging HU of skeletal muscle. Skeletal muscle gauge (SMG) will then be calculated by', 'multiplying SMI X SMD. Subcutaneous adipose tissue (SAT) area will also be calculated', 'from extra-muscular tissue with density between-190 and - -30 HU, and visceral adipose', 'tissue (VAT) from non-subcutaneous tissue with density between - 150 and -50 HU. The', 'primary measure of skeletal muscle mass will be SMI, and other measures will be assessed', 'secondarily.', '59', 'NCI Version Date: 5/29/2020', 'Update 5']"
59,page_60,"['Alliance A171601', 'Descriptive statistics will be provided for body composition variables including SMI, SMD,', 'SMG, and LBM. Sarcopenia will be treated as a binary variable (based on cut-points of SMI', 'from prior literature ; SMI <41cm2/m2 = sarcopenic 70) and differences in grades 67-69', 'chemotherapy toxicity and adverse events will be analyzed using two group t-tests and', ""Fisher's exact test. Depending on the number of abdominal versus thoracic scans that are"", 'utilized, analyses may be stratified by location of SMA measurement (L3 versus L1).', 'Relative risks (RR) and 95% Confidence Interval (CI) will be reported for associations', 'between sarcopenia and grade 3-5 toxicity and hospitalization, and secondarily for SMD', 'and SMG (based on literature based cut-points). 70,71 Both unadjusted and adjusted RR will', 'be calculated using Poisson regression models with robust variance. 72 Covariates in the', 'model include age, and race/ethnicity. Receiver operating characteristic (ROC) curves will', 'be generated, as well as the area under the curve (AUC), to evaluate the predictive ability', 'of each body composition measure with grades 3-5 toxicity. Depending on the availability', 'of subsequent follow up imaging after 3 treatment cycles, we will describe changes in body', 'composition from baseline to start of cycle 4. We will examine variables associated with', 'skeletal muscle loss during treatment and whether skeletal muscle loss during treatment is', 'associated with the presence of grade 3-5 toxicity and adverse events.', '13.4.9 EuroQol 5D 3L questionnaire:', 'The EQ-5D-3L will be scored and the results will be evaluated descriptively and graphically', '13.4.10 PRO-CTCAE:', 'We will evaluate feasibility of PRO-CTCAE reporting in this population by looking at the', 'compliancerate of the PRO-CTCAE. The PRO-CTCAE will be considered feasible if 75%', 'of the patients completed 75% of the PRO-CTCAE questionnaires. We will also compare', 'symptoms reported by patients on their PRO-CTAE inputs compared to what is reported in', 'clinic using traditional AE evaluations. PRO-CTCAE results will be summarized and', 'presented descriptively.', '13.5 Sample Size', ""The sample size was determined based on Turner et al.'s finding that the severe toxicity rate in"", 'patients age 29 - 88 (approximately 25% age > 70) was 70%.² The sample size is 88 patients', 'which will take into account potential dropout which will allow for 80 evaluable patients. Given', 'a sample of 80 patients, the widest half-width of the 95% confidence limits for the rate of severe', 'toxicities will be less than or equal to 0.1. Assuming a rate of severe toxicities of 70%, our 95%', 'confidence interval will range from 0.6 to 0.8.', 'Additionally, to ensure we have sufficient patients who are aged 75+ to estimate the severe', 'toxicity rate and safety of palbociclib, we will accrue patients until we have 40 patients who are', '75 or older. Given a sample of 40 patients, the widest half-width of the 95% confidence limits', 'for the rate of severe toxicities will be less than or equal to 0. 142. Assuming a rate of severe', 'toxicities of 70%, our 95% confidence interval will range from 0.558 to 0.842.', '13.6 Interim analysis and stopping rules:', 'After approximately 20 patients have completed one full cycle, the study team will review the', 'data (including the toxicity profile, rates of dose reduction, holds and hospitalizations) and', 'assess if the dose being studied is too high, that is if more than 50% of patients experience a', 'dose reduction. If so, a reduction of the dose will be considered, otherwise the study will', 'continue to completion at the planned dose.', '60', 'NCI Version Date: 5/29/2020', 'Update 5']"
60,page_61,"['Alliance A171601', 'Per correspondence with NCI, we include a separate stopping rule for patients with a', 'performance status of 3 or 4 to modify eligibility criteria if there is evidence that patients with', 'PS 3 or 4 do not seem to tolerate the regimen. If, in the review described above of the first 20', 'patients, more than 50% of the patients with performance status 3 or 4 experience an adverse', 'event, we will consider changing the eligibility requirements to preclude patients with PS 3or 4', 'from participating in the study.', 'With Update 2 to the study, we have revised eligibility criteria to restrict study participation to', 'patients with ECOG performance status 0-2. (See Section 3.2.11)', '13.7 Study Reporting', 'This study will be monitored by the study team (including the Study Chair, Committee Chair,', 'study statisticians, protocol coordinator, and Alliance Executive Officer) on a monthly basis, to', 'assess severe adverse events. Reports containing a summary of adverse events will be reviewed', 'on these calls. The study team will also monitor the accrual rate.', '61', 'NCIVersion Date: 5/29/2020', 'Update 5']"
61,page_62,"['Alliance A171601', '13.8 Inclusion of Women and Minorities', 'DOMESTIC PLANNED ENROLLMENT REPORT', 'Ethnic Categories', 'Racial Categories', 'Not Hispanic or Latino', 'Hispanic or Latino', 'Total', 'Female', 'Male', 'Female', 'Male', 'American Indian/', '0', '0', '0', '0', '0', 'Alaska Native', 'Asian', '2', '0', '1', '0', '3', 'Native Hawaiian or', 'Other Pacific', '0', '0', '0', '0', '0', 'Islander', 'Blackor African', 'American', '3', '0', '2', '0', '5', 'White', '70', '0', '10', '0', '80', 'More Than One', '0', '0', '0', '0', '0', 'Race', 'Total', '75', '0', '13', '0', '88', 'Ethnic Categories:', 'Hispanic or Latino - a pers on of Cuban, Mexican, Puerto Rican, Southor Central American, or other', 'Spanish culture or origin, regardless ofrace. The term""Spanishorigin"" canalso be used in', 'addition to ""Hispanic or Latino.""', 'Not Hispanic or Latino', 'Racial Categories', 'American Indian or Alaskan Native - a person having origins in any of the original peoples of North,', 'Central, or South America, and who maintains tribal affiliations or community attachment.', 'Asian - aperson having origins in any of the original peoples of the Far East, Southeast Asia, or the', 'Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia,', 'Pakistan, the Philippine Islands, Thailand, and Vietnam (Note: Individuals fromthe Philippine', 'Islands have beenrecorded as Pacific Is landers in previous datacollection strategies.)', 'Black or African American - a pers onhaving origins in any of the black racial groups of Africa. Terms', 'such as ""Haitian"" or ""Negro"" can be used in addition to ""Black or African American.""', 'Native Hawaiian or other Pacific Is lander - a pers on having origins in any of the original peoples of', 'Hawaii, Guam, Samoa, or other Pacific Is lands.', 'White - a personhaving origins in any of the original peoples of Europe, the Middle East, or North', 'Africa.', '62', 'NCIVersion Date: 5/29/2020', 'Update 5']"
62,page_63,"['Alliance A171601', '14.0', 'EXPLORATORY CORRELATIVE AND COMPANION STUDIES', 'There will be 3 sub studies and all patients are encouraged to participate.', '14.1 Correlative Science: Circulating markers of inflammation as potential markers', 'predictive of toxicity among elderly patients enrolled to Alliance A171601 (Alliance', 'A171601-ST1)', 'Alliance A171601-ST1 will evaluate circulating markers of inflammation as potential markers', 'predictive of toxicity among older patients with Estrogen receptor positive, HER2 negative', 'metastatic breast cancer.', '14.1.1 Background', 'There is great heterogeneity in the ability of older adults to tolerate cancer treatment. Some', 'older patients tolerate treatment well and derive as much benefit from treatment as younger', 'patients, while others have increased rates of toxicity resulting in treatment reductions', 'and/or cessation of treatment. The best-studied tools to predict toxicity are comprehensive', 'geriatric assessments, which require time and resources that limit their use in routine', 'oncology practice. A measure of circulating biomarkers to predict toxicity would be an', 'extremely valuable tool to complement the cancer-specific geriatric assessment to guide the', 'clinician in making treatment decisions and avoid excessivetoxicity in this population. This', 'proposal aims to evaluate circulating markers of inflammation as potential markers', 'predictive of toxicity among older women with metastatic breast cancer. This class of', 'markers was chosen based on their correlation with physical function, functional decline,', 'and mortality in the general geriatric population, as well as emerging evidence of their', 'secretion by senescent cells associated with the aging process. In addition to toxicity, this', 'study will also assess for a correlation between baseline markers of chronic inflammation', 'and other important outcomes such as functional dec line, and treatment modification.', 'Levels of circulating pro-inflammatory mediators such as IL-6 and TNF-alpha, D-dimer,', 'and plasminogen activator inhibitor (PAI)-1, increase with age. 73-75 These markers are', 'proposed to accelerate the aging process and exacerbate multiple age-related diseases. 76-78', 'There is a co-stimulatory affect between markers of inflammation and pro-thrombotic', 'factors. Cytokines such as TNF-a and IL-6 stimulate production of pro-thrombotic factors', 'such as PAI-1 and fibrinogen. 79 In turn, D-dimer, a marker of the clotting process, has been', 'shown to induce synthesis and release of cytokines IL-1B, IL-6, and PAI-1.80 Likewise,', 'when vascular cell adhesion molecule (VCAM) is exposed to inflammatory markers TNF-', 'a and IL-1B, it is cleaved to soluble (s)-VCAM, which is elevated in patients with age-', 'related diseases. 81 Thus, we refer to markers of inflammation and coagulation discussed in', 'this proposal collectively as ""inflammatory mediators\'.', 'Several studies have shown that inflammatory mediators correlate with measures of physical', 'function, and are elevated to a greater degree in frail patients than in age-matched, non-frail', 'controls. 10-16 A study of 110 patients > 75 years demonstrated that a combination of', 'inflammatory markers (TNF-a, IL-6, CRP) and low albumin correlated with lower physical', 'function scores, independent of age, sex, body mass index (BMI), smoking status, number', 'of co-morbidities and number of medica ations82', 'In the general geriatric population, elevated chronic inflammatory and pro-coagulant', 'markers predict functional decline. 83-90 An analysis of disabled women > 65 years showed', 'higher IL-6 levels at baseline were associated with higher levels of functional decline', 'including decreased mobility, activities of daily living deficits, increased walking', 'limitations and decreased walking speed, compared to women with low IL-6levels. 87 These', '63', 'NCI Version Date: 5/29/2020', 'Update 5']"
63,page_64,"['Alliance A171601', 'markers also correlate with functional decline after hospitalization and postoperative', 'complications from oncologic surgery. 85,91', 'Markers of chronic inflammation and coagulation are also associated with all-cause', 'mortality risk in the elderly 83,84,88,90 In a population of community dwelling adults (mean age', '78), soluble (s)-VCAM was independently correlated with poorer functional status at', 'baseline (HR 1.2, p = 0.002). 88 After adjusting for functional status, demographic factors', 'and comorbidities, higher plasma s-VCAM, D-dimer, and IL-6 concentrations were', 'independently related to mortality within 4 years. Inflammatory mediators can have greater', 'predictive ability among patients without baseline functional impairments, suggesting they', 'may identify pre-frail patients that may not otherw ise have been identified without extensive', 'geriatric assessment testing', '83, 90, and 92', 'Previous studies have demonstrated the utility of inflammatory marker measurement in', 'cancer patients. In a study evaluating gait speed of 329 older participants within two', 'physical activity intervention studies, those with an increasing number of elevated', 'inflammatory markers (IL-6, TNFR2, and D-dimer) had lower gait speeds (linear trend', 'p<0.0001; Table 1). This effect was more pronounced among the 6% of patients that were', 'cancer survivors (linear trend p=0.009). The patients with a cancer diagnosis and two', 'elevated biomarkers had a gait speed of 0.88 meters/second (+/-0.37), which is well below', 'the normal gait speed of 1.0 m/sec. The group of cancer survivors also had a clinically', 'meaningful slower gait speed compared to the group without a cancer diagnosis and three', 'elevated biomarkers (-0.20 m/sec). This study indicates circulating markers of', 'inflammation can identify cancer patients in need of targeted interventions to prevent further', 'functional decline.', 'Investigators outside of the United States have recognized that systemic inflammation plays', 'a major role in the decline of cancer patients, especially in terms of nutrition and physical', 'function. The systemic inflammation-based Glasgow Prognostic Score (GPS), based on', 'levels of C-reactive protein (CRP) and hypoalbuminemia, was derived as a surrogate of', 'systemic inflammatory status. Data from 8,333 patients from 28 studies in patients with', 'operable cancer demonstrate the GPS was an independent predictor of survival (HR range', '1.5 - 5.1). 94 Fourteen of these studies involved patients with colorectal cancer and the', 'prognostic significance of the GPS was independent of stage, pathological features, and', 'comorbidity. Similar prognostic ability of the GPS was seen in 11 studies involving 1,504', 'patients with metastatic cancer. In a study of 56 patients with advanced-stage colorectal', 'cancer, the GPS not only predicted survival, but it also predicted toxicity to chemotherapy95', 'A higher GPS score correlated with higher grade 2/3 diarrhea and higher incidence of grade', '2/3 toxicity compared to those with lower scores (p = 0.023 and 0.015 respectively). Other', 'cytokines including IL-1ß, IL-6, IL-2, IL-12, IL-8, TNF-a MIP-1a, and MIP-1ß correlated', 'with clinical outcomes.', 'Emerging data suggest cellular senescence is an underlying process contributing to the', 'increase in circulating inflammatory and pro-thrombotic factors associated with functional', 'decline and mortality in the elderly. 18,29 Senescent cells accumulate with age as a reaction', 'to life-long cellular stress. Although senescent cells are not mitotically active, they acquire', 'a senescence-associated secretory phenotype (SASP), with increased production of proteins', 'involved in chronic inflammation and coagulation, very similar to the markers associated', 'with poorer physical function and mortality in the elderly. 96-97 Therefore, this', 'proposal', 'includes some markers of chronic inflammation that are part of the SASP to evaluate if they', 'are elevated in patients who experienced adverse outcomes with cancer treatment.', '64', 'NCIVersion Date: 5/29/2020', 'Update 5']"
64,page_65,"['Alliance A171601', 'Although chronic inflammatory mediators have not been established as true aging', 'biomarkers, the fact that they correlate with measures of physical status, functional deci line,', 'and mortality in the older adult population suggests they may reflect underlying biologic', ""processes that could predict a patient's risk of toxicity from cancer treatment and therefore,"", 'their ability to tolerate it. The levels of inflammatory mediators can be measured with', 'ELISA assays on plasma samples collected during blood draws routinely done for cancer', 'management. Therefore, the measurement of these levels could become an efficient way of', 'providing the oncologist insight into potential tolerance of cancer therapy and provide', 'guidance as to the most appropriate regimens and doses to prevent excessive toxicity for the', 'older patient.', '14.1.2 Objectives', 'To explore the association between baseline chronic inflammatory mediator levels', 'and development of adverse events.', 'To explore the association between baseline chronic inflammatory mediator levels', 'and treatment modification.', 'To explore the association between baseline chronic inflammatory mediator levels', 'and baseline physical function as assessed by the cancer-specific geriatric', 'assessment.', 'To explore the association between baseline chronic inflammatory mediator levels', 'and decline in physical function as assessed by the cancer-specific geriatric', 'assessment.', '14.1.3 Methods', 'V-Plex panels are 10-spot 96-well plates. Individual panels measure 10 cytokines important', 'in inflammatory responses and immune system regulation, and we anticipate running three', 'V-plex panels for a total of 30 analytes tested. These 10-spot assays can detect secreted', 'biomarkers and assess cytokines important in characterizing THI and TH2 subsets of T cells', 'important in several inflammatory disorders. We will also runnon 10-spot panels for TNFR-', '1, TNFR-2, and D-dimer.', 'The MesoScale Discovery (MSD) platform will be utilized for testing (Meso Scale', 'Discovery Rockville, Maryland). Our proposed studies require 100uL of sample per 10', 'analytes tested on the V-Plex 10-spot platform. Since we plan to use 3 separate V-Plex', 'panels, we anticipate using approximately 300 uL of sample to characterize expression of', '30 cytokines. Additional markers being tested in separate kits include TNFR-1 and TNFR-', '2, as well as D-dimer, which will add another 200 uL of sample requirement. Therefore, the', 'total minimum sample requirement is 500 uL of plasma. Additional sample would be', 'favored, since at least 20% additional sample may be required for error and or pipetting', 'losses. The V-Plex kits are designed for the analysis of all or any combination of these', 'cytokine biomarkers in cell culture supernatants, serum, plasma, and urine.', 'Plasma samples are required for all testing, which will be run in duplicate using the', 'following kits:', '65', 'NCIVersion Date: 5/29/2020', 'Update 5']"
65,page_66,"['Alliance A171601', 'KIT#1:', 'IFN-gamma,IL-1beta,IL-2,IL-4,IL-6,IL-8,IL-10,IL-12p70,IL-13, TNF-alpha', 'Level of detection:', 'IFN-y: 0.04 pg/mL', 'IL-2:0.22 pg/mL', 'IL-4: 0.14 pg/mL', 'IL-5:0.07 pg/mL', 'IL-6:0.61 pg/mL', 'KC/GRO: 0.24 pg/mL', 'IL-10: 0.95 pg/mL', 'IL-12p70:9.95pp/mL', 'TNF-a: 0.13 pg/mL', 'KIT#2:', 'Eotaxin, MIP-1beta, Eotaxin-3, TARC, IP-10, MIP-1alpha, IL-8, MCP-1, MDC,', 'MCP-4', 'Level of detection:', 'Eotaxin: 3.26 pg/mL', 'MIP-1B: 0.37 pg/mL', 'Eotaxin-3: 1.77 pg/mL', 'TARC: 0.22 pg/mL', 'IP-10: 0.37 pg/mL', 'MIP-1a: 3.02 pg/mL', 'IL-8(HA): 95.6 pg/mL', 'MCP-1: 0.09 pg/mL', 'MDC: 1.22 pg/mL', 'MCP-4: 1.69 pg/mL', 'KIT#3:', 'CRP, ICAM-1, SAA, VCAM-1', 'Level of detection:', 'SAA: 10.9 pg/mL', 'CRP: 1.33 pg/mL', 'VCAM-1: 6.00 pg/mL', 'ICAM-1: 1.03 pg/mL', 'KIT#4:', 'TNFR1 and TNFR2', ""TNF-R1: Intra-assay C.V.'s are 6.9%, 3.1%, and 4.2% at 61.01, 4426.3, and"", '3841.2 pg/mL respectively.', ""TNF-R2: Intra-assay C.V.'s are 2.6%, 3.6%, and 3.4% at 126.6, 7158.6, and"", '6120.5 pg/mLrespectively.', '66', 'NCI Version Date: 5/29/2020', 'Update 5']"
66,page_67,"['Alliance A171601', 'KIT#5: D-dimer', 'Level of detection:', '110 - 2,000 ng/mL', 'The Immunochemical Core Laboratory at Mayo Clinic. The ICL is certified by', 'both the College of American Pathologists (CAP# 1808201, AU ID#1183832)', 'and the Department of Health and Human Services (CLIA ID# 24D0861265).', 'Regulatory requirements include thorough test validation, documentation,', 'standardized test procedures and review of quality control markers.', '14.1.4 Analyses', 'Baseline chronic inflammatory mediator levels will be summarized and presented', 'descriptively for all patients. The association between baseline chronic inflammatory', 'mediator levels and the rate of adverse events and treatment modifications will be assessed', 'graphically. Logistic regression models will also be utilized in an exploratory fashion to', 'assess these associations. To examine the association between baseline chronic', 'inflammatory mediator levels and the baseline geriatric assessment scores, we will use', ""graphical means and Spearman's correlation coefficient. Exploratory linear regression"", 'models will also be utilized for this aim. The association between baseline chronic', 'inflammatory mediator levels and the change in the geriatric assessment through time will', 'be analyzed graphically and with exploratory repeated measures models.', '14.2 Pharmacogenomics: (Alliance A171601-ST2): Genetic determinants of Palbociclib', 'Efficacy and toxicity in the elderly', 'Alliance A171601-ST2 will evaluate genetic determinants of palbociclib efficacy and toxicity', 'in elderly patients with estrogen receptor positive, HER2 negative metastatic breast cancer', '14.2.1 Background', 'Multiple endocrine therapy options exist for treatment and prevention of breast cancer in', 'post-menopausal women with estrogen receptor positive breast (HR positive) cancers.98', '100 Aromatase inhibitors (AI) such as letrozole, anastrozole and exemestane which function', 'by inhibiting the aromatase enzyme (CYP19), have improved the recurrence rates of breast', 'cancer after 5 years of tamoxifen treatment compared to placebo. 100 However, side effects', 'notably musculoskeletal symptoms, from AI therapy have led to intolerance and subsequent', 'discontinuation of treatment. 101-102 Data accumulated over the period now suggests that the', 'benefits associated with prolonged endocrine therapy should be balanced with treatment', 'tolerability and fracture risks103', 'Post-menopausal women with metastatic HR positive breast cancers are treated with', 'fulvestrant which acts differently from the AIs by targeting the estrogen receptor. As an', 'antagonist, fulvestrant binds to estrogen receptors competitively on tumors and other tissue', 'targets, producing anuc lear complex that causes a dose-related down-regulation of estrogen', 'receptors and inhibits tumor growth. 104 For advanced metastatic breast cancers exhibiting', 'both HR-positive and human epidermal growth factor receptor 2 (HER2)-negativ', 'characteristics, improved progression free survival has been associated with treatment', 'options that include an AI or fulvestrant together with a cyclin-dependent kinase (CDK) 4/6', 'inhibitor such as palbocic lib. 105-107', 'Palbociclib has been shown to specifically inhibit CDK 4/6 by blocking the progression of', 'cells from G1 into S phase of the cell cycle and resulting in reduced cellular proliferation of', 'ER-positive breast cancer cell lines 108,109 Reports indicate that palbocicl lib enhances the', '67', 'NCI Version Date: 5/29/2020', 'Update 5']"
67,page_68,"['Alliance A171601', 'efficacy of cytostatic agents, such as endocrine therapy or HER2-targeted therapy, but', 'decreases the efficacy of cytotoxic chemotherapy such as with carboplatin and doxorubicin', '110-112 Clinical trials have shown significant benefit in progression free survival for women', 'with metastatic breast cancer on palbociclib with or without prior AI (letrozole) or', 'fulvestrant treatment. The variation in median PFS among the patients have ranged from', '10.2 months (95 % CI, 5.7-12.6) for the letrozole group to 20.2 months (95% CI, 13.8-', '27.5) for the palbociclib-letrozole group suggesting that other factors associated with', 'palbociclib could be contributing to the clinical outcomes. 105 Similar PFS trends were seen', 'in the study of palbociclib with/without fulvestrant 106,107', 'Turner et al.', '106', 'reported a median', 'PFS of 9.2 months (95% CI, 7.5-not estimable) for palbociclib-fulvestrant group and 3.8', 'months (95 % CI, 3.5-5.5) for the placebo-fulvestrant group, 106, while Cristofanilli et', 'al107 reported a median PFS of 9.5 months (95% CI, 9.2-11.0) in thepalbociclib-fulvestrant', 'group and 4.6 months (95% CI, 3.5-5.6) in the placebo-fulvestrant group.', 'All of these trials have shown variations in the clinical outcomes 105-107 One factor that could', 'in part explain some of these variations might be the role of inherited genetic variants whose', 'proteins may be responsible for the biotrans formation of the AIs, fulvestrant and palbocio lib.', 'Several reports on candidate genes and genome wide association studies (GWAS) have', 'correlated single nucleotide polymorphisms (SNP) in the estrogen metabolism related', 'pathway genes with response to endocrine therapy for breast cancer. 114-118 To date, there is', 'no study that has looked at genetic variants associated with palbociclib biotrans formation', 'pathway genes with response to the treatment in metastatic breast cancer, let alone elucidate', 'how these polymorphisms are associated with tolerability and response to palbocic lib', 'therapy in the elderly, specifically women aged 70 years and over. This proposal plans to', 'elucidate the genetic determinants of palbociclib efficacy in post-menopausal women with', 'metastatic HR positive, HER2 negative breast cancers undergoing treatment in the parent', 'study.', 'Palbociclib metabolism, cell cycle proteins, genes and genetic variants : Palbociclib is', 'primarily metabolized by CYP3A enzyme and undergoes sulfonation by SULT2A1 enzyme', 'and undergoes acylation and glucuronidation as minor metabolic patheways 109, 119-121', 'Palbociclib is also a highly selective inhibitor of CDK4 and CDK6 kinases and in low', 'nanomolar concentrations blocks retinoblastoma (Rb) gene protein product pRb. 108', 'Cyclin-dependent kinases (CDKs) are serine/threonine kinases that play a key role in', 'regulating cell cycle progression by associating with cyclins. The cell cycle is a tightly', 'regulated process of five distinct phases: GO (quiescence) followed by G1 (pre-DNA', 'synthesis), S (DNA synthesis), G2 (pre-division) and M (cell division) with the G1 to S', 'phase being the key checkpoint in protecting the cell from abnormal replication.', '108', 'CDK4', 'and CDK6 interact with cyclin D1 early in this checkpoint phase resulting in the', 'phosphorylation of pRb and allowing the release of transcription factor E2F which leads to', 'transcription of other target genes to allow progression to the S phase. 108 CDK activity is', 'thus tightly regulated at severallevels by Cyclin D and retinoblastoma proteins and by CDK', 'inhibitory proteins the INK4 family (p16, p15, p18, p19) and CIP/KIP family (p21, p27,', 'p57). 122-124 Thus when the cell cycle regulatory mechanism is altered, uncontrolled cell', 'proliferation occurs which is a distinctive feature of human cancers. 125', 'Cell cycle genes, polymorphisms and cancer: Many of the genes encoding the cell cycle', 'proteins are frequently mutated in human cancers and this leads to uncontrolled cell division', 'and tumor growth as well. 126 For instance, in breast cancer, alterations in cell cycle', 'regulators have been reported to include amplification of cyclin D1 gene (15-20% cancers)', 'and overexpression of its protein product which has been associated with poor clinical', 'outcomes, to indolent estrogen receptor positive phenotype and to tamoxifen resistance', '68', 'NCI Version Date: 5/29/2020', 'Update 5']"
68,page_69,"['Alliance A171601', 'cycl lin D protein. 108,127-132 Furthermore, studies have been reported that show that inhibiting', 'CDK4 and CDK6 kinases induce G1 arrest in sensitive cell lines and primary bone marrow', 'cells and prevent tumor growth in human myeloma xenografts. 133-137', 'The genes encoding the proteins involved in the G1-S phase include CCNDI[cyclin D1],', 'CCND2 [cyclin D2], CCND3 [cyclin D3], CCNEI [cyclin E] (the cyclin family which', 'regulate cyclin-dependent kinases); CDK2 [p33], CDK4, and CDK6 (cyclin-dependent', 'kinases for the G1/S transition); CDKNIA [p21, Cip1], CDKNIB [p27, Kip1] (CIP/KIP', 'family cyclin-dependent kinase inhibitors); CDKN2A [p16], CDKN2B [p15], CDKN2C', '[p18], and CDKN2D [p19] (INK4 family cyclin-dependent kinase inhibitors) and RBI', 'retinoblastoma gene. Studies relating to genetic polymorphisms in cell cycle genes and risk', 'of some cancers including lung, bladder, prostate, breast, ovarian, endometrial, pancreas,', 'and colorectal¹ 138-145 have been published although none have taken into consideration the', 'effects these inherited genetic variations may have on the efficacy of palbociclit which', 'specifically inhibits the CDK4/6 check point.', 'In breast cancer studies, polymorphisms such as CDKNIB rs2066827 has been associated', 'with shortened disease-free survival in patients with infiltrating metastasis-free breast', 'cancer146 while CCND3 rs2479717 has been associated with an increased risk of death. 147', 'Other SNPs including CCNE. 1 rs997669, CDKNIA rs3176336, CDKNIB rs34330,', 'CDKN2B rs3218005 and CDKN2A rs3731239 have been associated with breast cancer as', 'well. 148 CCNDI rs9344 (CCND1-02 A870G or CCNDI G870A) the most studied SNP in', 'CCNDI and previously referred to as CCND1 rs603965 has been shown to be associated', 'with breast cancer survival in Chinese subjects, 149 and has also been associated with breast', 'cancer risk and poorer breast cancer specific survival in patients with metastatic breast', 'cancer. 15-152 Polymorphisms in CYP3A4 1153,154 and in SULT2A1 155,156 have', 'also', 'been', 'associated with breast and other cancers.', 'These associations of the cell cycle gene SNPs with breast cancer may be influenced by', ""palbociclib's action of inhibiting CDK4/6 in the G1-S transition point thereby modifying"", 'clinical response and toxicity outcomes. This study is ideal to elucidate the associations of', 'cell cycle SNPs in the presence of palbociclib on breast cancer in the elderly. We note that', 'polymorphisms in aromatase CYP19A, CYP2A6 and estrogen receptor ERSI genes 157-160', 'the targets for AI inhibitors and fulvestrant respectively, have also been associated with', 'breast cancer. Therefore SNPs in these 2 genes under the influence of their specific', 'inhibitors combined with palbociclib in the treatment (choice of AI or fulvestrant made at', 'the discretion of the treating investigator) will be studied for associations with clinical', 'response and toxicity to palbociclib Furthermore, the genetic variants in palbociclib related', 'genes will be correlated with the primary objective of the study which includes tolerability', '(adverse events); and with the secondary objectives which include toxicity, response to', 'treatment, and overall survival.', 'We hypothesize that inherited genetic polymorphisms in cell cycle pathway genes and in', 'genes that metabolize palbociclib will correlate with clinical outcomes in elderly patients', 'undergoing palbociclib treatment for estrogen receptor positive, HER2 negative metastatic', 'breast cancer. We further hypothesize that genes in CYP19A1, CYP2A6 and ESR1 will also', 'correlate will toxicity outcomes in this study.', 'We propose to achieve this hypothesis by genotyping patient DNA samples for SNPs in the', 'cell cycle genes including CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6,', 'CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D, CYP3A4,', 'CYP19A1, CYP2A6, ESRI RB1 and SULT2A1 and correlate these SNPs to efficacy and', 'toxicity of palbociclib.', '69', 'NCI Version Date: 5/29/2020', 'Update 5']"
69,page_70,"['Alliance A171601', '14.2.2 Objectives', 'To explore whether inherited genetic single nucleotide polymorphisms (SNPs) in', 'cell cycle pathway genes and in genes that metabolize palbociclib are associated', 'with efficacy and toxicity in elderly patients undergoing endocrine plus palbocic lib', 'therapy for estrogen receptor positive, HER2 negative metastatic breast cancer.', 'To explore whether SNPs in CYP19A1, CYP2A6 and ESRI will also correlate with', 'efficacy and toxicity in elderly patients undergoing endocrine plus palbociclib', 'treatment for estrogen receptor positive, HER2 negative metastatic breast cancer.', '14.2.3 Methods', 'Whole blood sample will be collected in 1 x10 mL EDTA vacutainer tube (purple top) from', 'patients at start of study for germline DNA isolation. Blood samples will be sent to a central', 'location at Mayo Clinic and DNA will be isolated in the Biospecimen Accessioning and', 'Processing (BAP) laboratory(submission instructions are in Section 6.2)', 'SNP selection Genotype data from the National Center for Biotechnology Information', '(NCBI) dbSNP database will be used with programs in National Institute of environmental', 'Health Sciences', 'Genome', 'variation', 'server', 'to derive tagged SNPs from the list of 18 genes', 'namely CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN1A,', 'CDKN1B, CDKN2A, CDKN2B, CDKN2C, CDKN2D, CYP3A4, CYP19A1, CYP2A6,', 'ESR1, RB1 and SULT2A1. SNPs with allele frequencies 30% and r2 0.80 will be', 'selected for genotyping. Since only 88 patients will be accrued for the study, this minor', 'allele frequency (maf) cut offof 30% will ensure that we observe at least 10% of the patients', 'with a SNP of interest. It is important to indicate here that the overall sample number of 88', 'is low, therefore any associations may serve as hypothesis generating for larger study', ""numbers in the future. It is also important to note that there's ethnic variation in specific"", 'SNPs and their frequencies, therefore whenever the patient numbers are large enough to', 'obtain meaningful information on diverse populations, genotype information from the', 'database should reflect the patient population on the trial. The acquired tagSNPs (See', 'Appendix VIII) will be genotyped in the Genotyping Core of the Mayo Clinic Medical', 'Genome Facility (MGF) or in any Alliance associated genotyping core on either the', 'Sequenom or the Illumina GoldenGate custom array. A partial list of tag SNPs to be', 'genotyped is shown in the Table below:', 'Partial list of cell cycle pathway genes and SNPs to be genotyped', 'Alleles', 'Global Minor', 'Variant location/', 'allele', 'Gene', 'description', 'dbSNPrsid', 'function', 'Major', 'Minor', 'frequency', '(MAF)', 'CDK4', 'Cyclin dependent', 'rs 2069502', 'intron', 'C', 'T', '0.3367', 'kinase4', 'Cyclin dependent', 'CDK6', 'rs 2282978', 'intron', 'T', 'C', '0.3141', 'kinase 4', 'CCND1', 'cyclin D1', 's9344', 'synonymous codon', 'G', 'A', '0.413', 'CDKNIA', 'p21', 'rs 3176336', 'intron', 'T', 'A', '0.3678', 'CDKN1B', 'p27', '334330', '2KB upstream, 5UTR', 'C', 'T', '0.3383', 'CDKN2A', 'p16', 'rs 2811710', '500B downstream 3UTR', 'C', 'T', '0.4708', 'CDKN2B', 'p15', 'rs 3217992', '3UTR, intron', 'C', 'T', '0.3482', 'CDKN2D', 'p19', 'rs 1465701', 'intron', 'C', 'T', '0.4193', '70', 'NCIVersion Date: 5/29/2020', 'Update 5']"
70,page_71,"['Alliance A171601', 'Genotyping', 'The Agena iPLEX (previously called sequenom) genotyping protocol involves PCR', 'amplification of DNA using SNP specific primers, followed by a base extension reaction', 'using the iPLEX Gold chemistry (Agena Biosciences, San Diego, CA). The protocol has', 'been used for years and will briefly be described here. SNP-specific PCR and extension', 'primers were designed and organized into pools with the Assay Design Suite (Agena). All', 'primers were purchased from Integrated DNA Technologies (Coralville, IA). A QC run was', 'performed with Coriell and CEPH controls, and results were tested for Mendelian', 'inconsistencies. HotStar Taq Polymerase (Qiagen) was used for all PCRs. 15 ng of DNA', 'was added to each 5-ul PCR reaction mixture in a 384-well microtiter plate. The PCR', 'condition was 94°C for 15 min for hot start, followed by 45 cycles of denaturing at 94°C', 'for 20 sec, annealing at 56°C for 30 sec, extension at 72°C for 1 min for 45 cycles, and final', 'incubation at 72°C for 3 min. The PCR products were then treated with SAP (shrimp', 'alkaline phosphatase, Agena) for 40 min at 37°C then ramped to 85°C for 5 min to remove', 'excess dNTPs. The final base extension products were diluted in double distilled water and', 'then treated with 6mg of SpectroCLEAN (Agena) resin per well to remove contaminating', 'salts. 10-18 nl of treated extension product was spotted to the appropriate location on a 384-', 'pad SpectroCHIP II (Agena) using a RS1000 Nanodispenser (Agena, San Diego, CA). A', 'MassARRAY Analyzer Compact MALDI-TOF MS (Agena) was used for data acquisitions', 'from the SpectroCHIP. All resultant genotyping calls were performed in real time by the', 'MassARRAY Typer Analyzer v4.0.26.73 (Agena)', '14.2.4 Analyses', 'SNP analysis: Results from genotyping will be sent to the bioinformatics/statisticians for', 'analyses to correlate the SNPs with the primary objective of the study which is adverse', 'events. The SNPs will also be correlated to the secondary objectives which include toxicity,', 'response to treatment and overall survival.', '14.2.5 Hypotheses', '1. Patients with higher biomarker levels have an increased incidence of grade 3+ adverse', 'events.', '2. Patients with higher biomarker levels have higher rates of treatment modification', 'during adjuvant therapy.', '3. Patients with higher biomarker levels have poorer baseline performance status and', 'higher rates of performance status dec line during adjuvant therapy.', '14.2.6 Statistical analyses', 'Treatment modification is defined as any dose reduction or omission during the course of', 'the study. Biomarker levels will be compared to grade 3+ adverse event incidence (as', 'measured by the CTCAE version 5.0), rate of treatment modification, baseline performance', 'status and performance status throughout the course of the study descriptively and', 'graphically. Any testing done will be done in an exploratory manner.', '71', 'NCIVersion Date: 5/29/2020', 'Update 5']"
71,page_72,"['Alliance A171601', '14.3 Pharmacokinetics: (Alliance A171601-PP1) Population Pharmacokinetics of Palbociclib', 'Alliance A171601- - PP1 will evaluate if palbociclib exposure (AUC/Cmux) is related to change', 'from baseline in neutrophil numbers i.e. neutropenia.', '14.3.1 Background and Hypotheses', 'Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6).', 'The FDA approved regimen is a 125 mg capsule of palbociclib taken orally once daily for', '21 consecutive days followed by 7 days off treatment combined with letrozole 2.5 mg PO', 'daily, on 28-day cycles.', 'Palbociclib is slowly absorbed with a Tmax of 6-12h following an oral 125 mg dose, with a', 'mean Cmax of 133 (+/-SD 18.6) ng/mL. The terminal elimination half-life is mean 29 +/- 5', 'h, and steady state concentrations are usually reached in 8 days. The palbociclib is 85%', 'bound to plasma proteins and its geometric mean apparent volume of distribution (Vz/F)', 'was 2583 L with a coefficient of variation (CV) of 26%. The geometric mean apparent oral', 'clearance (CL/F) of palbocic lib was 63.1 L/hr (29%CV). In 6 healthy male subjects given', 'a single oral dose of 14C- palbociclib, a median of 91.6% of the total administered', 'radioactive dose was recovered in 15 days; feces (74.1% of dose) was the major route of', 'excretion, with 17.5% of the dose recovered in urine. The majority of the material was', 'excreted as metabolites.', 'Palbociclib absorption and exposure were very low in approximately 13% of the population', 'under the fasted condition. Food intake increased the palbociclib exposure in this small', 'subset of the population, but did not alter palbociclib exposure in the rest of the population', 'to a clinically relevant extent. Therefore, food intake reduced the intersubject variability of', 'palbociclib exposure, which supports administration of palboci lib with food. Compared to', 'palbociclib given under overnight fasted conditions, the population average area under the', 'concentration-time curve from zero to infinity (AUC(inf) and Cmax of palbocicl lib increased', 'by 21% and 38%, respectively, when given with high-fat, high-calorie food (approximately', '800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, carbohydrate, and', 'fat, respectively), by 12% and 27%, respectively, when given with low-fat, low-calorie food', '(approximately 400 to 500 calories with 120, 250, and 28 to 35 calories from protein,', 'carbohydrate, and fat, respectively), and by 13% and 24%, respectively, when moderate-fat,', 'standard calorie food (approximately 500 to 700 calories with 75 to 105, 250 to 350 and 175', 'to 245 calories from protein, carbohydrate, and fat, respectively) was given 1 hour before', 'and 2 hours after palbocic lib dosing.', 'In vitro and in vivo studies indicate that palbociclib undergoes hepatic metabolism in', 'humans. Following oral administration of a single 125 mg dose of 14C palbociclib to', 'humans, the primary metabolic pathways for palbociclib involved oxidation and', 'sulfonation, with acylation and glucuronidation contributing as minor pathways. Palbociclib', 'was the major circulating drug-derived entity in plasma (23%). The major circulating', 'metabolite was a glucuronide conjugate of palbociclib although it only represented 1.5% of', 'the administered dose in the excreta. Palbociclib was extensively metabolized with', 'unchanged drug accounting for 2.3% and 6.9% of radioactivity in feces and urine,', 'respectively. In feces, the sulfamic acid conjugate of palbociclit was the major drug-related', 'component, accounting for 26% of the administered dose. Data from a clinical trial in', 'patients with breast cancer showed that there was no drug interaction between palbociclib', 'and letrozole when the 2 drugs were coadministered.', 'In vitro studies with human hepatocytes, liver cytosolic and S9 fractions, and recombinant', 'SULT enzymes indicated that CYP3A and SULT2A1 are mainly involved in the', '72', 'NCI Version Date: 5/29/2020', 'Update 5']"
72,page_73,"['Alliance A171601', 'metabolism of palbociclib. In vivo, palbociclib exposure was increased by 1.9-fold when it', 'was coadministered with itraconazole (strong CYP3A4 inhibitor), and co-administration of', 'strong CYP3A4 inhibitors should be avoided. If co-administration with a strong CYP3A', 'inhibitor cannot be avoided, the daily palbociclib dose should be reduced to 75 mg. In vivo,', 'palbociclib exposure was decreased by 85% when it was coadministered with rifampin', '(strong CYP3A inducer), and co-administration of strong CYP3A inducers should be', 'avoided. The effect of moderate CYP3A inducers on palbociclib exposure is not known,', 'and co-administration of moderate CYP3A4 inducers should be avoided. Co-administration', 'of palbociclib with multiple doses of rabeprazole (proton pump inhibitor) under fed', 'conditions did not have a clinically significant effect on palbociclib exposure. In vitro,', 'palbociclib caused time-dependent inhibition of CYP3A4. Palbociclib increased the', 'midazolam (CYP3A substrate) AUC by 61% in healthy subjects, and therefore co-', 'administration of sensitive CYP3A substrates with narrow therapeutic indices should be', 'avoided.', 'Based on prior population pharmacokinetic analysis from male and female patients treated', 'with palbociclib, neither gender, age nor body weight had a clinically important effect on', 'palbociclib exposure. Furthermore, no dose reduction is needed in patients with mild or', 'moderate renal impairment, or mild hepatic impairment. No clinically significant change in', 'the QTc interval was detected when palboc ic lib was administered to steady state. Definitive', 'conclusions regarding an exposure-response relationship for progression free survival (PFS)', 'could not be made based on the limited data at a fixed dose of 125 mg from prior clinical', 'studies. However, a greater reduction in absolute neutrophil count is suggested to be', 'associated with increased palbociclib exposure. These exposure effect relationships for', 'older patients (over 70 and over 75 years of age) have not been defined.', 'The primary hypothesis of this population-pharmacokinet nested study is', '(1) That palbociclib exposure (AUC/Cmax) is related to change from baseline in neutrophil', 'numbers i.e. neutropenia.', 'Secondary exploratory hypotheses are that palbocic lib exposure is associated with (i) degree', 'of thrombocytopenia in older patients (ii) progression free survival in older patients (iii)', 'these relationships will be strengthened by consideration of known polymorphisms in', 'palbociclib drug metabolizing enzymes (especially CYP3A and SULT-2A1) and drug', 'transporters.', '14.3.2 Objectives:', 'To refine a population pharmacokinetic model (of Sun and Wang) using', 'NONMEM for palbociclib taking account of relevant intrinsic and extrinsic', 'factors.', 'To determine the intrapatient and interpatient variability of palbociclib (AUC) in', 'older breast cancer patients receiving palbociclib plus letrozole', 'To explore the exposure (AUC/Cmax) toxicity (neutropenia, thrombocytopenia)', 'relationship for palbociclib when combined with letrozole in older breast cancer', 'patients', '14.3.3 Methods', 'For patients in the study who are receiving palbociclib plus letrozole or fulvestrant, venous', 'blood samples for palbociclib concentrations will be obtained at baseline, and at the', 'scheduled follow-up clinic visits on day 15 of cycle 1 and cycle 2, while still receiving study', 'drug therapy. These samples will have the time of day they were obtained documented. At', '73', 'NCI Version Date: 5/29/2020', 'Update 5']"
73,page_74,"['Alliance A171601', 'these follow up visits a Patient Pharmacokinetic Questionnaire (see Appendix IX) will be', 'filled in which will request information about the prior 48h dosing of palbociclit and the', 'concomitant medications. This will detail the time of day the last two doses of study drug', 'were taken, and relationship of when the doses were taken in relation to meals.', 'Palbociclib plasma concentrations will be measured using an LC-MS-MS assay validated', 'in the Alliance Pharmacology/Pharmacokinetic core lab at the Univ. of Pittsburgh using a', 'modification of the validated and published assay by Paul et al Biomed Chromatogr. 2018', 'Dec 13:e4469.', 'Pharmacokinetic population data modeling of the Cmin (trough) drug concentrations will be', 'performed using NONMEM to derive palbociclib specific AUCs and the intra and inter-', 'patient variability (see below for details).', '14.3.4 Statistical design:', 'The primary scientific hypothesis is that palbociclib exposure (AUC/Cmux) is related to', 'change from baseline in neutrophil numbers i.e. degree of neutropenia.', 'Population Pharmacokinetic Modeling: We will develop parametric population', 'pharmacokinetics models for the exposure of palbociclib. To capture both between and', 'within-subject variabilities in palbociclib exposures, a non-linear mixed effects model will', 'be used. In particular, we will consider models of the form', 'yi [t] = y [t,0,ni;D,x] + Ei [t]', 'where denotes yi [t] the observed plasma concentration at time t, t (t1 tk), obtained', 'through sparse sampling as previously described, for the i-th individual and denotes the', 'vector of population parameters of size p. The quantity D denotes the dose level and X is a', 'vector of additional covariates. The random vectorsiand = (i[t1]', 'i[tk]) account for the', 'between and within subject variabilities respectively. If possible, non-linearities with', 'respect to time will be explored. The model will be fitted using first-order conditional', 'maximum likelihood estimation in the NONMEM program (version 5) 161 For this purpose', 'it will be assumed that the random effects i. in are independent q-variate mean-zero normal', 'random variables with common variance i where q is at most equal to p (the dimension of', 'the population parameter vector 0). It is also assumed that the measurement errors 1', ',n', 'are independent k-variate mean-zero normal vectors with common covariance matrix.', 'Individual armacokinetic parameter estimates will be obtained from the estimated', 'population PK model for palbociclib.', 'Covariate testing will be performed to identify sources of variability in exposure to', 'palbociclib among individuals. Covariates that will be tested include: demographic', 'characteristics, organ function markers, disease severity, genetic markers, and concomitant', 'medications and time relationship to ingestion of the previous meal. All derived PK', 'parameters will be summarized using standard numerical and graphical displays.', 'Pharmacometric Analyses:', 'Patients with pharmacokinetic, key toxicity and efficacy data will be included in the', 'pharmacometric analyses. First a population pharmacokinetic approach will be employed', 'to analyze the plasma concentration data for palbociclib. Relevant demographic and', 'intrinsic /extrinsic factors will be explored for covariate relationship. Different empirical', 'Bayesian PK parameters will be correlated initially with toxicity and later with efficacy', 'endpoints such as the overall survival. Pharmacokinetic-biomarker relationships using key', 'markers will also be conducted.', '74', 'NCI Version Date: 5/29/2020', 'Update 5']"
74,page_75,"['Alliance A171601', 'Population PK sampling schedule', 'Patients are scheduled to bereviewed in the clinic on Day 15 of cycle 1 and 2. Venous blood', '(5 ml) will be obtained at the time of these clinic visits and medical evaluations. Patients', 'MUST be instructed NOT to take their palbociclit dose on the day of these visits before', 'being seen and having this blood sample obtained. Blood will be collected into potassium', 'EDTA (lavender top) tubes, and plasma separated by centrifugation at 1500 g for 10', 'minutes. Aliquots of plasma will then be placed in labelled polypropylene tubes (1 mL in', 'each of two tubes) and stored at - -70 to - 80 °C until shipped on dry ice to the Alliance', 'Pharmacology/Pharmacokinetic core as indicated in Section 6.2.1.', '75', 'NCIVersion Date: 5/29/2020', 'Update 5']"
75,page_76,"['Alliance A171601', '15.0', 'GENERAL REGULATORY CONSIDERATIONS AND CREDENTIALING', '15.1 Geriatric Assessment Training', 'At each participating site, a research nurse or clinical research professional (CRP) (person who', 'intends to administer the geriatric assessment) will receive training on administration of the', 'geriatric assessment using the online video training module through the Alliance website,', 'hyperlink below:', 'To login, select ""Member Login"" on the Alliance homepage and enter the CTEP-IAM account', 'username and password. After logging in, the training module can be found under education and', 'training > online training and under ""For Site Staff."" Once the training is complete, print a copy', 'of the completion certificate to keep in the study records and submit it to CTSU according to', 'Section 4.2.3. Training completed within the past two years is acceptable, as it is not study', 'specific.', 'Any further questions or concerns regarding administering the geriatric assessment may be', 'directed to the study chair.', '76', 'NCIVersion Date: 5/29/2020', 'Update 5']"
76,page_77,"['Alliance A171601', '16.0', 'REFERENCES', '1.', 'Finn RS, Crown JP, Lang I, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in', 'combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-', 'positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase', '2', 'study. Lancet Oncol 16:25-35, 2015', '2.', 'Turner NC, Ro J, Andre F, et al: Palbociclib in Hormone-Receptor-Positive Advanced Breast', 'Cancer. N Engl J Med 373:209-19, 2015', '3.', 'Hurria A, Gupta S, Zauderer M, et al: Developing a cancer-specific geriatric assessment. Cancer', '104:1998-2005, 2005', '4.', 'Hurria A, Cirrincione CT, Muss HB, et al: Implementing a geriatric assessment in cooperative', 'group clinical cancer trials: CALGB 360401. J Clin Oncol 129:1290-6, 2011', '5.', 'Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with', 'cancer: a prospective multicenter study. J Clin Oncol29:3457-65, 2011', '6.', 'Hurria A, Dale W, Mooney M, et al: Designing therapeutic clinical trials for older and frail adults', 'with cancer: U13 conference rec commendations. J Clin Oncol 32:2587-94, 2014', '7.', 'Hurria A, Naylor M, Cohen HJ: Improving the quality of cancer care in an aging population:', 'recommendations from an IOM report. JAMA 310:1795-6, 2013', '8.', 'Sawhney R, Sehl M, Naeim A: Physiologic aspects of aging: impact on cancer management and', 'decision making, part I. Cancer J 11:449-460, 2005', '9.', 'Sehl M, Sawhney R, Naeim A: Physiologic aspects of aging: impact on cancer management and', 'decision making, part II. Cancer J 11:461-473, 2005', '10.', 'Duthie E: Comprehensive Geriatric Oncology, Taylor and Francis, 2004', '11.', 'Yuen G: Altered pharmacokinetics in the elderly. Clin Geratr Med 6:257-267, 1990', '12.', 'Baker S, Grochow L: Pharmacology of chemotherapy in the older person. Clin Geratr Med', '13:169-183, 1997', '13.', 'Kastrissios H, Blaschke T: Medication compliance as a feature in drug development. Annu Rev', 'Pharmacol Toxico 37:451-475, 1997', '14.', 'Vestal RE: Aging and pharmacology. Cancer 80:1302-1310, 1997', '15.', 'Baker S, van Schaik R, Rivory L, et al: Factors affecting cytochrome P-450 activity in cancer', 'patients. Clin Cancer Res 10:8341-8350, 2004', '16.', 'Sotaniemi E, Arranto A, Pelkonen O, et al: Age and cytochrome P450-linked drug metabolism in', 'humans: an analysis of 226 subjects with equal histopathological conditions. Clin Pharmacol Ther', '61:331-339, 1997', '17.', 'Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of', 'kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of', 'progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Eng J Med', '307:652-659, 1982', '18.', 'Lichtman SM, Wildiers H, Launay-Vacher V, et al: International Society of Geriatric Oncology', '(SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal', 'insufficiency. Eur J Cancer 43:14-34, 2007', '19.', 'Hurria A, Lichtman SM: Pharmacokinetics of Chemotherapy in the Older Patient. Cancer Control', '14:32-43, 2007', '20.', 'Baker S, Grochow L: Pharmacology of chemotherapy in the older person. Clin Geriatr Med', '13:169-183, 1997', '21.', 'Crome P, Flanagan R: Pharmacokinetic studies in elderly people. Pharmacokine 26:243-247,', '1994', '77', 'NCIVersion Date: 5/29/2020', 'Update 5']"
77,page_78,"['Alliance A171601', '22.', 'Kimmick G, Fleming R, Muss H, et al: Cancer chemotherapy in older adults: A tolerability', 'perspective. Drugs Aging 10:34-49, 1997', '23.', 'BalducciL Corcoran M: Antineoplastic chemotherapy of the older cancer patient. Hematol', 'Oncol Clin N Am 14:193-212, 2000', '24.', 'Maione P, Perrone F, Gallo C, et al: Pretreatment quality of life and functional status assessment', 'significantly predict survival of elderly patients with advanced non-small-cell lung cancer', 'receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer study in the', 'elderly study. J Clin Oncol 123:6865-6872, 2005', '25.', 'Freyer G, Geay J, Touzet S, et al: Comprehensive geriatric assessment predicts tolerance to', 'chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO', 'study. Ann Oncol 16:1795-1800, 2005', '26.', 'Repetto L, Fratino L, Audisio R, et al: Comprehensive geriatric assessment adds information to', 'Eastern Cooperative Group performance status in elderly cancer patients; an Italian Group for', 'Geriatric Oncology Study. J Clin Oncol 20:494-502, 2002', '27.', 'Rao A, Hsieh F, Feusser J, et al: Geriatric evaluation and management units in the care of the frail', 'elderly patient. J Gerontol A Biol Sci Med Sci 60:798-803, 2005', '28.', 'Extermann M, Aapro M, Bernabei R, et al: Use of coprehensive geriatric assessment in older', 'cancer patients: recommendation from the task force on CGA of the International Society of', 'Geriatric Oncology. Crit Rev Oncol Hematol 55:241-252, 2005', '29.', 'Giacinti C, Giordano A: RB and cell cycle progression. Oncogene 25:5220-7, 2006', '30', 'Finn, R.S. et al: Primary results from a phase III trial of palbociclib (P) with letrozole (L)', 'compared with letrozole alone in postmenopausal women with ER+/HER2- - advanced breast', 'cancer (ABC). NEJM 2016', '31.', 'Crown J, Finn RS, Ettl J, et al: Efficacy and safety of first-line palbociclit plus letrozole', 'compared with letrozole alone in patients aged >= 65 years with estrogen receptor-positive,', 'HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18', 'trial. Journal of Clinical Oncology 33, 2015', '32.', 'Slamon DJ, Crown J, Lang I, et al: Long-term safety profile of palbociclib (P) in combination', 'with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2-', 'advanced breast cancer (ABC) (PALOMA-1/TRIO-18). Journal of Clinical Oncology 33, 2015', '33', 'Visser M, Goodpaster BH, Kritchevsky SB, et al. Muscle mass, muscle strength, and muscle fat', 'infiltration as predictors of incident mobility limitations in well-functioning older persons. The', 'journals of gerontology. Series A, Biological sciences and medical sciences. 2005;60(3):324-333', '34', 'Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older', 'persons is associated with functional impairment and physical disability. Journal of the American', 'Geriatrics Society. 2002;50(5):889-896.', '35.', 'Rolland Y, Czerwinskis Abellan Van Kan G, et al. Sarcopenia: its assessment, etiology,', 'pathogenesis, consequences and future perspectives. The journal of nutrition, health & aging.', '2008;12(7):433-450.', '36.', 'Metter EJ, Conwit] R, Tobin J, Fozard JL. Age-associated loss of power and strength in the upper', 'extremities in women and men. The journals of (gerontology. Series A, Biological sciences and', 'medical sciences. 1997;52(5):B267-276.', '37.', 'Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. The American journal of', 'clinical nutrition. 2010;91(4):1123S-1127S.', '38.', 'Molina-Garrido MJ, Guillen-Ponce C, Fernandez-Felix BM. Relationship Between Sarcopenia', 'and Frailty in a Spanish Cancer in the Elderly Unit: The ONCOSARCO Project. Journal of the', 'American Medical Directors Association. 2016;17(8):760-761', '78', 'NCI Version Date: 5/29/2020', 'Update 5']"
78,page_79,"['Alliance A171601', '39.', 'Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer', 'cachexia. Nat Rev Clin Oncol. 2013;10(2):90-99.', '40.', 'Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793-', '799.', '41.', 'Weinberg M, Shachar S, Deal A, et al. Characterization of skeletal muscle and body mass indices', 'in younger and older women with stage II and III breast cancer. Journal of the American', 'Geriatrics Society. 2016;supplement:S86.', '42.', 'Strulov Shachar S, Deal AM, Weinberg M, et al. Skeletal Muscle Measures as Predictors of', 'Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving', 'Taxane Based Chemotherapy. Clinical cancer research : an official journal of the American', 'Association for Cancer Research. 2016.', '43.', 'Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. Apractical and', 'precise approach to quantification of body composition in cancer patients using computed', 'tomography images acquired during routine care. Appl Physiol Nutr Me. 2008;33(5):997-1006.', '44.', 'Aubrey J, EsfandiariN, Baracos VE, et al. Measurement of skeletal muscle radiation attenuation', 'and basis of its biological variation. Acta physiologica. 2014;210(3):489-497.', '45', 'Shaw JW, Johnson JA, Coons SJ (2005). US valuation of the EQ-5D health states: development', 'and testing of the D1 valuation model. Med Care; 43(3): 203-220', '46', 'Rock, E. P., D. L. Kennedy, et al. (2007). ""Patient-reported outcomes supporting anticancer', 'product approvals."" J Clin Oncol 25(32): 5094-5099.', '47', 'Basch, E., X. Jia, et al. (2009). ""Adverse symptom event reporting by patients VS clinicians:', 'relationships with clinical outcomes."" J Natl Cancer Inst 101(23): 1624-1632.', '48', 'Fromme, E. K., K. M. Eilers, et al. (2004). ""How accurate is clinician reporting of chemotherapy', 'adverse effects? Acomparison with patient-reported symptoms from the Quality-of-Life', 'Questionnaire C30."" J Clin Oncol 22(17): 3485-3490.', '49', 'Petersen, M. A., H. Larsen, et al. (2006). ""Assessing health-related quality of life in palliative', 'care: comparing patient and physician assessments."" Eur J Cancer 42(8): 1159-1166.', '50', 'Rabin, R. and F. de Charro (2001). ""EQ-5D: a measure of health status from the EuroQol Group.""', 'Ann Med 33(5): 337-343.', '51', 'Herdman, M., C. Gudex, et al. (2011). ""Development and preliminary testing of the new five-', 'level version of EQ-5D (EQ-5D-5L). Qual Life Res 20(10): 1727-1736.', '52', 'Hurria A, Cirrincione CT, Muss HB, et al: Implementing a geriatric assessment in cooperative', 'group clinical cancer trials: CALGB 360401. J Clin Oncol 29:1290-6, 2011', '53.', 'Repetto L, Fratino L, Audisio RA, et al: Comprehensive geriatric assessment adds information to', 'Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian', 'Group for Geriatric Oncology Study. J Clin Oncol 20:494-502, 2002', '54.', 'Kimmick GG, Fleming R, Muss HB, et al: Cancer chemotherapy in older adults. A tolerability', 'perspective. Drugs Aging 10:34-49, 1997', '55.', 'Maione P, Perrone F, Gallo C, et al: Pretreatment quality of life and functional status assessment', 'significantly predict survival of elderly patients with advanced non-small-cell lung cancer', 'receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly', 'study. J Clin Oncol 23:6865-72, 2005', '56.', 'Extermann M, Aapro M, Bernabei R, et al: Use of comprehensive geriatric assessment in older', 'cancer patients: recommendations from the task force on CGA of the International Society of', 'Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241-52, 2005', '79', 'NCI Version Date: 5/29/2020', 'Update 5']"
79,page_80,"['Alliance A171601', '57', 'Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients', 'with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.', 'Lancet. 2011;377(9779):1749-1759.', '58', 'Atherton, P., et al., What Can Phase I Clinical Trials Tell Us About Quality Of Life? A Pilot', 'Study (Mc0115). Clin Res Trials 1, 2015.', '59', 'Chauhan, C., et al., Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials:', 'Was It Worth It? (N0392). J Clin Oncol, 2012. 30(15_Suppl): P. 6133.', '60', 'Chauhan, C., et al., Patient Satisfaction with Participation, Adverse Events and Hospitalizations', 'in Phase II/III NCCTG Clinical Trials: Was It Worth It? (N0392). Quality Of Life Research,', '2012. 21 (Oct2012 Supplement): P. Abstract Nr 202.204.', '61', 'Le-Rademacher, J., et al. Association between Patient Perception of Oncology Clinical Trial', 'Participation and Survival. In Asco Annual Meeting. 2016.', '62', 'Sloan, J., et al. Patient Satisfaction With Participation, Adverse Events And Hospitalizations In', 'Phase II/III NCCTG Clinical Trials: Was It Worth It? In Support Care Cancer. 2012.', '63.', 'Sloan, J., et al. Was It Worth It (WIWI)? Measuring Patient Satisfaction with Clinical Trial', 'Participation. In Support Cancer Care. 2011.', '64', 'Eisenhauer EA, Therasse P, Bogaert J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S,', 'Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.', 'New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J', 'Cancer 45(2): 228-247, 2009.', '65', 'Kazemi-Bajestani SM, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat', 'wasting are associated with cancer clinical outcomes. Seminars in cell & developmental biology.', '2015.', '66', 'Kim EY, Kim YS, Park I, et al. Evaluation of sarcopenia in small-cell lung cancer patients by', 'routine chest CT. Support Care Cancer. 2016;24(11):4721-4726.', '67', 'Rolland Y, CzerwinskiS, Abellan Van Kan G, et al. Sarcopenia: its assessment, etiology,', 'pathogenesis, consequences and future perspectives. The journal of nutrition, health & aging.', '1008;12(7):433-450.', '68', 'Metter EJ, Conwit R, Tobin J, Fozard JL. Age-associated loss of power and strength in the upper', 'extremities in women and men. The journals of gerontology. Series A, Biological sciences and', 'medical sciences. 097;52(5):B267-276.', '69', 'Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. The American journal of', 'clinical nutrition. 2010;91(4):1123S-1127S.', '70', 'Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle', 'depletion is a powerful prognostic factor, independent of body mass index. Journal of clinical', 'oncology : official journal of the American Society of Clinical Oncology. 2013;31(12):1539-1547.', '71', 'Shachar SS, Deal AM, Weinberg M, et al. Body Composition as a Predictor of Toxicity in', 'Patients Receiving Anthracycline and Taxane Based Chemotherapy for Early Stage Breast', 'Cancer. Clinical cancer research : an official journal of the American Association for Cancer', 'Research. 2017.', '72', 'Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences.', 'American journal of epidemiology. 2005;162(3):199-200.', '73', 'Ershler WB, Sun WH, Binkley N, et al: Interleukin-6 and aging: blood levels and mononuclea', 'cell production increase with advancing age and in vitro production is modifiable by dietary', 'restriction. Lymphokine and cytokine research 12:225-30, 1993', '74', 'Fagiolo U, Cossarizza A, Scala E, et al: Increased cytokine production in mononuclear cells of', 'healthy elderly people. European journal of immunology 23:2375-8, 1993', '75', 'Sindermann J, Kruse A, Frerks HJ, et al: Investigations of the lymphokine system in elderly', 'individuals. Mechanisms of ageing and development 70:149-59, 1993', '80', 'NCIVersion Date: 5/29/2020', 'Update 5']"
80,page_81,"['Alliance A171601', '76', 'Bruunsgaard H, Pedersen M, Pedersen BK: Aging and proinflammatory cytokines. Current', 'opinion in hematology 8:131-6, 2001', '77.', 'Franceschi C, CapriM, MontiD, et al: Inflammaging and anti-inflammaging: a systemic', 'perspective on aging and longevity emerged from studies in humans. Mechanisms of ageing and', 'development 128:92-105, 2007', '78', 'Vasto S, Candore G, Balistreri CR, et al: Inflammatory networks in ageing, age-related diseases', 'and longevity. Mechanisms of ageing and development 128:83-91, 2007', '79', 'Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer', 'cachexia. Nat Rev Clin Oncol. 2013;10(2):90-99.', '80', 'Robson SC, Shephard EG, Kirsch RE: Fibrin degradation product D-dimer induces the synthesis', 'and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from', 'monocytes in vitro. British journal of haematology 86:322-6, 1994', '81', 'Carter RA, Wicks IP: Vascular cell adhesion molecule 1 (CD106): a multifaceted regulator of', 'joint inflammation. Arthritis and rheumatism 44:985-94, 2001', '82', ""Hubbard RE, O'Mahony MS, Savva GM, et al: Inflammation and frailty measures in older"", 'people. Journal of cellular and molecular medicine 13:3103-9, 2009', '83.', 'Cohen HJ, Harris T, Pieper CF: Coagulation and activation of inflammatory pathways in the', 'development of functional decline and mortality in the elderly. The American journal of medicine', '114:180-7, 2003', '84.', 'De Martinis M, Franceschi C, Monti D, et al: Inflammation markers predicting frailty and', 'mortality in the elderly. Experimental and molecular pathology 80:219-27, 2006', '85.', 'de Saint-Hubert M, Jamart J, Morrhaye G, et al: Serum IL-6 and IGF- 1 improve clinical', 'prediction of functional decline after hospitalization in older patients. Aging clinical and', 'experimental research 23:106-11, 2011', '86.', 'FerrucciL, Harris TB, Guralnik JM, et al: Serum IL-6 level and the development of disability in', 'older persons. Journal of the American Geriatrics Society 47:639-46, 1999', '87.', 'FerrucciL, Penninx BW, Volpato S, et al: Change in muscle strength explains accelerated dec line', 'of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc', '50:1947-54, 2002', '88.', 'Huffman KM, Pieper CF, Kraus VB, et al: Relations of a marker of endothelial activation (s-', 'VCAM) to function and mortality in community-dwelling older adults. The journals of', 'gerontology. Series A, Biological sciences and medical sciences 66:1369-75, 2011', '89.', 'Puts MT, Visser M, Twisk JW, et al: Endocrine and inflammatory markers as predictors of', 'frailty. Clin Endocrinol (Oxf) 63:403-11, 2005', '90.', 'Reuben DB, Cheh AI, Harris TB, et al: Peripheral blood markers of inflammation predict', 'mortality and functional decline in high-functioning community-dwelling older persons. Journal', 'of the American Geriatrics Society 50:638-44, 2002', '91', 'Ronning B, Wyller TB, Seljeflot I, et al: Frailty measures, inflammatory biomarkers and post-', 'operative complications in older surgical patients. Age and ageing 39:758-61, 2010', '92', 'Pieper CF, Rao KM, Currie MS, et al: Age, functional status, and racial differences in plasma D-', 'dimer levels in community-dwelling elderly persons. The journals of gerontology. Series A,', 'Biological sciences and medical sciences 55:M649-57, 2000', '81', 'NCIVersion Date: 5/29/2020', 'Update 5']"
81,page_82,"['Alliance A171601', '93', 'MJ P, MC M, HJ C: Allostatic load of circulating biomarkers on gait speed in cancer survivors.', 'Bethesda, MD, 2012', '94', 'McMillan DC: The systemic inflammation-based Glasgow Prognostic Score: a decade of', 'experience in patients with cancer. Cancer Treat Rev 39:534-40, 2013', '95.', 'Sharma R, Zucknick M, London R, et al: Systemic inflammatory response predicts prognosis in', 'patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 7:331-7, 2008', '96.', 'Campisi J: Senescent cells, tumor suppression, and organismal aging: good citizens, bad', 'neighbors. Cell 120:513-22, 2005', '97.', 'Coppe JP, Patil CK, Rodier F, et al: Senescence-associated secretory phenotypes reveal cell-', 'nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS biology', '6:2853-68, 2008', '98', 'Dowsett M, Cuzick J, Ingle J, Coates A, et al: Meta-analysis of breast cancer outcomes in', 'adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28(3):509-', '518.10.1200/JCO.2009.23.1274 [PubMed: 19949017]', '99', 'Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, et al : Exemestane for', 'breast-cancerprevention in postmenopausal women. N Engl J Med. 2011; 364(25):2381-', '2391.10.1056/NEJMoal103507 [PubMed: 21639806]', '100', 'Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, et al: A randomized trial of letrozole in', 'postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N', 'Engl J Med. 2003; 349(19):1793-1802. [PubMed: 14551341]', '101', 'Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in', 'postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst.', '2011;103(17):1299-1309.10.1093/jnci/djr242| [PubMed: 21743022]', '102', 'Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, et al :Prospective', 'characterization of musculoskeletal symptoms in early stage breast cancer patients treated with', 'aromatase inhibitors. Breast Cancer Res Treat. 2008; 111(2):365-372. [PubMed: 17922185]', '103', 'Bartsch R, Bergen E. ASCO 2016: highlights in breast cancer. Memo.2016;9(4):211-214.', '10.1007/s12254-016-0300-6. Review. PubMed PMID: 28058064;PubMed Central PMCID:', 'PMC5165027', '104', 'Poggio F, Lambertini M, Blondeaux E, Vaglica M, Levaggi A, et al: Role of fulvestrant in the', 'treatment of postmenopausal metastatic breast cancer patients. Expert Rev Clin Pharmacol 2016', 'Sep;9(9):1153-61. doi:10.1080/17512433.2016.1215243. PubMed PMID: 27545815.', '105', 'Finn RS, Crown JP, Lang I, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in', 'combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-', 'positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2', 'study. Lancet Oncology 16:25-35, 2015.', '106', 'Turner NC, Ro J, Andrél F, Lois, Verma S, et al: PALOMA3 Study Group. Palbociclib in', 'Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19', 'doi: 10.1056/NEJMoal505270. PubMed PMID:26030518.', '107', 'Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, et al: Fulvestrant plus palbociclib versus', 'fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic', 'breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the', 'multicentre, double-blind, phase 3 randomised controlled trial.Lancet Oncol. 2016', 'Apr;17(4):425-39. doi: 10.1016/S1470-2045(15)00613-0 PubMed PMID: 26947331.', '108', 'Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor,', 'preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell', 'lines in vitro. Breast Cancer Research : BCR. 2009;11(5):R77. doi:10.1186/bcr2419', '82', 'NCIVersion Date: 5/29/2020', 'Update 5']"
82,page_83,"['Alliance A171601', '109', 'Pfizer Inc. IbranceR (palbociclib): HIGHLIGHTS OF PRESCRIBING INFORMATION,', 'Revised: 2/2016. https://www.pfizermedicalinformation.com/en-us/ibrance:HIGHLIGHTS OF', 'PRESCRIBING INFORMATION, Revised: 2/2016.', '110', 'Mangini NS, WesolowskiR, Ramaswamy B, Lustberg MB, Berger MJ. Palbociclib: A Novel', 'Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.', 'Ann Pharmacother 2015 Nov;49(11):1252-60. doi:10.1177/1060028015602273.Review.', 'PubMed PMID: 26324355', '111', 'Roberts PJ, Bisi JE, Strum JC, et al. Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in', 'Cancer Therapy. JNCI Journal of the National Cancer Institute. 2012;104(6):476-487.', 'doi:10.1093/jmci/djo02.', '112', 'McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic', 'response to anthracycline therapy. Cell Cycle. 2012;11(14):2747-2755. doi:10.4161/cc.21127.', '113', 'Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, et al:. Palbociclib in', 'Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative', 'Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized,', 'Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist. 2016 Oct;21(10):1165-1175.', 'PubMed PMID: 27368881; PubMed Central PMCID: PMC5061543.', '114', 'Henry NL, Skaar TC, Dantzer J, LiL, Kidwell K, et al: Genetic associations with toxicity-related', 'discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat. 2013', 'Apr;138(3):807-16. doi: 10.1007/s10549-013-2504 3. PubMed PMID: 23546553; PubMed', 'Central PMCID: PMC3646626.', '115', 'Colomer R, Monzo M, Tusquets I, Rifa J, et al: A single-nucleotide polymorphism in the', 'aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced', 'breast carcinoma. Clin Cancer Res. 2008; 14(3):811-816.10.1158/1078-0432.CCR-07-1923', '[PubMed: 18245543]', '116', 'Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, et al: Genome-wide associations and', 'functional genomic studies of musculoskeletal adverse events in women receiving aromatase', 'inhibitors. JClin Oncol. 2010; ;28(31):4674-4682.10.1200/JCO.2010.28.5064 [PubMed:', '20876420]', '117', 'Mao JJ, Sul HI, Feng R, Donelson ML, et al: Association of functional polymorphisms in', 'CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer', 'Res. 2011; 13(1):R8.10.1186/bcr2813 [PubMed: 21251330]', '118', 'Park IH, Lee YS, Lee KS, Kim SY, et al :. Single nucleotide polymorphisms of CYP19A1 predict', 'clinical outcomes and adverse events associated with letrozole in patients with metastatic breast', 'cancer. Cancer Chemother Pharmacol. 2011; 68(5): 1263-1271.10.1007/s00280-011-1615-1', '[PubMed: 21442439]', '119', 'Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA approval: palbociclib for the treatment of', 'postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.', 'Clin Cancer Res. 2015;21(21):4760-4766.', '120', 'Dhillon S. Palbociclib: first global approval. Drugs. 2015;75(5):543-551.', '121', 'Yu Y, Loi CM, Hoffman J, Wang D. Physiologically Based Pharmacokinetic Modeling of', 'Palbociclib. J Clin Pharmacol. 2017 Feb;57(2):173-184. doi:10. 1.002/jcph.792. PubMed PMID:', '27402157.', '122', 'MusgroveEA Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin Das a therapeutic target', 'in cancer. Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi:10.1038/nrc3090. Review. PubMed', 'PMID: 21734724.', '123', 'Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell.', '2008 Feb; 14(2):159-69. doi: 10.1016/j.devcel.2008.01.013. Review. PubMed PMID: 18267085.', '124', 'Sherr CJ. ANew Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6. N', 'Engl J Med. 2016 Nov 17;375(20):1920-1923. PubMed PMID :27959598.', '83', 'NCI Version Date: 5/29/2020', 'Update 5']"
83,page_84,"['Alliance A171601', '125', 'Nam EJ, Kim YT. Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol', 'Cancer. 2008 Nov-Dec;18(6):1169-82. doi:10.1111/j.1525-1438.2008.01191.x.Review. PubMed', 'PMID: 18298566.', '126', 'Canavese M, Santo L, Raje N. Cyclin dependent kinases in cancer: potential for therapeutic', 'intervention. Cancer Biol Ther.2012 May;13(7):451-7.doi:10.4161/cbt.19589.Review. PubMed', 'PMID: 22361734.', '127', 'Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J: Cyclin D1 protein expression and', 'function in human breast cancer. Int J Cancer 1994, 57:353-361.', '128', 'Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and', 'overexpression of cyclin D1 in breast cancer detected by immunohistochemica staining. Cancer', 'Res 1994, 54:1812-1817.', '129 Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson', 'JF: Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-', 'positive breast cancer. Clin Cancer Res 1999, 5:2069-2076.', '130', 'Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS: Prognostic value of combined analysis of cyclin', 'D1 and estrogen receptor status in breast cancer patients. Pathol Int 2003, 53:74-80.', '131', 'Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, et al: Cyclin D1 expression in breast', 'cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res 2008, 14:1767-1774.', '132', 'Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G: Adverse effect', 'of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer', 'Res 2005, 65:8009-8016.', '133', 'Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al: Specific inhibition of fcyclin-', 'dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.', 'Mol Cancer Ther 2004, 3:1427-1438.', '134', 'Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, Vander Wel SN, et al: Discovery of a potent and', 'selective inhibitor of cyclin-dependent kinase 4/6. JMed Chem 2005, 48:2388-2406.', '135', 'Marzec M, Kasprzycka M, Lai R, Gladden AB, et al: Mantle cell lymphoma cells express', 'predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase', 'activity. Blood 2006, 108:1744-1750.', '136', 'Saab R, Bills JL, Miceli AP, Anderson CM, et al: Pharmacologie inhibition of cyclin-dependent', 'kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol', 'Cancer Ther 2006, 5:1299-1308.', '137', 'Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, et al: A novel orally active', 'small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by', 'specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006, 66:7661-7667.', '138', 'Deng Q, Guo H, DaiJ, Yang L, Wu C, Wang Q, Hu Z, et al: Imputation-based association analyses', 'identify new lung cancer susceptibility variants in CDK6 and SH3RF1 and their interactions with', 'smoking in Chinese populations. Carcinogenesis. 2013 Sep;34(9):2010-6.', 'doi:', '10.1093/carcin/bgt145. PubMed PMID: 23644744.', '139', 'Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control', 'pathway confer susceptibility to bladder cancer. Cancer. 2008 [un;112(11):2467-74. doi:', '10.1002/cncr.23472. PubMed PMID: 18361427.', '140.', 'Kibel AS, Ahn J, Isikbay M, Klim A, Wu WS, Hayes RB, Isaacs WB, Daw EW. Genetic variants', 'in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. Prostate. 2016', 'Apr;76(5):479-90. doi:10.1002/pros.23139.PubMed PMID: 26708993', '141.', 'Driver KE, Song H, Lesueur F, Ahmed S, Barbosa-Morais NL, Tyrer JP, et al: Studies in', 'Epidemiology and Risks of Cancer Heredity (SEARCH) Team Association of single-nucleotide', 'polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis.', '2008 Feb;29(2):333-41. doi: 10.1093/carcin/bgm284.PubMed PMID:1 18174243; PubMed Central', 'PMCID: PMC2346546.', '84', 'NCIVersion Date: 5/29/2020', 'Update 5']"
84,page_85,"['Alliance A171601', '142.', 'Goode EL, Fridley BL, Vierkant RA, Cunningham JM, et al: Candidate gene analysis using', 'imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer', 'Epidemiol Biomarkers Prev. 2009 Mar;18(3):935-44. doi: 10.1158/1055-9965.EPI-08-0860.', 'PubMed PMID: 19258477; PubMed Central PMCID: PMC2743184.', '143.', 'Cai H, Xiang YB, Qu S, Long J, Cai Q, Gao J, Zheng W, Shu XO. Association of genetic', 'polymorphisms in cell-cycle control genes and susceptibility to endometrial cancer among Chinese', 'women. Am J Epidemiol. 2011 Jun 1;173(11):1263-71. doi: 10.1093/aje/kwr002. PubMed PMID:', '21454826; PubMed Central PMCID: PMC3101066.', '144.', 'Campa D, Pastore M, Gentiluomo M, Talar-Wojnarowska R, et al:. Functional single nucleotide', 'polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer', 'risk. Oncotarget. 2016 Aug 30;7(35):57011-57020. doi:10.18632/oncotarget.10935. PubMed', 'PMID: 27486979; PubMed CentralPMCID:PMC5302969', '145.', 'Cacina C, Yaylim-Eraltan I, Arikan S, Saglam EK, Zeybek U, Isbir T. Association between', 'CDKN1A Ser31Arg and C20T gene polymorphisms and colorectal cancer risk and prognosis. In', 'Vivo. 2010 Mar-Apr;24(2):179-83. PubMed PMID:20363991.', '146.', 'Schondorf T, Eisele L, Gohring UJ, Valter MM, et al : The V109G polymorphism of the p27 gene', 'CDKN1B indicates a worse outcome in node-negative breast cancer patients. Tumour Biol. 2004,', '25: 306-312. 10.1159/000081396. PubMed PMID: 15627896.', '147.', 'Azzato EM, Driver KE, Lesueur F, Shah M, et al : Effects of common germline genetic variation', 'in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast', 'Cancer Res. 2008;10(3):R47. doi: 10.1186/bcr2100. PubMed PMID: 18507837; PubMed Central', 'PMCID: PMC2481496.', '148.', 'Driver KE, Song H, Lesueur F, Ahmed S, Barbosa-Morais NL, Tyrer JP, Ponder BA, Easton DF,', 'Pharoah PD, Dunning AM; Studies in Epidemiology and Risks of Cancer Heredity (SEARCH)', 'Team Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer', 'in the British population. Carcinogenesis. 2008 Feb;29(2):333-41. doi: 10.1093/carcin/bgm284.', 'PubMed MID:18174243; PubMed Central PMCID: PMC2346546.', '149.', 'Shu XO, Moore DB, CaiQ, Cheng J, Wen W, Pierce L, CaiH, Gao YT, Zheng W: Association of', 'cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev. 2005,', '14: 91-97. PubMed PMID: 15668481.', '150.', 'Soleimani Z, Kheirkhah D, Sharif MR Sharif A, Karimian M, Aftabi Y. Association of CCND1', 'Gene c.870G>A Polymorphism with Breast Cancer Risk: A Case-ControlStudy and a Meta-', 'Analysis. Pathol Oncol Res. 2016 Dec 21. oi:10.1007/s12253-016-0165-3. [Epub ahead of print]', 'PubMed PMID: 28004353.', '151.', 'Yaylim-Eraltan I, Ergen A, Görmüs U, Arikan S, Küiçücük S, Sahin O, Yigit N, Yildiz Y, Isbir T.', 'Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo. 2009 Sep-', 'Oct;23(5):767-72. PubMed PMID: 19779113.', '152.', 'Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and CCND1 and', 'survival after treatment for metastatic breast cancer. J Clin Oncol. 2006 Dec 20;24(36):5645-51.', 'PubMed PMID: 17116943.', '153.', 'Zhou LP, Yao F, Luan H, Wang YL, Dong XH, Zhou WW, Wang QH. YP3A4*1Bpolymorphism', 'and cancer risk: a HuGE review and meta-analysis. Tumour Biol. 2013 Apr;34(2):649-60. doi:', '10.1007/s13277-012-0592-z. Review. PubMed PMID: 23179402.', '154.', 'Johnson N, Dudbridge F, Orr N, Gibson L, Jones ME, Schoemaker MJ, et al. Genetic variation at', 'CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast', 'Cancer Res. 2014 May 26;16(3) R51. doi: 10.1186/bcr3662. PubMed PMID: 24887515; PubMed', 'Central PMCID: PMC4522594.', '85', 'NCIVersion Date: 5/29/2020', 'Update 5']"
85,page_86,"['Alliance A171601', '155.', 'Wilborn TW, Lang NP, Smith M, Meleth S, Falany CN. Association of SULT2A1 allelic variants', 'with plasma adrenal androgens and prostate cancer in African-Americanmen. J Steroid Biochem', 'Mol Biol. 2006 Jun;99(4-5):209-14 PubMed PMID: 16617014.', '156.', 'Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL, Ostrander EA. Androgen', 'metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol. 2012', 'Aug;36(4):347-53. doi: 0.1016/j.canep.2012.04.002. PubMed PMID: 22542949; PubMed', 'Central PMCID: PMC3392409.', '157.', 'Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, et al: Associations between genetic', 'variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast', 'Cancer Res Treat. 2015 Nov; 154(2):263-73. doi: 10.1007/s10549-015-3608-8.1 PubMed PMID:', '26536870; PubMed Central PMCID: PMC4807610.', '158.', 'Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, et al; BIG 1-98 Collaborative', 'Group ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole', 'versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat. 2015', 'Dec;154(3):543-55.doi:10.1007/s10549-015-3634-6 PubMed PMID: 26590813; PubMed', 'Central PMCID:PMC4730949.', '159.', 'ArtigalÃ¡S O, Vanni T, Hutz MH, Ashton-Prolla P, Schwartz IV. Influence of CYP19A1', 'polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review', 'and meta-analysis. BMC Med. 2015 Jun 1;13:139.doi: 10.1186/s12916-015-0373-9. PubMed', 'PMID: 26067721; PubMed Central PMCID:PMC4475294', '160.', 'Raunio H, etal Br J Clin Pharmacol 2001 Oct; 52(4): 357-363', '161.', 'Beal, S. and L. Sheiner, NONMEM Users Guide. 1992, NONMEM Project Group, University of', 'California at San Francisco: San Francisco', '86', 'NCIVersion Date: 5/29/2020', 'Update 5']"
86,page_87,"['Alliance A171601', '17.0 MODEL CONSENT FORM', 'Study Title for Study Participants:', 'Testing the effects of palbociclib and fulvestrant or letrozole for patients', '70 years of age and older with metastatic breast cancer', 'Official Study Title for Internet Search on http://www.ClinicalTrials.gov', 'Alliance A171601: A Phase II Trial Assessing the tolerability of Palbociclib in', 'combination with letrozole or fulvestrant in patients aged 70 and older with', 'estrogen receptor positive, HER-2 negative metastatic breast cancer', 'This study is conducted by the Alliance for Clinical Trials in Oncology, a national clinical', 'research group supported by the National Cancer Institute This study has public funding from the', 'National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United', 'States Department of Health and Human Services. The Alliance is made up of cancer doctors,', 'health professionals, and laboratory researchers, whose goal is to develop better treatments for', 'cancer, to prevent cancer, to reduce side effects from cancer, and to improve the quality of life of', 'cancer patients.', 'What is the usual approach to my breast cancer?', 'We are asking you to take part in this study because you are 70 years old or over and have been', 'recently diagnosed with estrogen receptor positive, HER2 negative metastatic breast cancer.', 'Patients with this metastatic breast cancer are usually treated with a drug called palbociclib along', 'with a hormonal agent, either fulvestrant or letrozole, as determined by your doctor. Palbociclib', 'and letrozole are given by mouth and fulvestrant is an injection. This study follows the usual', 'Food and Drug Administration (FDA) approved treatment, but we are conducting this study', ""because we don't know if older patients have more side effects than younger patients."", 'What are my other choices ifl do not take part in this study?', 'If you decide not to take part in this study, you have other choices. For example:', 'You may choose to have the usual approach described above without being in a', 'study.', 'You may choose to take part in a different study, if one is available.', 'You may choose not to be treated for cancer and may want to receive comfort care to', 'relieve symptoms.', 'Why is this study being done?', 'The purpose of this study is to find out the side effects that the standard, FDA-approved', 'combination treatment of letrozole or fulvestrant and palbociclib has on patients 70 years old and', 'over. Palbociclib given along with letrozole or fulvestrant instead of letrozole or fulvestrant', '87', 'NCI Version Date: 5/29/2020', 'Update 5']"
87,page_88,"['Alliance A171601', 'alone seems to prevent the cancer from getting worse. However, few patients aged 75 and older', 'participated in previous studies. There will be about 88 people taking part in this study.', 'What are the study groups?', 'In this study, all study participants will get the same treatment. You will take one capsule of', 'palbociclib once a day with food for 21 days. You will not take palbociclib for the next 7 days.', 'This 28 day period is called a cycle. You should try to take the palbociclib capsules at about the', 'same time each day. You should not have grapefruit or grapefruit juice while on this study. You', 'should also check with your doctor or pharmacist before using any new medicines, including', 'over-the-counter drugs because of possible drug interactions.', 'During this period, you will also be given either letrozole or fulvestrant based on what your', 'doctor decides. If your doctor prescribes letrozole, you will take one pill daily for 28 days. If', 'your doctor prescribes fulvestrant you will receive injections on the first day and fifteenth day of', 'the first cycle and then on the first day of every cycle after that. You will continue on this', 'treatment plan until your cancer progresses or if you have side effects that may prevent you from', 'continuing to take the treatment.', 'Each cycle is 28 days (4 weeks)', 'Palbociclib plus Letrozole', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Week 5+', 'Palbociclib', '1 capsule every day for', '1 capsule', '1 capsule', '1 capsule', 'every day', 'every day', 'No capsule', '21 days, then 7 days no', 'everyday', 'capsules', 'Letrozole', '1 pill every', '1 pill', '1 pill every', '1 pill every', '1 pill every day for 28', 'day', 'every day', 'day', 'day', 'days', 'If you forget to take a capsule of palbociclib or letrozole, do not make up the missed dose. Skip', 'that dose and take the drug on the next day.', 'Or', 'Palbociclib plus Fulvestrant', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Weeks 5+', 'Palbociclib', '1 capsule', '1 capsule', '1 capsule', '1 capsule every day for', 'No capsule', '21 days, then 7 days no', 'every day', 'every day', 'everyday', 'capsules', 'Fulvestrant', 'Injection', 'No', 'Injection on', 'No', 'Injection on Day 1 of', 'on Day 1', 'injection', 'Day 15', 'injection', 'every 28-day cycle', 'If you forget to take a capsule of palbociclib, do not make up the missed dose. Skip that dose and', 'take the capsule on the next day.', '88', 'NCIVersion Date: 5/29/2020', 'Update 5']"
88,page_89,"['Alliance A171601', 'How long will I be in this study?', 'You will receive the study treatment for as long as you do not have severe side effects and your', 'cancer does not get worse. If you develop severe side effects or your cancer gets worse, your', 'doctor may decide to remove you from the study treatment. After you stop the study treatment,', 'your doctor will continue to follow your progress every year for up to five years.', 'What extra tests, and procedures will I have if I take part in this study?', 'Most of the exams, tests, and procedures you will have are part of the usual approach for your', 'cancer. However, there are some extra questionnaires that you will need to complete if you take', 'part in this study.', 'You will be asked to complete four questionnaires and perform some tasks as part of this study.', 'The questionnaires will be used in this study in order to find out more about how you feel during', 'cancer treatment and what the effect of the treatment may be.', 'The questionnaires will be completed at the following time points:', 'Geriatric Assessment: You will be asked to complete the geriatric assessment before you begin', 'treatment, prior to cycle 4, and at the end of your treatment period. It will take about 30 minutes', 'to complete. The geriatric assessment involves a questionnaire, an interview and a task. Some', 'questions will be asked by a member of the health care team. You will complete other questions', 'on your own. If you have difficulty completing any of the questions or tasks, a member of the', 'team will help you. You may skip any questions you do not wish to answer. The walking task', 'involves minimal risk. It will involve you getting up from a chair, walking 10 feet, and returning', 'to the chair. Possible risks include feeling tired, dizziness, increased heart rate, and falling. To', 'minimize this risk you will be closely monitored by a member of the health care team during this', 'task. If you are uncomfortable with walking, you may skip this task.', 'You will be asked to complete three other questionnaires, two of which will be required at the', 'beginning of every cycle for the first 6 cycles of treatment, and at the end of your treatment', 'period. These questionnaires will involve questions about the side effects you are experiencing', 'from your treatment and about your general quality of life. They will take about fifteen to twenty', 'minutes to complete. The other questionnaire will only need to be completed at the end of your', 'treatment. It will ask questions regarding how the study helped you. It will take about five', 'minutes to complete.', '89', 'NCIVersion Date: 5/29/2020', 'Update 5']"
89,page_90,"['Alliance A171601', 'Pill Diary', 'You will also be completing a pill diary every day, for the first three cycles. You will be asked to', 'bring the completed pill diary at the end of every cycle, to make sure you are taking the correct', 'dose and not more than the standard dose.', 'You will receive routine scans every 12 weeks to see if your cancer is getting worse or better, as', 'part of your cancer care. Your doctor will send copies of these scans to the Alliance, so that', 'researchers can evaluate whether the treatment you are receiving may cause loss of muscle', 'tissue.', 'What possible risks can I expect from taking part in this study?', 'If you choose to take part in this study, there is a risk that:', ""You may spend more time in the hospital or doctor's office than usual"", 'You may be asked sensitive or private questions which you normally do not discuss', 'The drugs used in this study may affect how different parts of your body work such as your liver,', 'kidneys, heart, and blood. The study doctor will test your blood and let you know if changes', 'occur that may affect your health.', 'There is also a risk that you could have side effects from the study drugs.', 'Here are important points about side effects:', 'The study doctors do not know who will or will not have side effects.', 'Some side effects may go away soon, some may last a long time, or some may never go', 'away.', 'Some side effects may be serious and may even result in death.', 'You can ask the study doctor questions about side effects at any time. Here are important points', 'about how you and the study doctor can make side effects less of a problem:', 'Tell the study doctor if you notice or feel anything different, so they can see if you are', 'having a side effect.', 'The study doctor may be able to treat some side effects.', 'The study doctor may adjust the study drugs to try to reduce side effects.', 'The tables below show the most common and the most serious side effects that researchers know', 'about. Keep in mind that there might be other side effects that researchers do not yet know about.', 'If important new side effects are found, the study doctor will discuss these with you.', 'Possible side effects of Palbociclib, Letrozole and Fulvestrant:', '90', 'NCIVersion Date: 5/29/2020', 'Update 5']"
90,page_91,"['Alliance A171601', 'Possible Side Effects for Palbociclib (PD-0332991)', 'COMMON, SOME MAY BE SERIOUS', 'In 100 people receiving Palbociclib (PD-0332991), more than 20 and up to 100 may have:', 'Anemia which may require blood transfusion', 'Nausea', 'Tiredness', 'Infection, especially when white blood cell count is low', 'OCCASIONAL, SOME MAY BE SERIOUS', 'In 100 people receiving Palbociclib (PD-0332991), from 4 to 20 may have:', 'Blurred vision, watering eyes', 'Dry eye, skin', 'Constipation, diarrhea, vomiting', 'Sores in the mouth which may cause difficulty swallowing', 'Fever', 'Bruising, bleeding', 'Loss of appetite', 'Changes in taste', 'Headache', 'Nose bleed', 'Hair loss, rash', 'RARE, AND SERIOUS', 'In 100 people receiving Palbociclib (PD-0332991), 3 or fewer may have:', 'Damage to the lungs which may cause shortness of breath', 'Possible Side Effects of Fulvestrant', 'COMMON, SOME MAY BE SERIOUS', 'In 100 people receiving Fulvestrant, more than 20 and up to 100 may have:', 'Pain', 'Tiredness', 'Increased sweating', 'Hot flashes, flushing', 'Swelling and redness at the site of the medication injection', 'OCCASIONAL, SOME MAY BE SERIOUS', 'In 100 people receiving Fulvestrant, from 4 to 20 may have:', 'Constipation, diarrhea, nausea, vomiting, loss of appetite, heartburn', 'Swelling of the body', 'Loss of bone tissue, broken bone, or decreased height', 'Dizziness, headache', '91', 'NCIVersion Date: 5/29/2020', 'Update 5']"
91,page_92,"['Alliance A171601', 'OCCASIONAL, SOME MAY BE SERIOUS', 'In 100 people receiving Fulvestrant, from 4 to 20 may have:', 'Difficulty sleeping', 'Fluid around lungs', 'Swelling of the liver which may cause belly pain', 'Worry, depression, mood swings', 'Hair thinning', 'Cough', 'RARE, AND SERIOUS', 'In 100 people receiving Fulvestrant, 3 or fewer may have:', 'Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of', 'breath, swelling of the face or throat', 'Liver damage which may cause yellow eyes and skin', 'Vaginal bleeding', 'Blood clot which may cause swelling, pain, shortness of breath', 'Heart attack or heart failure which may result in chest pain, shortness of breath, swelling', 'of ankles, and tiredness', 'Stroke which may cause weakness, paralysis', 'Possible Side Effects ofLetrozole', 'COMMON, SOME MAY BE SERIOUS', 'In 100 people receiving Letrozole, more than 20 and up to 100 may have:', 'Pain', 'Tiredness', 'Increased sweating', 'Hot flashes, flushing', 'OCCASIONAL, SOME MAY BE SERIOUS', 'In 100 people receiving Letrozole, from 4 to 20 may have:', 'Constipation, diarrhea, nausea, vomiting, loss of appetite, heartburn', 'Swelling of the body', 'Loss of bone tissue, broken bone, or decreased height', 'Dizziness, headache', 'Difficulty sleeping', 'Fluid around lungs', 'Swelling of the liver which may cause belly pain', 'Worry, depression, mood swings', 'Hair thinning', '92', 'NCIVersion Date: 5/29/2020', 'Update 5']"
92,page_93,"['Alliance A171601', 'RARE, AND SERIOUS', 'In 100 people receiving Letrozole, 3 or fewer may have:', 'Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of', 'breath, swelling of the face or throat', 'Liver damage which may cause yellow eyes and skin', 'Vaginal bleeding', 'Blood clot which may cause swelling, pain, shortness of breath', 'Heart attack or heart failure which may cause shortness of breath, swelling of ankles, and', 'tiredness', 'Stroke which may cause weakness, paralysis', 'Risks from questionnaires', 'You may become tired from the amount of time needed to fill out the questionnaires and do the', 'other evaluations. The questionnaire will focus on life issues that could cause you to become', 'emotionally upset. If you become distressed a member of the study team will talk with you. If', 'needed, you can be referred to your doctor to determine how best to handle your concerns.', 'Risks from walking task', 'As part of the geriatric assessment, you will be asked to complete a walking task. You may feel', 'tired, dizzy, have an increased heart rate or fall during the walking task. To minimize this risk,', 'you will be closely monitored by a member of the health care team during this task. If you are', 'uncomfortable with walking, you may skip this task.', 'What possible benefits can I expect from taking part in this study?', 'This study may or may not help you. However, this study may help us understand how this study', 'drug works in older adults, and may help researchers learn things that may help other older', 'people in the future.', 'Can I stop taking part in this study?', 'Yes. You can decide to stop at any time. If you decide to stop for any reason, it is important to let', 'the study doctor know as soon as possible so you can stop safely. If you stop, you can decide', 'whether or not to let the study doctor continue to provide your medical information to the', 'organization running the study.', 'The study doctor will tell you about new information or changes in the study that may affect', 'your health or your willingness to continue in the study.', 'In turn, the study doctor may remove you from the study, if:', 'Your health changes and the study is no longer in your best interest', 'New information becomes available', 'You do not follow the study rules', 'The study is stopped by the sponsor, Institutiona 1 Review Board (IRB) or FDA.', '93', 'NCIVersion Date: 5/29/2020', 'Update 5']"
93,page_94,"['Alliance A171601', 'What are my rights in this study?', 'Taking part in this study is your choice. No matter what decision you make, and even if your', 'decision changes, there will be no penalty to you. You will not lose medical care or any legal', 'rights.', 'For questions about your rights while in this study, call the', '(insert', 'name of center) Institutional Review Board at', '(insert telephone number).', 'What are the costs of taking part in this study?', 'Your Potential Costs:', 'You and/or your health plan/insurance company will need to pay for all of the costs of treating', 'your cancer while in this study, including the cost of tests, procedures, or medicines to manage', 'any side effects, unless you are told that certain tests are supplied at no charge. Before you', 'decide to be in the study, you should check with your health plan or insurance company to find', 'out exactly what they will pay for.', 'You and/or your health plan/insurance company will be responsible for:', 'Palbociclib, letrozole or fulvestrant and all premedications, fluids and procedures.', 'Exams, tests, and procedures that may be needed to manage side effects and to monitor', 'your safety.', 'Costs Paid by the Study', 'Exams, tests, and procedures done for research purposes only will not be billed to you or your', 'insurance plan. These include blood collections for the optional studies and submission of', 'images to the Alliance for evaluating whether the treatment you are receiving may cause loss of', 'muscle tissue.', 'You will not be paid for taking part in this study.', 'What happens if I am injured because I took part in this study?', 'If you are injured as a result of taking part in this study and need medical treatment, please tell', 'your study doctor. The study sponsors will not offer to pay for medical treatment for injury. Your', 'insurance company may not be willing to pay for study-related injury. If you have no insurance,', 'you would be responsible for any costs.', 'If you feel this injury was a result of medical error, you have legal rights to receive payment for', 'this injury even though you are in a study.', 'Who will see my medical information?', 'Your privacy is very important to us and the researchers will make every effort to protect it. The', 'study doctors have a privacy permit to help protect your records if there is a court case.', '94', 'NCIVersion Date: 5/29/2020', 'Update 5']"
94,page_95,"['Alliance A171601', 'However, your information may be given out if required by law. For example, certain states', 'require doctors to report to health boards if they find a disease like tuberculosis. However, the', 'researchers will do their best to make sure that any information that is released will not identify', 'you. Some of your health information and information about your specimen from this study will', 'be kept in a central database for research. Your name or contact information will not be put in', 'the database.', 'There are organizations that may look at or receive copies of some of the information in your', 'study records. Your health information in the database may also be shared with these', 'organizations. They are required to make sure your information is kept private, unless required', 'by law to provide information. Some of these organizations are:', 'The Alliance for Clinical Trials in Oncology', 'The NCI Central IRB is a group of people who review the research with the goal of', 'protecting the people who take part in the study.', 'The Food and Drug Administration and the National Cancer Institute in the U.S., and', 'similar ones if other countries are involved in the study.', 'In addition to storing data in the study database, data from studies that are publicly funded may', 'also be shared broadly for future research with protections for your privacy. The goal of this data', ""sharing is to make more research possible that may improve people's health. Your study records"", 'may be stored and shared for future use in public databases. However, your name and other', 'personal information will not be used.', 'Some types of future research may include looking at your information and information from', 'other patients to see who had side effects across many studies or comparing new study data with', ""older study data. However, right now we don't know what research may be done in the future"", 'using your information. This means that:', 'You will not be asked if you agree to take part in the specific future research studies', 'using your health information.', 'You and your study doctor will not be told when or what type of research will be done.', 'You will not get reports or other information about any research that is done using your', 'information.', 'Where can I get more information?', 'You may visit the NCI web site at http://cancer.gov/ for more information about studies or', 'general information about cancer. You may also call the NCI Cancer Information Service to get', 'the same information at: 1-800-4-CANCER (1-800-422-6237).', 'A description of this clinical trial will be available on http://www.ClinicalTrials.gov. as required', 'by U.S. law. Once the study is over, the site may include a summary of the results. This', 'summary will not include any information that can identify you.', '95', 'NCI Version Date: 5/29/2020', 'Update 5']"
95,page_96,"['Alliance A171601', 'Who can answer my questions about this study?', 'You can talk to the study doctor about any questions or concerns you have about this study or to', 'report side effects or injuries. Contact the study doctor', '(insert name of', 'study doctor at', '(insert telephone number).', 'Additional Studies Section:', 'This section is about optional studies you can choose to take part in', 'This part of the consent form is about optional studies that you can choose to take part in. They', 'are separate from the main study described above. These optional studies will not benefit your', 'health. The researchers leading these optional studies hope the results will help other people with', 'cancer in the future.', 'The results will not be added to your medical records and you or your study doctor will not know', 'the results.', 'Neither you nor your insurance will be billed for these optional studies. You can still take part in', 'the main study even if you say ""no"" to any or all of these studies. If you sign up for but cannot', 'complete any of the optional studies for any reason, you can still take part in the main study.', 'Circle your choice of ""yes"" or ""no"" for each of the following studies.', 'Optional sample collections for laboratory studies and bio banking for possible', 'future studies', 'Researchers are trying to learn more about cancer and other health problems using samples from', ""people's tissue, blood, urine, or other fluids. By conducting research on these samples,"", 'researchers hope to find new ways to prevent, detect, treat, or cure health problems.', 'Some of these studies may be about how genes affect health and disease and how people respond', 'to treatment. Genes carry information about features that are found in you and your family, from', 'the color of your eyes to health conditions for which you may be at risk. Research that studies', 'your genes is known as genomics or genetics.', 'If you choose to take part in these optional studies, the study doctor for the main study would', 'like to collect blood for research on why patients have different side effects from the treatment.', 'In addition, the researchers ask your permission to store and use your samples and related health', 'information (for example, your response to cancer treatment, results of study tests and medicines', 'you are given) for medical research. The additional research that may be done is unknown at this', 'time. Storing samples for future studies is called ""biobanking"". The Biobank is being run by the', 'Alliance and supported by the National Cancer Institute.', '96', 'NCI Version Date: 5/29/2020', 'Update 5']"
96,page_97,"['Alliance A171601', 'What is involved?', 'If you agree to take part, here is what will happen next:', '1) About 6 teaspoons of blood will be collected from a vein in your arm. Four teaspoons', 'of blood will be drawn before you begin treatment, and two teaspoons will be drawn', 'after you have taken three cycles of treatment.', '2) In addition, one teaspoon of blood will be collected before you start study treatment,', 'at your cycle 1 day 1 and day 15 clinic visits, and cycle 2 day 15 clinic visit, for', 'research on how the study drug changes in your body over time and if that can change', 'your side effects. You will also complete a form at these visits when blood is', 'collected for this research. It will take less than five minutes to complete this form.', 'For this study, your blood will be sent to researchers at the University of Pittsburgh', 'Cancer Center with your initials and collection date and time on it.', '3) Your baseline blood sample and some related health information will be sent to a', 'researcher for use in the study described above. Remaining baseline blood samples', 'may be stored in the Biobank, along with samples from other people who take part.', 'The samples will be kept until they are used up.', '4) Only qualified researchers canreceive samples from the biobank. There will be', 'scientific and ethics reviews to ensure that the research is necessary and proper.', 'Researchers will not be given your name or any other information that could directly', 'identify you.', '5) Neither you nor your study doctor will be notified when research will be conducted.', 'You will not receive reports or other information about any research that is done', 'using your samples.', '6) Some of your genetic and health information may be placed in central databases that', 'will be available to qualified researchers. Information that could directly identify you', 'will not be included.', 'What are the possible risks?', '1) The most common risks related to drawing blood from your arm are brief pain and', 'maybe a bruise.', '2) Even without your name or other identifiers, your genetic information is unique to', 'you. There is a risk that someone outside of the research could get access to your', 'personal information in your medical records or trace information in a database back', 'to you. The researchers believe the chance that someone could re-identify you is very', 'small, but the risk may change in the future as people come up with new ways of', 'tracing information.', '3) In some cases, this information could be used to make it harder for you to get or keep', 'a job or insurance. There are laws against the misuse of genetic information, but they', 'may not give full protection. There can also be a risk in knowing genetic information.', 'New health information about inherited traits that might affect you or your blood', 'relatives could be found during a study. The researchers believe the chance these', 'things will happen is very small, but cannot promise that they will not occur.', '97', 'NCI Version Date: 5/29/2020', 'Update 5']"
97,page_98,"['Alliance A171601', 'How will information about me be kept private?', 'Your privacy is very important to the researchers and they will make every effort to protect it.', 'Here are just a few of the steps they will take:', '1) When your samples are sent by the biobank to the qualified researchers, no', 'information identifying you (such as your name) will be sent. Samples will be', 'identified by a unique code only.', '2) The list that links the unique code to your name will be kept separate from your', 'sample and health information. Any biobank and Alliance staff with access to the list', 'must sign an agreement to keep your identity confidential.', '3) Your blood sample collected for one of the additional studies will be sent to', 'researchers at the University of Pittsburgh Cancer Center with your initials and', 'collection date and time on it.', '4) Researchers to whom the Alliance sends your sample and information will not know', 'who you are. They must also sign an agreement that they will not try to find out who', 'you are.', '5) Information that identifies you will not be given to anyone, unless required by law.', '6)', 'If research results are published, your name and other personal information will not', 'be used.', 'What are the possible benefits?', 'You will not benefit from taking part. The researchers, using the samples from you and others,', 'might make discoveries that could help people in the future.', 'Are there any costs or payments?', 'There are no costs to you or your insurance. You will not be paid for taking part. If any of the', 'research leads to new tests, drugs, or other commercial products, you will not share in any', 'profits.', 'What if I change my mind?', 'If you decide you no longer want your samples to be used, you cancall the study doctor,', ', (insert name of istudy doctor for main trial) at', '(insert telephone number of study doctor for main trial) who will', 'let the researchers know. Then, any sample that remains in the biobank will no longer be used', 'and related health information will no longer be collected. This will not apply to those samples', 'or related information that have already been given to or used by qualified researchers.', '98', 'NCIVersion Date: 5/29/2020', 'Update 5']"
98,page_99,"['Alliance A171601', 'What if I have questions?', 'If you have questions about the use of your samples for research, contact the study doctor,', ', (insert name of study doctor for main trial), at', '(insert telephone number of study doctor for main trial).', 'Please circle your answer to show whether or not you would like to take part in each option:', 'Samples for the laboratory studies:', '1. I agree to have my specimen collected and I agree that my specimen sample(s) and', 'related information may be used for the laboratory studies described above.', 'YES', 'NO', 'Samples for future research studies:', '2. My samples and related information may be kept in a biobank for use in future health', 'research.', 'YES', 'NO', '3. I agree that my study doctor, or their representative, may contact me or my physician to', 'see if I wish to participate in other research in the future.', 'YES', 'NO', 'This is the end of the section about optional studies.', 'My signature agreeing to take part in the main study', 'I have read this consent form or had it read to me. I have discussed it with the study doctor and', 'my questions have been answered. I will be given a signed copy of this form. I agree to take part', 'in the main study and any additional studies where I circled ""yes\'.', ""Participant's signature"", 'Date of signature', 'Signature of person(s) conducting the informed consent', 'discussion', 'Date of signature', '99', 'NCIVersion Date: 5/29/2020', 'Update 5']"
99,page_100,"['Alliance A171601', 'APPENDIX I: PATIENT INFORMATION SHEETS', 'Patient Completed Booklet A: Cycle 1 and 4, Day 1', 'You have been given a bookle t to complete for this study. This bookletcontainssome questions about', 'your ""quality-of-life\' as a patient receiving treatment for cancer. Your answers will help us to better', 'understand how the treatment you are receiving is affecting the way you feel.', '1. You are being asked to complete a questionnaire booklet for this study. This booklet must be', 'completed on Day 1 of Cycle 1 and 4 of your study treatment. It contains the following', 'questionnaires:', 'Geriatric Assessment', 'EQ-5D 3L', 'PRO-CTCAE questionnaire Day 1', 'Geriatric Assessment: Healthcare Professional Questionnaire', '-Note: This form is to be completed by the healthcare professional, not the', 'patient.', '2. Directions on how to complete each set of questions are written on the top of each set.', '3. It is very important that you return the booklets to us, whether you finish the study or not.', ""4. You will be given the nurse's or study coordinator's name and telephone number. You can call"", 'anytime with any concerns or questions.', '5. After completing this booklet, please return it to your nurse or physician.', 'Thank you for taking the time to help us.', '100', 'NCIVersion Date: 5/29/2020', 'Update 5']"
100,page_101,"['Alliance A171601', 'PATIENT INFORMATION SHEET', 'Patient Completed Booklet B: Cycles 1 and 2, Day 15', 'You have been given a booklet to complete for this study. This bookletcontains some questions about', 'your ""quality-of-life\' as a patient receiving treatment for cancer. Your answers will help us to better', 'understand how the treatment you are receiving is affecting the way you feel.', '1. You are being asked to complete a questionnaire booklet for this study. This booklet must', 'be completed on Day 15 of Cycles 1 and 2 of your study treatment. It contains the', 'following questionnaires:', 'PRO-CTCAE questionnaire Day 15', '2. Directions on how to complete each set of questions are written on the top of each set.', '3. It is very important that you return the booklets to us, whether you finish the study or not.', ""4. You will be given the nurse's or study coordinator's name and telephone number. You can call"", 'anytime with any concerns or questions.', '5. After completing this booklet, please return it to your nurse or physician.', 'Thank you for taking the time to help us.', '101', 'NCIVersion Date: 5/29/2020', 'Update 5']"
101,page_102,"['Alliance A171601', 'PATIENT INFORMATION SHEET', 'Patient Completed Booklet C: Cycle 2, Day 1, and Cycles 3, 5, and 6', 'You have been given a booklet to complete for this study. This bookletcontains some questions about', 'your ""quality-of-life\' as a patient receiving treatment for cancer. Your answers will help us to better', 'understand how the treatment you are receiving is affecting the way you feel.', '1. You are being asked to complete a questionnaire booklet for this study. This booklet must be', 'completed on Day 1 of Cycle 2, and Cycles 3, 5, and 6 of your study treatment. It contains the', 'following questionnaires:', 'EQ-5D 3L', 'PRO-CTCAE questionnaire Day 1', '2. Directions on how to complete each set of questions are written on the top of each set.', '3. It is very important that you return the booklets to us, whether you finish the study or not.', ""4. You will be given the nurse's or study coordinator's name and telephone number. You can call"", 'anytime with any concerns or questions.', '5. After completing this booklet, please return it to your nurse or physician.', 'Thank you for taking the time to help us.', '102', 'NCIVersion Date: 5/29/2020', 'Update 5']"
102,page_103,"['Alliance A171601', 'PATIENT INFORMATION SHEET', 'Patient Completed Booklet D: END OF TREATMENT', 'You have been given a booklet to complete for this study. This bookletcontains some questions about', 'your ""quality-of-life\' as a patient receiving treatment for cancer. Your answers will help us to better', 'understand how the treatment you are receiving is affecting the way you feel.', '1. You are being asked to complete a questionnaire booklet for this study. This booklet must be', 'completed at the end of your treatment. It contains the following questionnaires:', 'Geriatric Assessment', 'PRO-CTCAE questionnaire', 'EQ-5D 3L', 'Was it Worth It Questionnaire', 'Geriatric Assessment: Healthcare Professional Questionnaire', '-Note: This form is to be completed by the healthcare professional, not the', 'patient.', '2. Directions on how to complete each set of questions are written on the top of each set.', '3. It is very important that you return the booklets to us, whether you finish the study or not.', ""4. You will be given the nurse's or study coordinator's name and telephone number. You can call"", 'anytime with any concerns or questions.', '5. After completing this booklet, please return it to your nurse or physician.', 'Thank you for taking the time to help us.', '103', 'NCIVersion Date: 5/29/2020', 'Update 5']"
103,page_104,"['Alliance A171601', 'APPENDIX II: GERIATRIC ASSESSMENT', 'GERIATRIC ASSESSMENT SURVEY', 'To be completed by Physician, Nurse, or CRA:', 'Responsible person name (Physician, Nurse, or CRA)', 'Assessment Period (as applicable to this study)', 'Pre-treatment', 'Cycle #', 'End of Treatment', 'PATIENT QUES TIO NNAIRE', 'Patient Instructions: If you are unable to complete the questionnaire, a member of your health care team will assist', 'you. Please do not have a family member complete the questionnaire for you.', 'Mark box with an ""X"", if form was not completed at specified timepoint and specify reason:', '(Mark one with an X.)', 'Patient refused', 'Patient W ithdrew consent', 'Not done', 'Other, specify', '(For assessment date, record approximate date form was to be completed.)', 'A. BACKGROUND INFORMATION', '1.', 'What is the highest grade you finished in school? (Mark one with an X.)', '8th grade or less', 'Vocational/ technical school', '9-11th grade', ""Bachelor's degree"", 'High school graduate/GED', 'Advanced degree', 'Associate degree/some', 'I prefer not to answer', 'college', '2.', 'What is your marital status? (Mark one with an X.)', 'Married', 'Divorced', 'I prefer not to answer', 'Domestic partnership', 'Separated', 'Widow ed', 'Never married', '3.', 'With W hom do you live? (Mark all that apply with an X.)', 'Spouse / partner', 'Parent(s)/parent(s)-in-law', 'Girlfriend / boyfriend', 'Live alone', 'Children aged 18 years or younger', 'Others, specify:', 'Children aged 19 years or older', 'Other relative, specify:', '104', 'NCI Version Date: 5/29/2020', 'Update 5']"
104,page_105,"['Alliance A171601', '4. What is your current employment status? (Mark one with an X.)', 'Employed 32 hours or more per week', 'Unemployed', 'Employed less than 32 hours per W eek', 'Retired', 'Homemaker', 'Full-time student', 'Disabled', 'Part-time student', 'On medical leave', 'Other, specify:', 'B. DAILY ACTIVITIES*', 'PATIENT INSTRUCTIONS: Indicate your response by marking an X in one box per question.', '1.', 'Can you use the telephone', 'W ithouthelp, including looking up and dialing;', 'W ith some help (can answ er phone or dial operator in an emergency, but need a special phone or help in', 'getting the phone number or dialing); or', 'are you completely unable to use the telephone?', '2.', 'Can you get to places out of W alking distance', 'W ithout help (can travel alone on busses, taxis, or drive your ow n car);', 'with some help (need someone to help you or go with you W hen traveling); or', 'are you unable to travel unless emergency arrangements are made for a specialized vehicle like an', 'ambulance?', '105', 'NCIVersion Date: 5/29/2020', 'Update 5']"
105,page_106,"['Alliance A171601', '3. Can you go shopping for groceries or clothes (assuming you have transportation)', 'W ithout help (taking care of all shopping needs yourself, assuming you have transportation);', 'w ith some help (need someone to go withyou on all shopping trips); or', 'are you completely unable to do any shopping?', '4.', 'Can you prepare your ow n meals', 'W ithout help (plan and cook full meals yourself);', 'W ith some help (can prepare some things but unable to cook full meals yourself); or', 'are you completely unable to prepare any meals?', '5.', 'Can you do your housew ork.', 'W ithout help (can clean floors, etc);', 'W', 'ith some help (can do light housew ork but need help with heavy work); or', 'are you completely unable to do any housew ork?', '6.', 'Can you take your ow n medicines', 'w ithout help (in the right doses at the right time);', 'W ith some help (able to take medicine if someone prepares it for you and/or reminds you to take it); or', 'are you completely unable to take your medicines?', '7.', 'Can you handle your ow n money', 'W ithout help (w rite checks, pay bills, etc.);', 'with some help (manage day-to-day buying but need help with managing your checkbook and paying your', 'bills); or', 'are you completely unable to handle money?', '*', 'OARS IADL 33', '106', 'NCIVersion Date: 5/29/2020', 'Update 5']"
106,page_107,"['Alliance A171601', 'c. PHYSICAL ACTIVITIES*', '1.', 'The follow ing items are activities you might do during a typical day. Does your health limit you in these activities?', '(M ark an x in the box on each line that best reflects your situation.)', 'Limited', 'Limited', 'Not limited', 'Activities', 'a lot', 'a little', 'at all', 'a.', 'Vigorous activities such as: running, lifting heavy objects,', 'participating in strenuous sports', 'b.', 'Moderate activities such as: moving a table, pushing a vacuum', 'cleaner, bowling, or playing golf', 'c. Lifting or carrying groceries', 'd. Climbing several flights of stairs', 'e.', 'Climbing one flight of stairs', 'f.', 'Bending, kneeling, or stooping', 'g. Walking more than a mile', 'h. Walking several blocks', 'i.', 'Walking one block', 'j.', 'Bathing or dressing yourself', '* MOS, Physical Functioning Scale 34', '107', 'NCIVersion Date: 5/29/2020', 'Update 5']"
107,page_108,"['Alliance A171601', 'D. CURRENT HEALTH RATING*', 'Which one of the following phrases best describes you at this time? (Mark one with an X.)', 'Normal, no complaints, no symptoms of disease', 'Able to carry on normal activity, minor symptoms of disease', 'Normal activity with effort, some symptoms of disease', 'Care for self, unable to carry on normal activity or do active W ork', 'Require occasional assistance but able to care for most of personal needs', 'Require considerable assistance for personal care', 'Disabled, require special care and assistance', 'Severely disabled, require continuous nursing care', '*', 'Patient KPS35', 'E. FALLS', 'How many times have you fallen in the last 6 months?', 'F. YOUR HEALTH', '1. Your General Health*', 'Patient Instructions: Do you have any of the follow ing illnesses at the present time, and if so, how much does it', 'interfere with your activities: Not at all, Somewhat or A Great Deal? (Mark an X in the box that best reflects your', 'answer.)', 'If you have this illness:', 'How much does it interfere with your activities?', 'Not', 'A great', 'Illness', 'No', 'Yes', 'at all', 'A little', 'deal', 'a.', 'Other cancers or leukemia', 'b.', 'Arthritis or rheumatism', '108', 'NCI Version Date: 5/29/2020', 'Update 5']"
108,page_109,"['Alliance A171601', 'If you have this illness:', 'How much does it interfere with your activities?', 'Not', 'A great', 'Illness', 'No', 'Yes', 'at all', 'A little', 'deal', 'c. Glaucoma', 'd.', 'Emphysema or chronic bronchitis', 'e.', 'High blood pressure', 'f.', 'Heart disease', 'g.', 'Circulation trouble in arms or legs', 'h. Diabetes', 'i.', 'Stomach or intestinal disorders', 'j.', 'Osteoporosis', 'k.', 'Liver disease', 'I.', 'Kidney disease', 'm. Stroke', 'n. Depression', '* OARS IADL³³', '109', 'NCIVersion Date: 5/29/2020', 'Update 5']"
109,page_110,"['Alliance A171601', '2. How is your eyesight (with glasses or contacts)? (Mark one with an X.)', 'Excellent', 'Good', 'Fair', 'Poor', 'Totally blind', '3.', 'How is your hearing (w ith a hearing aid, if needed)? (Mark one with an X.)', 'Excellent', 'Good', 'Fair', 'Poor', 'Totally deaf', '4.', 'Do you have any other physical problems or illnesses (other than listed in questions 1-4) at the present time that', 'seriously affect your health?', 'No', 'Yes, specify:', 'If yes, how much does this interfere W ith your activities? (Mark one with an X.)', 'Not at all', 'Somew hat', 'A great deal', '* OARS IADL³³', '110', 'NCIVersion Date: 5/29/2020', 'Update 5']"
110,page_111,"['Alliance A171601', 'G. NUTRITIONAL STATUS', '1.', 'Have you lost W eight involuntarily over the past 6 months?', 'No', 'Yes', 'If yes, how much?', 'pounds', '2.', 'What is your weight now ?', 'pounds', '3.', 'What W as your weight 6 months ago?', 'pounds', 'H. HEALTH QUESTIONNAIRE*', 'INSTRUCTIONS: These questions are about how you have been feeling within the past month. Please mark', 'an ""X"" in the box on each line that best reflects your situation.', 'All', 'Most', 'A Good', 'Some', 'A Little', 'None', 'Bit of', 'How much of the time during the past', 'of the', 'of the', 'of the', 'of the', 'of the', 'the Time', 'month:', 'Time', 'Time', 'Time', 'Time', 'Time', '1.', 'has your daily life been full of things', 'that W ere interesting to you?', '2.', 'did you feel depressed?', '3.', 'have you felt loved and W anted?', '4.', 'have you been a very nervous', 'person?', '5.', 'have you been in firm control of your', 'behavior, thoughts, emotions,', 'feelings?', '6.', 'have you felt tense or high-strung?', '7.', 'have you felt calm and peaceful?', '8.', 'have you felt emotionally stable?', '9. have you felt dow nhearted and blue?', '10. have you felt restless, fidgety, or', 'impatient?', '11. have you been moody, or brooded', 'about things?', '111', 'NCIVersion Date: 5/29/2020', 'Update 5']"
111,page_112,"['Alliance A171601', '12. have you felt cheerful, light-hearted?', '13. have you been in low or very low', 'spirits?', '14. were you a happy person?', '15. did you feel you had nothing to look', 'forw ard to?', '16. have you felt so dow in the dumps', 'that nothing could cheer you up?', '17. have you been anxious or worried?', '*', 'MHI-17 34 - Stewart, A.L. and Ware, J.E., 1992', '112', 'NCI Version Date: 5/29/2020', 'Update 5']"
112,page_113,"['Alliance A171601', 'I. SOCIAL ACTIVITIES*', '1.', 'During the past 4 weeks, how much time has your physical health or emotional problems interfered with your', 'social activities (like visiting with friends, relatives, etc.)? (Mark one with an X.)', 'All of the time', 'Most of the time', 'Some of the time', 'A little of the time', 'None of the time', '2.', 'Compared to your usual level of social activity, has your social activity during the past 6 months decreased,', 'stayed the same, or increased because of a change in your physical or emotional condition? (Mark one with an', 'X.)', 'Much less socially active than before', 'Somew hat less socially active than before', 'About as socially active as before', 'Somew hat more socially active as before', 'Much more socially active than before', '3.', 'Compared to others your age, are your social activities more or less limited because of your physical health or', 'emotional problems? (Mark one with an X.)', 'Much more limited than others', 'Somew hat more limited than others', 'About the same as others', 'Somew hat less limited than others', 'Much less limited than others', '* MOS, Social Activities34', '113', 'NCIVersion Date: 5/29/2020', 'Update 5']"
113,page_114,"['Alliance A171601', ""J. SOCIAL SUPPORT'"", 'INSTRUCTIONS: People sometimes look to others for companionship, assistance or other types of s upport.', 'How often is each of the following kinds of support available to you if you need it? (M ark an x in the box on', 'each line that best reflects your situation.)', 'None', 'A Little', 'Some', 'Most', 'All', 'of the', 'of the', 'of the', 'of the', 'of the', 'Time', 'Tim e', 'Time', 'Time', 'Time', '1.', 'Someone to help you if you W ere confined to bed.', '2.', 'Someone you can count on to listen to you w hen', 'you need to talk.', '3.', 'Someone to give you good advice about a crisis.', '4.', 'Someone to take you to the doctor if needed.', '5.', 'Someone to give you information to help you', 'understand a situation.', '6.', 'Someone to confide in or talk to about yourself or', 'your problem.', '7.', 'Someone to prepare your meals if you W ere unable', 'to do it yourself.', '8.', 'Someone whose advice you really want.', '9.', 'Someone to help you ith daily chores if you were', 'sick.', '10. Someone to share your most private w orries and', 'fears vith.', '11. Someone to turn to for suggestions about how to', 'deal with a personal problem.', '12. Someone who understands your problems.', '*', 'MOS Social Support Survey', '36', '114', 'NCIVersion Date: 5/29/2020', 'Update 5']"
114,page_115,"['Alliance A171601', 'K. SPIRITUALITY/RELIGION', 'Directions: Please answer the following questions about your religious beliefs and/or involvement. (Please', 'mark an ""X"" in the box on each line that best reflects your situation.)', '1. How often do you attend church, synagogue, or other religious meetings? (Mark one with an X.)', 'More than once per W eek', 'Once a week', 'A few times a month', 'A few times a year', 'Once a year or less', 'Never', '2. How often do you spend time in private religious activities, such as prayer, meditation, or Bible study? (Mark one', 'with an X.)', 'More than once a day', 'Daily', 'Tw o or more times per W eek', 'Once a W eek', 'A few times a month', 'Rarely or never', 'The following section contains 3 statements about religious belief or experience. Please mark the extent to which', 'each statement is true or not true for you.', '3.', 'In my life, I experience the presence of the Divine (i.e., God). (Mark one with an X.)', 'Definitely true of me', 'Tends to be true', 'Unsure', 'Tends not to be true', 'Definitely not true', '4.', 'My religious beliefs are whatreally lie behind my whole approach to life. (Mark one with an X.)', 'Definitely true of me', 'Tends to be true', 'Unsure', 'Tends not to be true', 'Definitely not true', '115', 'NCIVersion Date: 5/29/2020', 'Update 5']"
115,page_116,"['Alliance A171601', '5. I tried hard to carry my religion over into all other dealings in my life. (Mark one with an X.)', 'Definitely true of me', 'Tends to be true', 'Unsure', 'Tends not to be true', 'Definitely not true', '*DUREL: Duke University ReligionIndex37 - Koeniget al., 1997', 'L. YOUR FEELINGS*', '1. Do you often feel sad or depressed? (Mark one with an X.)', 'No', 'Yes', '2. How W ould you describe your level of anxiety, on average? Please circle the number (0-10) best reflecting your', 'response to the follow ing that describes your feelings during the past week, including today.', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', 'No anxiety', 'Anxiety as bad as', 'It can be', '*Mahoney et al., 1994; LASA38', 'M. QUESTIONS CONCERNING THE QUESTIONNAIRE', '1.', 'Were there any questions difficult to understand?', 'No', 'Yes', 'If Yes, W hich questions were they?', '2.', 'Was the time it took to answ er all the questions too long, just right or too short?', 'Too short', 'How long W ould you have liked the questionnaire to be?', 'minutes', 'Just right', 'Too long', 'How long would you have liked the questionnaire to be?', 'minutes', 'Which items would you remove?', 'NCI Version Date: 5/29/2020', 'Update 5']"
116,page_117,"['Alliance A171601', '3.', 'Did you find any of the questions upsetting?', 'No', 'Yes', 'If Yes, W hich questions were they?', 'Could you tell me why they W vere upsetting?', '4.', 'Do you think the questionnaire left out any questions that W ere important to ask?', 'Thank you for your participation.', '117', 'NCIVersion Date: 5/29/2020', 'Update 5']"
117,page_118,"['Alliance A171601', 'Geriatric Assessment: Healthcare Professional Questionnaire', 'To be completed by Physician, Nurse, or CRA', 'I. This form completed by:(Markallthatapplywithan) X.) Assessment Period (as applicable to this study)', 'Physician', 'Nurse', 'CRA', 'Pre-treatment', 'Cycle #', 'End of Treatment', 'Mark box with an ""X"", if form was not completed at specified timepoint and s pecify reason:', '(Mark one with an X.)', 'Patient refused', 'Patient withdrew consent', 'Not done', 'Other, specify', '(For assessment date, record approximate date form was to be completed.)', 'II.', 'FUNCTIONAL STATUS', 'A.', 'KPS (Healthcare professional rated*)', ""Please rate your assessment of patient's Karnofsky Performance Status as of date this formis completed. (Scale"", 'is listed below.)', '%', '%', 'CRITERIA', '100', 'Normal: no complaints; no evidence of disease.', '90', 'Able to carry on normal activity; only minor signs or symptoms of disease.', '80', 'Normal activity with effort; some signs or symptoms of disease.', '70', 'Cares for self, but unable to carry on normal activity or do active work.', '60', 'Requires occasional assistance, but is able to care for most personal needs.', '50', 'Requires considerable assistance and frequent medical care.', '40', 'Disabled; requires special care and assistance.', '30', 'Severely disabled; hospitalization is indicated although death not imminent.', '20', 'Very sick; hospitalization necessary; active supportive treatment necessary.', '10', 'Mbribund; fatal processes progressing rapidly.', '0', 'Dead.', '* Physician KPS³', '118', 'NCIVersion Date: 5/29/2020', 'Update 5']"
118,page_119,"['Alliance A171601', 'B. Timed ""Up and Go""*', 'INSTRUCTIONS: The timed ""Up and Go"" measures, in seconds, the time it takes for an individual to stand up', 'from a standard arm chair (approximate seat height of 46 cm [approximately 1.5 ft]), W alk a distance of 3 meters', '(approximately 10 feet), turn, W alk back to the chair, and sit dow n again. The subject w ears his/her regular', 'footw ear and uses their customary W alking aid (none, cane, walker, etc.) No physical assistance is given. The', ""subject starts W ith his back against the chair, his arm resting on the chair's arm, and his W alking aid in hand. He"", 'is instructed that on the W ord ""go"", he is to get up and W alk at a comfortable and safe pace to a line on the floor 3', 'meters (approximately 10 feet) law ay, turn, and return to the chair and sit dow n again. The subject W alks through', 'the test once before being timed in order to become familiar with the test. Either a W rist W atch w ith a second', 'hand or a stop-w atch can be used to time the performance.', 'Time to perform ""Up and Go""', 'seconds', '*', 'Timed ""Up and Go""do', 'III.', 'COGNITION This section is only completed Pretreatment and at the end of treatment', '6-ITEM ORIENTATION-M EMORY-CONCENTRATION TEST**', 'Final', ""Patient's"", 'Maximum', 'Response', 'errors', 'Score', 'Weight', 'score', '1. What year is it now ?', '[w ithout looking at a calendar]', '1', 'X', '4', '=', '2.', ""What month is it now' ?"", '[w ithout looking at a calendar]', '1', 'X', '3', '=', 'Memory Phrase:', 'Repeat this phrase after me:', ""'John Brow n, 42 Market Street,"", ""Chicago'"", '3.', 'About w hat time is it?', '1', '[ W ithin 1 hour - W ithout looking at', 'X', '3', '=', 'your W atch]', '4.', 'Count backw ards 20 to 1.', '2', 'X', '2', '=', '5.', '2', 'Say the months in reverse order.', 'X', '2', '=', '6.', '5', 'Repeat the Memory Phrase.', 'X', '2', '=', 'TOTAL SCORE:', '119', 'NCIVersion Date: 5/29/2020', 'Update 5']"
119,page_120,"['Alliance A171601', 'Scoring: For items 1 to 3, the response is either correct (score 0) or incorrect (score 1). For items 4 to 6, add one', 'point for each error (item 4 and 5 maximum error is 2; for item 6, maximum error is 5); total all scores in ""Final Score""', 'column. Data from participants found to have gross cognitive impairment as determined by the Orientation-Memory-', 'Concentration Score >11 wi be excluded from the analysis. Maximum score = 28.', '** OMC - Katzman, R., et al., 1983; Kaw as, C., et al., 1995', '120', 'NCIVersion Date: 5/29/2020', 'Update 5']"
120,page_121,"['Alliance A171601', 'IV. SCORING This section is only applicable if OMC-Test is completed Pretreatment and Post treatment', 'Did the patient score>11 on the 6-Item Orientation-Memory-Concentration Test?', 'No', ""Yes (If yes, notify the patient's treating physician.)"", 'This question is only applicable to question #1 in ""Section K. Your Feelings"" from the Patient', 'Questionnaire.', '1. How did the patient answer the question ""Do you often feel sad or depressed?"" in the Patient', 'Questionnaire (Section K)?', 'No', ""Yes (If yes, notify the patient's treating physician.)"", 'V. NUTRITION', ""What is the patient's height? (from patient's chart)"", 'cm', ""What is the patient's current w eight? (from patient's chart)"", 'kg', ""What W as the patient's w eight approximately 6 months ago? (from patient's chart or patients selfreport)"", 'kg', 'Calculated Body Mass Index:', 'Percent Unintentional Weight Loss:', '%', 'VI. QUESTIONS REGARDING THE QUESTIONNAIRES', 'A. Were any of the questionnaires in the ""Geriatric Assessment - Healthcare Professional Questionnaire"" difficult', 'for you to administer?', 'Yes', 'No', '121', 'NCIVersion Date: 5/29/2020', 'Update 5']"
121,page_122,"['Alliance A171601', 'If no, please proceed to the next question.', 'If yes, please indicate which questionnaire was difficult to administer? (Mark all that apply with an X.)', 'KPS Healthcare Professional Rated (page 1)', 'Timed Up and Go (page 2)', '6-Item Orientation-Memory-Concentration Test (page 2)', 'Other: Please specify', 'B.', 'Were any of the questionnaires in the ""Geriatric Assessment - Patient Questionnaire"" difficult for the patient to', 'complete?', 'Yes', 'No', 'B. If no, please proceed to the next question. If yes, please indicate which questionnaire(s) was difficult for the', 'patient to complete? (Mark all that apply with an X.)', 'Background Information (page 1)', 'Daily Activities (page 2-3)', 'Physical Activities (page 3)', 'Current Health Rating (page 4)', 'Falls (page 4)', 'Your Health (page 4-5)', 'Nutritional Status (page 7-8)', 'Health Questionnaire (page 9)', 'Social Activities (page 10)', 'Social Support (page 11)', 'Spirituality or religion (page 12)', 'Your Feelings (page 13)', 'C.', 'Was the patient able to complete ""Geriatric Assessment - Patient Questionnaire"" on his/her own?', 'Yes', 'No', 'If no, w hy? (Mark all that apply with an X.)', 'Not literate (does not read or write)', 'Visual problem', 'Fatigue', '122', 'NCIVersion Date: 5/29/2020', 'Update 5']"
122,page_123,"['Alliance A171601', ""Questions too difficult (above the patient's reading ability)"", 'Other: specify', 'D. Length of time to complete both the Patient and Healthcare Professional Questionnaires', 'Length of time to complete healthcare professional questionnaire', 'minutes', 'Length of time to complete patient questionnaire', 'minutes', 'Total length of time to complete both questionnaires', 'minutes', 'Completed by:', 'Date form completed:', '/', '/', '(Last name, First name)', 'MM', 'DD', 'Y Y Y Y', '123', 'NCIVersion Date: 5/29/2020', 'Update 5']"
123,page_124,"['Alliance A171601', 'APPENDIX III : WAS IT WORTH IT QUESTIONNAIRE', 'To be completed by Physician, Nurse, or CRA:', 'Patient Name:', 'Date:', 'Patient Number:', 'Participating in a clinical trial / research study is a personal choice and an individual experience.', 'We would like to get your feedback on your experience in this research study.', 'Directions: Please answer each question by circling Y (for yes), N (for no), or U (for uncertain).', '1. Was it worthwhile for you to participate in this research study?', 'Y', 'N', 'U', '2. If you had to do it over, would you participate in this research study again?', 'Y', 'N', 'U', '3. Would you recommend participating in this research study to others?', 'Y', 'N', 'U', '4. Overall, did your quality of life change by participating in this research study? (circle one response)', 'It improved', 'It stayed the same', 'It got worse', '5. Overall how was your experience participating in this research study? (circle one response)', 'Better than I expected', 'The same as I expected', 'Worse than I expected', '6. If there was one thing that could have been done to improve your experience in this research study,', 'what would it be?', '7. Would you like to talk to someone about your concerns?', 'Yes', 'No', '(circle one response)', '124', 'NCIVersion Date: 5/29/2020', 'Update 5']"
124,page_125,"['Alliance A171601', 'APPENDIX IV: OVERALL TREATMENT UTILITY', 'OTU is a novel clinical outcome measure incorporating objective and subjective measures of anticancer', 'efficacy, tolerability, and acceptability, assessed at the end of treatment and condensed into a simple 3', 'point score.', 'OTU may be regarded as asking the clinician: ""With the benefit of hindsight, are you glad you gave this', 'treatment?"" and asking the patient: ""With the benefit of hindsight, are you glad you received it?"". OTU', 'is', 'scored as good, intermediate or poor, corresponding to ""yes"", ""uncertain"" or ""no"" replies to these', 'questions.', 'To score the OTU, the patient is assessed at the end of treatment, using the following criteria:', '1) Clinical benefit? Categorized as:', 'a.', 'Both radiologically progression- free (RECIST response or stable disease) and no clinical', 'deterioration as assessed by treating consultant', 'b. Either radiologically progression- free (RECIST progressive disease) or clinical', 'deterioration as assessed by treating consultant', '2) Tolerable and acceptable? Categorized as:', 'a.', 'All of the following:', 'No SAE or SUSAR attributed to treatment', 'No episodes of grade >3 non-hematologicaltoxic ity', 'Patient response to ""Which one of the following phrases best describes you at', 'this time?"" in section D of the Geriatric Assessment at the end of treatment is not', '""Require considerable assistance for personal care"", ""Disabled, require special', 'care and assistance"" or ""Severely disabled, require continuous nursing care.""', 'Patient response to ""Was it worthwhile for you to undergo this cancer', 'treatment?"" from the Was It Worth It questionnaire is ""Y""', 'b. Any of the following:', 'An SAE or SUSAR (suspected unexpected serious adverse reaction) attributed to', 'treatment', 'An episode of grade >3 non-hematologicaltoxicity', 'Patient response to ""Which one of the following phrases best describes you at', 'this time?"" in section D of the Geriatric Assessment at the end of treatment is', '""Require considerable assistance for personal care"", ""Disabled, require special', 'care and assistance"" or ""Severely disabled, require continuous nursing care.""', '125', 'NCIVersion Date: 5/29/2020', 'Update 5']"
125,page_126,"['Alliance A171601', 'Patient response to ""Was it worthwhile for you to undergo this cancer', 'treatment?"" from the Was It Worth It questionnaire is not ""Y""', 'Scoring:', 'Good OTU: Patient is alive and scores 1a/2a', 'Intermediate OTU: Patient is alive and scores 1a/2b or 1b/2a', 'Poor OTU: Patient is alive and scores 1b/2b, or patient is dead', '126', 'NCIVersion Date: 5/29/2020', 'Update 5']"
126,page_127,"['Alliance A171601', 'APPENDIX V: EQ-5D-3L HEALTH QUESTIONNAIRE', 'EQ-5D-3L', 'Under each heading, please check the ONE box that best describes your health TODAY.', 'MOBILITY', 'I have no problems walking', 'I have moderate problems walking', 'I am confined to bed', 'SELF-CARE', 'I have no problems washing or dressing myself', 'I have moderate problems washing or dressing myself', 'I am unable to wash or dress myself', 'USUAL ACTIVITIES (e.g. work, study, housework, family or leisure', 'activities)', 'I have no problems doing my usual activities', 'I have moderate problems doing my usual activities', 'I am unable to do my usual activities', 'PAIN /DISCOMFORT', 'I have no pain or discomfort', 'I have moderate pain or discomfort', 'I have extreme pain or discomfort', 'ANXIETY / DEPRESSION', 'I am not anxious or depressed', 'I am moderately anxious or depressed', 'I am extremely anxious or depressed', '127', 'NCI Version Date: 5/29/2020', 'Update 5']"
127,page_128,"['Alliance A171601', '100', 'We would like to know how good or bad your health is TODAY.', '95', 'This scale is numbered from 0 to 100.', '90', '100 means the best health you can imagine.', '0 means the worst health you can imagine.', '85', 'Mark an X on the scale to indicate how your health is TODAY.', '80', '75', 'Now, please write the number you marked on the scale in the box below.', '70', '65', '60', '55', 'YOUR HEALTH TODAY =', '50', '45', '40', '35', '30', '25', '20', '15', '10', '5', '0', '128', 'NCIVersion Date: 5/29/2020', 'Update 5']"
128,page_129,"['Alliance A171601', 'APPENDIX VI: PRO-CICAE -NCI-PRO-CTCAE TM ITEMS', 'Item Library version 1.0', 'As individuals go through treatment for their cancer they sometimes experience', 'different symptoms and side effects. For each question, please check or mark an', 'in the one box that best describes your experiences over the past 7 days.', '1.', 'In the last 7 days, what was the SEVERITY of your DRY MOUTH at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', '2.', 'In the last 7 days, what was the SEVERITY of your MOUTH OR THROAT SORES at their', 'WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did MOUTH OR THROAT SORES INTERFERE with your', 'usual or daily activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', '3.', 'In the last 7 days, what was the SEVERITY of your PROBLEMS WITH TASTING FOOD', 'OR DRINK at their WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', '4.', 'In the last 7 days, what was the SEVERITY of your DECREASED APPETITE at its', 'WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did DECREASED APPETITE INTERFERE with your usual or', 'daily activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', '5.', 'In the last 7 days, how OFTEN did you have NAUSEA?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your NAUSEA at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'The PRO-CTCAE TM items and information herein were developed by the NATIONAL CANCER INSTITUTE at the', ""NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE TM is subject to NCI's"", 'Terms of Use', '129', 'NCIVersion Date: 5/29/2020', 'Update 5']"
129,page_130,"['Alliance A171601', '6.', 'In the last 7 days, how OFTEN did you have VOMITING?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your VOMITING at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', '7.', 'In the last 7 days, how OFTEN did you have HEARTBURN?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your HEARTBURN at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', '8.', 'In the last 7 days, what was the SEVERITY of your CONSTIPATION at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', '9.', 'In the last 7 days, how OFTEN did you have LOOSE OR WATERY STOOLS (DIARRHEA)?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', '10. In the last 7 days, did you have any RASH?', 'Yes', 'No', '11. In the last 7 days, what was the SEVERITY of your DRY SKIN at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', '12. In the last 7 days, did you have any HAIR LOSS?', 'Not at all', '0', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', 'The PRO-CTCAE TM items and information herein were developed by the NATIONAL CANCER INSTITUTE at the', ""NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE TM is subject to NCI's"", 'Terms of Use', '130', 'NCIVersion Date: 5/29/2020', 'Update 5']"
130,page_131,"['Alliance A171601', '13. In the last 7 days, what was the SEVERITY of your NUMBNESS OR TINGLING IN YOUR', 'HANDS OR FEET at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did NUMBNESS OR TINGLING IN YOUR HANDS OR FEET', 'INTERFERE with your usual or daily activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', '14. In the last 7 days, how OFTEN did you have PAIN?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your PAIN at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did PAIN INTERFERE with your usual or daily activities?', 'Not at all', 'O', 'A little bit', 'Somewhat', 'O', 'Quite a bit', 'Very much', '15.', 'In the last 7 days, how OFTEN did you have a HEADACHE?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your HEADACHE at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did your HEADACHE INTERFERE with your usual or daily', 'activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', 'The PRO-CTCAE TM items and information herein were developed by the NATIONAL CANCER INSTITUTE at the', ""NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAETM is subject to NCI's"", 'Terms of Use', '131', 'NCIVersion Date: 5/29/2020', 'Update 5']"
131,page_132,"['Alliance A171601', '16. In the last 7 days, how OFTEN did you have ACHING MUSCLES?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your ACHING MUSCLES at their WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did ACHING MUSCLES INTERFERE with your usual or', 'daily activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', '17. In the last 7 days, how OFTEN did you have ACHING JOINTS (SUCH AS ELBOWS,', 'KNEES, SHOULDERS)?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your ACHING JOINTS (SUCH AS ELBOWS,', 'KNEES, SHOULDERS) attheir WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did ACHING JOINTS (SUCH AS ELBOWS, KNEES,', 'SHOULDERS) INTERFERE with your usual or daily activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', '18. In the last 7 days, what was the SEVERITY of your INSOMNIA (INCLUDING DIFFICULTY', 'FALLING ASLEEP, STAYING ASLEEP, OR WAKING UP EARLY) atits WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did INSOMNIA (INCLUDING DIFFICULTY FALLING ASLEEP,', 'STAYING ASLEEP, OR WAKING UP EARLY) INTERFERE with your usual or daily', 'activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', 'The PRO-CTCAE TM items and information herein were developed by the NATIONAL CANCER INSTITUTE at the', ""NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE TM is subject to NCI's"", 'Terms of Use', '132', 'NCIVersion Date: 5/29/2020', 'Update 5']"
132,page_133,"['Alliance A171601', '19. In the last 7 days, what was the SEVERITY of your FATIGUE, TIREDNESS, OR LACK OF', 'ENERGY atits WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did FATIGUE, TIREDNESS, OR LACK OF ENERGY', 'INTERFERE with your usual or daily activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', '20. In the last 7 days, how OFTEN did you feel ANXIETY?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your ANXIETY at its WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did ANXIETY INTERFERE with your usual or daily', 'activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', '21. In the last 7 days, how OFTEN did you have SAD OR UNHAPPY FEELINGS?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your SAD OR UNHAPPY FEELINGS at', 'their WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'In the last 7 days, how much did SAD OR UNHAPPY FEELINGS INTERFERE with your', 'usual or daily activities?', 'Not at all', 'A little bit', 'Somewhat', 'Quite a bit', 'Very much', '22. In the last 7 days, what was the SEVERITY of your DECREASED SEXUAL INTEREST at its', 'WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very', 'Not', 'Prefer', 'severe', 'sexually', 'not to', 'active', 'answer', 'The PRO-CTCAE TM items and information herein were developed by the NATIONAL CANCER INSTITUTE at the', ""NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE TM is subject to NCI's"", 'Terms of Use', '133', 'NCIVersion Date: 5/29/2020', 'Update 5']"
133,page_134,"['Alliance A171601', '23. In the last 7 days, how OFTEN did you have UNEXPECTED OR EXCESSIVE SWEATING', 'DURING THE DAY OR NIGHTIME (NOT RELATED TO HOT FLASHES)?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your UNEXPECTED OR EXCESSIVE', 'SWEATING DURING THE DAY OR NIGHTIME (NOT RELATED TO HOT FLASHES) at its', 'WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', '24. In the last 7 days, how OFTEN did you have HOT FLASHES?', 'Never', 'Rarely', 'Occasionally', 'Frequently', 'Almost', 'constantly', 'In the last 7 days, what was the SEVERITY of your HOT FLASHES at their WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very severe', 'Do you have any other symptoms that you wish to report?', 'Yes', 'No', 'The', 'PRO-CTCAETM items and information herein were developed by the NATIONAL CANCER INSTITUTE at the', ""NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE TM is subject to NCI's"", 'Terms of Use', '134', 'NCIVersion Date: 5/29/2020', 'Update 5']"
134,page_135,"['Alliance A171601', 'Please list any other symptoms:', '1.', 'In the last 7 days, what was the SEVERITY of this symptom at its', 'WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very', 'severe', '2.', 'In the last 7 days, what was the SEVERITY of this symptom at its', 'WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very', 'severe', '3.', 'In the last 7 days, what was the SEVERITY of this symptom at its', 'WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very', 'severe', '4.', 'In the last 7 days, what was the SEVERITY of this symptom at its', 'WORST?', 'None', '0 Mild', 'Moderate', 'Severe', 'Very', 'severe', '5.', 'In the last 7 days, what was the SEVERITY of this symptom at its', 'WORST?', 'None', 'Mild', 'Moderate', 'Severe', 'Very', 'severe', 'The PRO-CTCAE TM items and information herein were developed by the NATIONAL CANCER INSTITUTE at the', ""NATIONAL INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE TM is subject to NCI's"", 'Terms of Use', '135', 'NCIVersion Date: 5/29/2020', 'Update 5']"
135,page_136,"['Alliance A171601', 'APPENDIX VII: PATIENT MEDICATION DIARY - PALBOCICLIB', ""Today's date"", 'Patient Name', '(initials acceptable)', 'Patient Study ID', 'INSTRUCTIONS TO THE PATIENT:', '1. Complete this form while you take palbociclib and if you are taking letrozole. This form', ""is a 28 day diary. You don't need to complete the letrozole column if you are not taking"", 'it. You may need to complete more than one form between clinic visits.', '2. You will take your dose of palbociclib daily for 21 days. You will also take your dose', 'of letrozole daily for 28 days.', '3.', 'Palbociclib interacts with other medications. Do not start any new prescription or over', 'the counter medications without discussing with your doctor or pharmacist.', '4 Take the palbociclib capsule with food at about the same time every day. Letrozole can', 'be taken once daily without regard to food.', '5. Record the date, and when you took the capsule and pill. Record doses as soon as you', 'take them; do not batch entries together at a later time.', '6.', 'If you vomit or miss a dose, do not make up that dose; resume dosing with the next', 'scheduled dose at the usual time.', '7. Swallow capsule whole, do not crush or chew. It should be taken in combination with', 'endocrine therapy (if taking Letrozole). The combination that you are being treated with', 'may be palbociclib along with letrozole pill or fulvestrant injection. Do not take', 'grapefruit or grapefruit juice when you are taking this drug.', '8.', 'If you have any comments or notice any side effects, please record them in the', 'Comments column. If you make a mistake while you write, please cross it out with one', 'line, put your initials next to it, and then write the corrected information next to your', 'initials. Example: 10:30 am SB 9:30 am', ""9. If you don't take your palbociclib dose for any reason, contact your physician."", '10. Please return this form to your physician at your next appointment. You may need to', 'return more than one form per clinic visit.', '136', 'NCIVersion Date: 5/29/2020', 'Update 5']"
136,page_137,"['Alliance A171601', 'Time of daily', 'Time of daily', 'If you missed a', 'dose-', 'dose-', 'Date', 'dose,', 'Day', 'Comments', 'Palbociclib(21', 'Letrozole (28', 'Reason for not', 'days)', 'days)', 'taking the capsule', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', 'No capsule', '23', 'No capsule', '24', 'No capsule', '25', 'No capsule', '26', 'No capsule', '27', 'No capsule', '28', 'No capsule', ""Patient's signature"", 'Date', 'Additional space for Comments:', '137', 'NCIVersion Date: 5/29/2020', 'Update 5']"
137,page_138,"['Alliance A171601', 'APPENDIX VIII: TABLE OF TAGSNPs FOR A171601 STUDY', 'GENE', ""dbSNP l's id"", 'GENE', 'dbSNP rs id', 's7177', 'rs2811710', 'CCND1', 'rs9344', 'CDKN2A', 'rs3218020', 'rs678653', 'rs3731239', 'rs1049606', 'rs1063192', 'rs3217805', 'rs3217992', 'rs3217827', 'CDKN2B', 'rs545226', 'rs3217869', 'rs573687', 'rs3217901', 'rs10811640', 'rs3217907', 'rs12855', 'CCND2', 'CDKN2C', 'rs 3217916', 'rs3176459', 'rs3217936', 'rs17677316', 'CDKN2D', 'rs 12299509', 'rs3218222', 'rs 3217840', 'CYP3A4', 's2246709', 'rs3217882', 'rs4646450', 'CYP3A5', 'rs3217926', 'rs 15524', 'rs9529', 'rs9568036', 'RB1', 'rs4607417', 'rs 198584', 'rs4714554', 'rs296365', 'rs4714556', 'rs 7508610', 'rs 7774393', 'SULT2A1', 'rs 296364', 'rs9369324', 'rs2547238', 'CCND3', 'rs9369325', 'rs2932766', 'rs', '7753265', 'rs2445761', 'rs', '1051130', 'rs1062033', 'rs 13340461', 'rs', '2470152', 'rs4415146', 'rs 10519297', 'r44560643', 'CYP19A1', 'rs 1004983', 'rs4711703', 'rs 10459592', 'rs 1406', 'rs 12591359', 'CCNE1', 'rs997669', 'rs 7172156', 'CDK2', 'rs2069408', 'rs3751592', '138', 'NCIVersion Date: 5/29/2020', 'Update 5']"
138,page_139,"['Alliance A171601', 'rs 2072052', 'rs 12592697', 'CDK4', 'rs 2270777', 'rs2982712', 'rs1005346', 'rs2077647', 'rs 191777', 'rs3798577', 'CDK6', 'rs', '2079147', 'rs1643821', 'rs', '42038', 's3020363', 'rs42039', 'ESR1', 'rs9340835', 'rs2395655', 'rs', '532010', 'CDKN1A', 'rs3176336', 'rs11155820', 'rs34329', 'rs3020370', 'rs3759216', 'rs', '2982683', 'CDKN1B', 'rs 7330', 'rs3020323', 'rs34330', 'rs1137115', 'rs2066827', 'rs2316213', 'CYP2A6', 'rs56113850', 'rs7250713', '139', 'NCIVersion Date: 5/29/2020', 'Update 5']"
139,page_140,"['Alliance A171601', 'APPENDIX IX: PATIENT PHARMACOKINETIC QUESTIONNAIRE', 'Note: This form is required to be completed at all blood draw time points associated with the', 'pharmacokinetic substudy (A171601-PP1).', 'On pre-study treatment visit (baseline), Cycle 1 Day 15 and Cycle 2 Day 15, this form is to be', 'administered by a nurse/CRP, completed by the patient, and entered into Rave by site staff.', 'For baseline visit: The patient may indicate N/A for the questions that are not applicable.', 'Note: study medication should ONLY be taken on the day of the clinic visit after providing the PK', 'blood sample.', 'Patient Initials:', 'Patient ID #:', 'Study #:', 'Cycle #:', 'Day #:', 'Date:', 'The following question refers to the day before yesterday (2 days ago):', 'What time did you take your oral study medication (palbociclib)?', ':', 'AM / PM', 'What dose of oral study medication (palbociclib) did you take on the day before yesterday', 'mg', 'The following question refers to yesterday (1 day ago):', 'What time did you take your oral study medication (palbociclib)', ':', 'AM / PM', 'What dose of oral study medication (palbociclib) did you take yesterday', 'mg', 'The following question refers to today (THIS ONLY APPLIES IF YOU HAVE TAKEN YOUR', 'STUDY MEDICATION BEFORE BEING SEEN IN THE CLINIC TODAY):', 'What time did you take your study medication (palbociclib)?', ':', 'AM / PM', 'What dose of oral study medication (palbociclib) did you take today?', 'mg', 'List concomitant medications patient is taking at baseline study visit ONLY:', '140', 'NCIVersion Date: 5/29/2020', 'Update 5']"
